<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: eac70d85-6037-4b89-b350-bf712f021df9 -->
<!-- Creation date: 2017-03-01T19:51:21Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:amrn="http://www.amarincorp.com/20161231" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="amrn-20161231.xsd" xlink:type="simple" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_1002_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_1002_0" unitRef="iso4217_USD">150000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_27EA26E1-15BA-4CFE-BED3-2272FCF4FFC1_3001_0" unitRef="iso4217_USD">23800000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865_1330096x1419380" decimals="4" id="id_6322976_DB673CC7-A9B8-4CE0-B5F8-0EDFA5B35F2F_4001_2" unitRef="iso4217_USD_per_shares">8.8125</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865_1334996x1364094" decimals="-5" id="id_6322976_27EA26E1-15BA-4CFE-BED3-2272FCF4FFC1_4001_1" unitRef="iso4217_USD">126200000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_1405686B-53A5-42B2-9EE6-25D8F3C0EA56_2001_2" unitRef="iso4217_USD">15100000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_1405686B-53A5-42B2-9EE6-25D8F3C0EA56_2001_0" unitRef="iso4217_USD">16200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="INF" id="id_6322976_CAA30D32-129B-4270-9878-6EAB2F874F85_3001_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_7B7AAF62-1B20-4A29-9916-A305547BE1A3_2001_0" unitRef="iso4217_USD">500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_BBC5E1E4-42F3-475A-93F5-D2336C3264D5_3001_0" unitRef="iso4217_USD">27500000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DeferredFinanceCostsGross contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_BBC5E1E4-42F3-475A-93F5-D2336C3264D5_3001_2" unitRef="iso4217_USD">100000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_96BD1B54-B670-4BA5-AB68-2FDA181C1F1E_2002_1" unitRef="iso4217_USD">3800000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865_1330096x1419380" decimals="2" id="id_6322976_9C5EA559-9344-4180-877A-803988BE8DB7_4001_3" unitRef="iso4217_USD_per_shares">2.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ConvertibleDebtCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20170131_0_1324529x1461424_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_3004_5" unitRef="iso4217_USD">100000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20170131_0_1324529x1461424_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_3004_4" unitRef="iso4217_USD">15000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20170131_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_4004_7" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20170131_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_4004_6" unitRef="iso4217_USD">30000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20170220_0_1330096x1419380" decimals="INF" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_2002_500010" unitRef="shares">269369455</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20170220_0_1330096x1433040" decimals="INF" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_3002_500011" unitRef="shares">2692102</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0" decimals="INF" id="id_6322976_CE75DCA9-E1F7-487F-A995-E4421024247A_6001_0" unitRef="iso4217_GBP_per_shares">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0" decimals="INF" id="id_6322976_CE75DCA9-E1F7-487F-A995-E4421024247A_4001_3" unitRef="shares">0.1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:SharePrice contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0" decimals="INF" id="id_6322976_5E4107FA-A547-4EC6-BD7B-F2A09C60FDD4_3_1" unitRef="iso4217_USD_per_shares">2.39</us-gaap:SharePrice>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0_1330096x1335797" decimals="INF" id="id_6322976_DF1B9592-DEF9-4DCC-86C2-ACC6D377F1FD_3001_2" unitRef="iso4217_GBP_per_shares">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0_1330097x1393080" decimals="INF" id="id_6322976_6A605ADE-25DB-4918-8611-C8C14672F6D5_1001_0" unitRef="iso4217_USD_per_shares">0.15</amrn:ConversionPricePerShare>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0_1330097x1400959" decimals="INF" id="id_6322976_6A605ADE-25DB-4918-8611-C8C14672F6D5_2001_1" unitRef="iso4217_USD_per_shares">1.50</amrn:ConversionPricePerShare>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6322976_34611778-5D87-472B-8002-26FE1E9E6F41_2001_0" unitRef="iso4217_USD">900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20150305_0_1330926x1353534" decimals="-5" id="id_6322976_D7A544B8-48EE-4A4E-81CD-FDD32EEDC8E4_1001_0" unitRef="iso4217_USD">900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20150330_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6322976_34611778-5D87-472B-8002-26FE1E9E6F41_2003_4" unitRef="iso4217_USD">1800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <dei:EntityPublicFloat contextRef="eol_PE46938---1610-K0013_STD_0_20160630_0" decimals="0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_3_600008" unitRef="iso4217_USD">381800000</dei:EntityPublicFloat>
  <amrn:NumberOfLeasableSquareFeet contextRef="eol_PE46938---1610-K0013_STD_0_20110701_0_1410977x1379917" decimals="INF" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2001_0" unitRef="sqft">9747</amrn:NumberOfLeasableSquareFeet>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6322976_08C7B214-7267-4E54-BCA8-1C60C4FE0914_2001_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_09ACE5E6-C7C6-4B17-B4A5-9B85B91DA62B_2002_0" unitRef="iso4217_USD">3500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_08C7B214-7267-4E54-BCA8-1C60C4FE0914_2001_0" unitRef="iso4217_USD">118700000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_64964F01-29CC-48A2-B42A-C4865AD381E2_4001_1" unitRef="iso4217_USD">90800000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DeferredFinanceCostsGross contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_64964F01-29CC-48A2-B42A-C4865AD381E2_4001_3" unitRef="iso4217_USD">2500000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_96BD1B54-B670-4BA5-AB68-2FDA181C1F1E_1001_0" unitRef="iso4217_USD">27900000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865_1330096x1419380" decimals="2" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_6001_7" unitRef="iso4217_USD_per_shares">2.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_08C7B214-7267-4E54-BCA8-1C60C4FE0914_3001_4" unitRef="iso4217_USD">31300000</us-gaap:DebtInstrumentFaceAmount>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330097x1393080_1330125x1482162" decimals="INF" id="id_6322976_60F1AF73-1E22-447E-81D7-B829AE5F8696_2001_3" unitRef="iso4217_USD_per_shares">0.15</amrn:ConversionPricePerShare>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330097x1400959_1330125x1482162" decimals="INF" id="id_6322976_60F1AF73-1E22-447E-81D7-B829AE5F8696_3001_4" unitRef="iso4217_USD_per_shares">1.50</amrn:ConversionPricePerShare>
  <us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable contextRef="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330125x1482162" decimals="-5" id="id_6322976_25D5318D-B3F2-425A-838A-089551683DA0_4001_4" unitRef="iso4217_USD">5800000</us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330125x1482162" decimals="INF" id="id_6322976_60F1AF73-1E22-447E-81D7-B829AE5F8696_4001_2" unitRef="shares">3886718</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_1002_14" unitRef="iso4217_USD_per_shares">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_1002_13" unitRef="shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_2002_8" unitRef="iso4217_USD_per_shares">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_2002_7" unitRef="shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1328615x1330534_1330125x1468605" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_3002_11" unitRef="iso4217_USD_per_shares">0.90</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1330125x1468605_1333769x1451741" decimals="-5" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_8001_15" unitRef="shares">35200000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1610-K0013_STD_0_20091016_0_1330125x1468605_1333769x1451741_1335482x1328677" decimals="-5" id="id_6322976_42E10B2E-A6A2-4B44-8D86-6B5C51A0A3FE_1001_0" unitRef="shares">36100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <amrn:ClassOfWarrantOrRightCommonStockExchangeRatio contextRef="eol_PE46938---1610-K0013_STD_0_20091031_0_1330097x1403450_1330125x1468605" decimals="1" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_5002_5" unitRef="Point">0.5</amrn:ClassOfWarrantOrRightCommonStockExchangeRatio>
  <amrn:NumberOfLeasableSquareFeet contextRef="eol_PE46938---1610-K0013_STD_0_20110930_0_1410977x1363599" decimals="INF" id="id_6322976_3367C059-7BB1-4EC0-8B00-33F82E4332A5_2002_0" unitRef="sqft">320</amrn:NumberOfLeasableSquareFeet>
  <amrn:NumberOfLeasableSquareFeet contextRef="eol_PE46938---1610-K0013_STD_0_20131101_0_1410977x1363599" decimals="INF" id="id_6322976_3367C059-7BB1-4EC0-8B00-33F82E4332A5_1004_0" unitRef="sqft">270</amrn:NumberOfLeasableSquareFeet>
  <amrn:LeaseAgreementMonthlyPayment contextRef="eol_PE46938---1610-K0013_STD_0_20131101_0_1410977x1363599" decimals="0" id="id_6322976_3367C059-7BB1-4EC0-8B00-33F82E4332A5_1003_3" unitRef="iso4217_EUR">2900</amrn:LeaseAgreementMonthlyPayment>
  <amrn:LeaseAgreementMonthlyPayment contextRef="eol_PE46938---1610-K0013_STD_0_20131101_0_1410977x1363599" decimals="0" id="id_6322976_3367C059-7BB1-4EC0-8B00-33F82E4332A5_1004_3" unitRef="iso4217_USD">3100</amrn:LeaseAgreementMonthlyPayment>
  <amrn:PrivatePlacementIssuanceNumberOfTranches contextRef="eol_PE46938---1610-K0013_STD_0_20150630_0" decimals="INF" id="id_6322976_CB4EEAF8-2629-4D62-AD30-1EAB110AAABF_1_0" unitRef="Tranche">2</amrn:PrivatePlacementIssuanceNumberOfTranches>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20160831_0_1330097x1419380" decimals="3" id="id_6322976_08C25418-58F7-4A7A-907F-EB398EA80385_4001_3" unitRef="iso4217_USD_per_shares">2.679</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_5003_5" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_5003_4" unitRef="iso4217_USD">118700000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1486557_1328615x1333865" decimals="INF" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_8003_8" unitRef="pure">3.5</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1486557_1328615x1333865" decimals="INF" id="id_6322976_9C5EA559-9344-4180-877A-803988BE8DB7_3002_0" unitRef="iso4217_USD">0</us-gaap:SeniorLongTermNotes>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_8003_7" unitRef="iso4217_USD">31300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20121206_0_1333242x1356609" decimals="-5" id="id_6322976_1921279F-8565-462C-AF0C-56555E3481D6_2001_0" unitRef="iso4217_USD">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1610-K0013_STD_0_20121206_0_1333242x1356609" decimals="-5" id="id_6322976_6989EFA7-2ED1-44CB-B043-D648378A2922_2001_1" unitRef="iso4217_USD">150000000</us-gaap:OtherCommitment>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1610-K0013_STD_0_20121231_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_1002_0" unitRef="iso4217_USD">150000000</us-gaap:OtherCommitment>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1009_1200001" unitRef="iso4217_USD">-33856000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_2001_0" unitRef="iso4217_USD">1674000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3001_40" unitRef="iso4217_USD">191514000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1008_1100001" unitRef="iso4217_USD">-913870000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1006_900001" unitRef="iso4217_USD">738754000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1330220" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1003_600001" unitRef="shares">-20079</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1330220" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1003_1000001" unitRef="iso4217_USD">-217000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1002_500001" unitRef="shares">172691063</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_1002_800001" unitRef="iso4217_USD">141477000</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_1001_2" unitRef="iso4217_USD_per_shares">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3009_1200009" unitRef="iso4217_USD">-88448000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_1004_1" unitRef="iso4217_USD">7519000</us-gaap:DerivativeLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_1005_1" unitRef="iso4217_USD">7090000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_1003_0" unitRef="iso4217_USD">2487000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="-3" id="id_6322976_6A4079F6-9CC7-4B27-830B-CB3A91A893BA_2001_0" unitRef="iso4217_USD">85965000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2003_40" unitRef="iso4217_USD">119539000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_1001_2" unitRef="shares">2256000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_1003_1" unitRef="iso4217_USD">481000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_1001_1" unitRef="iso4217_USD">2207000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_1004_1" unitRef="iso4217_USD">792000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_1002_1" unitRef="iso4217_USD">3610000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3008_1100009" unitRef="iso4217_USD">-970234000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3006_900009" unitRef="iso4217_USD">738890000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1330220" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3003_600009" unitRef="shares">-20079</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1330220" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3003_1000009" unitRef="iso4217_USD">-217000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3002_500009" unitRef="shares">174610451</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_3002_800009" unitRef="iso4217_USD">143113000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330926x1327893" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_1002_1" unitRef="iso4217_USD">7400000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1330926x1451741" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_1001_1" unitRef="iso4217_USD">119000</us-gaap:DerivativeLiabilities>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20141231_0_1333769x1451741" decimals="INF" id="id_6322976_12AC26CD-35AD-453A-8100-2C49A5073DFF_1002_0" unitRef="shares">8087388</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_33" unitRef="shares">328184640</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_3001_6" unitRef="iso4217_USD_per_shares">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_41" unitRef="shares">174502</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_38" unitRef="shares">183403263</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1002_36" unitRef="iso4217_GBP_per_shares">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_37" unitRef="shares">183577765</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_32" unitRef="shares">328184640</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_2001_400001" unitRef="shares">17818000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_2001_1" unitRef="iso4217_USD_per_shares">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1002_31" unitRef="iso4217_GBP_per_shares">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-5" id="id_6322976_82DF7DED-D95A-423B-AF12-ED70CB1C46FC_2_0" unitRef="iso4217_USD">1400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_22" unitRef="iso4217_USD">136734000</us-gaap:SeniorLongTermNotes>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_42" unitRef="iso4217_USD">-1117654000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_30" unitRef="iso4217_USD">24364000</us-gaap:PreferredStockValue>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_26" unitRef="iso4217_USD">335000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LongTermDebtFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_733CA625-F48C-477B-9F8A-7D7C24CF622E_2_0" unitRef="iso4217_USD">87700000</us-gaap:LongTermDebtFairValue>
  <us-gaap:Liabilities contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_27" unitRef="iso4217_USD">300782000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_44" unitRef="iso4217_USD">173230000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_2_0" unitRef="iso4217_USD">5241000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_24" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_19" unitRef="iso4217_USD">923000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccruedMarketingCostsCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_2_2" unitRef="iso4217_USD">3141000</us-gaap:AccruedMarketingCostsCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_15" unitRef="iso4217_USD">10832000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_43" unitRef="iso4217_USD">-127552000</us-gaap:StockholdersEquity>
  <us-gaap:SeniorNotesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_17" unitRef="iso4217_USD">2266000</us-gaap:SeniorNotesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_23" unitRef="iso4217_USD">91512000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_3004_6" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilities>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_25" unitRef="iso4217_USD">13308000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_35" unitRef="iso4217_USD">149978000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_39" unitRef="iso4217_USD">816171000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_2_5" unitRef="iso4217_USD">754000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_3005_6" unitRef="iso4217_USD">15796000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_1002_0" unitRef="iso4217_USD">1550000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_2_4" unitRef="iso4217_USD">4284000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-5" id="id_6322976_27EA26E1-15BA-4CFE-BED3-2272FCF4FFC1_3_3" unitRef="iso4217_USD">11500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_28" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_16" unitRef="iso4217_USD">24226000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_18" unitRef="iso4217_USD">12476000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebt contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_A00EE401-47FD-4EC3-B5CB-84A7095C9A61_2_0" unitRef="iso4217_USD">91512000</us-gaap:LongTermDebt>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_20" unitRef="iso4217_USD">50723000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_7" unitRef="iso4217_USD">95999000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_7" unitRef="iso4217_USD">143524000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_5" unitRef="iso4217_USD">2796000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_FF91E523-634F-44E5-AF0A-0D812403EAD3_2_1" unitRef="iso4217_USD">1640000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_8" unitRef="iso4217_USD">243000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_2" unitRef="iso4217_USD">106961000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_1" unitRef="iso4217_USD">88996000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_4" unitRef="iso4217_USD">6030000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_12" unitRef="iso4217_USD">19872000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_9" unitRef="iso4217_USD">19872000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_5" unitRef="iso4217_USD">18985000</us-gaap:InventoryNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_4" unitRef="iso4217_USD">13826000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_2" unitRef="iso4217_USD">17975000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_2_4" unitRef="iso4217_USD">997000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_3" unitRef="iso4217_USD">600000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableGrossCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_2_0" unitRef="iso4217_USD">18270000</us-gaap:AccountsReceivableGrossCurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_12" unitRef="iso4217_USD">173230000</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_6" unitRef="iso4217_USD">115871000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_8" unitRef="iso4217_USD">19872000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_11" unitRef="iso4217_USD">9417000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_FF91E523-634F-44E5-AF0A-0D812403EAD3_2_0" unitRef="iso4217_USD">9096000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_FF91E523-634F-44E5-AF0A-0D812403EAD3_2_2" unitRef="iso4217_USD">8249000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_10" unitRef="iso4217_USD">174000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_6" unitRef="iso4217_USD">3152000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_40" unitRef="iso4217_USD">411000</us-gaap:TreasuryStockValue>
  <amrn:AccruedLiabilitiesSalesAllowancesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_2_3" unitRef="iso4217_USD">10732000</amrn:AccruedLiabilitiesSalesAllowancesCurrent>
  <amrn:DeferredTaxAssetsDepreciationAndAmortization contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_2_3" unitRef="iso4217_USD">74000</amrn:DeferredTaxAssetsDepreciationAndAmortization>
  <amrn:ResearchAndDevelopmentAccruedExpenseCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_2_1" unitRef="iso4217_USD">828000</amrn:ResearchAndDevelopmentAccruedExpenseCurrent>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_2_34" unitRef="shares">32818464</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1375482" decimals="-5" id="id_6322976_64964F01-29CC-48A2-B42A-C4865AD381E2_2002_6" unitRef="iso4217_USD">1800000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_64964F01-29CC-48A2-B42A-C4865AD381E2_3002_5" unitRef="iso4217_USD">-1800000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1486557" decimals="-5" id="id_6322976_BBC5E1E4-42F3-475A-93F5-D2336C3264D5_1002_4" unitRef="iso4217_USD">100000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_BBC5E1E4-42F3-475A-93F5-D2336C3264D5_2002_3" unitRef="iso4217_USD">-100000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1333245x1332467" decimals="-5" id="id_6322976_F8FC5159-F0B8-4E32-B501-9FA116009DBD_1001_1" unitRef="iso4217_USD">-1900000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1333245x1332467" decimals="-5" id="id_6322976_F8FC5159-F0B8-4E32-B501-9FA116009DBD_1001_0" unitRef="iso4217_USD">-1900000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_3001_6" unitRef="shares">10887000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_4002_0" unitRef="iso4217_USD">2100000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1002_4" unitRef="iso4217_USD">1900000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-3" id="id_6322976_733CA625-F48C-477B-9F8A-7D7C24CF622E_1002_2" unitRef="iso4217_USD">108034000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1002_0" unitRef="iso4217_USD">94600000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-3" id="id_6322976_A00EE401-47FD-4EC3-B5CB-84A7095C9A61_1002_2" unitRef="iso4217_USD">96364000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865_1333245x1345793" decimals="-5" id="id_6322976_70A93DB3-5167-42EF-8C55-B01E933A158C_2002_2" unitRef="iso4217_USD">24100000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_3003_5" unitRef="iso4217_USD">300000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6322976_733CA625-F48C-477B-9F8A-7D7C24CF622E_2002_1" unitRef="iso4217_USD">13637000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_3003_1" unitRef="iso4217_USD">15100000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6322976_A00EE401-47FD-4EC3-B5CB-84A7095C9A61_2002_1" unitRef="iso4217_USD">15107000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6322976_70A93DB3-5167-42EF-8C55-B01E933A158C_1002_0" unitRef="iso4217_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_5002_1" unitRef="iso4217_USD">600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1002_4" unitRef="iso4217_USD">100000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-3" id="id_6322976_733CA625-F48C-477B-9F8A-7D7C24CF622E_3002_3" unitRef="iso4217_USD">28448000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1002_0" unitRef="iso4217_USD">27000000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-3" id="id_6322976_A00EE401-47FD-4EC3-B5CB-84A7095C9A61_3002_3" unitRef="iso4217_USD">27134000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865_1333245x1345793" decimals="-5" id="id_6322976_70A93DB3-5167-42EF-8C55-B01E933A158C_4002_3" unitRef="iso4217_USD">4200000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324896x1324925_1331211x1328015" decimals="-3" id="id_6322976_3A8D39A1-FD2B-45A3-B74B-B14966B37867_4_3" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1324896x1327983_1331211x1328015" decimals="-3" id="id_6322976_3A8D39A1-FD2B-45A3-B74B-B14966B37867_2_1" unitRef="iso4217_USD">14184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1327036x1498782_1328480x1458944" decimals="-5" id="id_6322976_31BC1017-8868-41D8-8DA0-066C60F69DA5_1002_0" unitRef="iso4217_USD">2500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_3003_6" unitRef="iso4217_USD">535000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1327217" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_2002_1" unitRef="iso4217_USD">4296000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1366356" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_3002_2" unitRef="iso4217_USD">148000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_3004_6" unitRef="iso4217_USD">1084000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_3002_6" unitRef="iso4217_USD">9881000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1325837" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5001_400024" unitRef="shares">328184640</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1325837" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5001_700024" unitRef="iso4217_USD">24364000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1325837_1333245x1335616" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7001_400022" unitRef="shares">328184640</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1325837_1333245x1335616" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7001_700022" unitRef="iso4217_USD">24364000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5008_1100024" unitRef="iso4217_USD">-1117654000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1326044_1333245x1332387" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_6008_1100023" unitRef="iso4217_USD">1639000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1326044_1333245x1335616" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7008_1100022" unitRef="iso4217_USD">-1119293000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5006_900024" unitRef="iso4217_USD">816171000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1327190_1333245x1335616" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7006_900022" unitRef="iso4217_USD">816171000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1330220" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5003_600024" unitRef="shares">-174502</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1330220" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5003_1000024" unitRef="iso4217_USD">-411000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1330220_1333245x1335616" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7003_600022" unitRef="shares">-174502</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1330220_1333245x1335616" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7003_1000022" unitRef="iso4217_USD">-411000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5002_500024" unitRef="shares">183577765</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_5002_800024" unitRef="iso4217_USD">149978000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1333806_1333245x1335616" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7002_500022" unitRef="shares">183577765</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1333806_1333245x1335616" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7002_800022" unitRef="iso4217_USD">149978000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330926x1327893" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_3002_6" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_4001_7" unitRef="iso4217_USD">5500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1331211x1328015" decimals="-3" id="id_6322976_3A8D39A1-FD2B-45A3-B74B-B14966B37867_1_3" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1331211x1328015" decimals="-3" id="id_6322976_3A8D39A1-FD2B-45A3-B74B-B14966B37867_1_1" unitRef="iso4217_USD">14184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:LongTermDebt contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1333242x1356609" decimals="-5" id="id_6322976_683733D4-8948-4A17-B5B2-26E0DCD04D2B_3002_0" unitRef="iso4217_USD">91500000</us-gaap:LongTermDebt>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1333245x1332387" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_6009_1200023" unitRef="iso4217_USD">1639000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1333245x1335616" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_7009_1200022" unitRef="iso4217_USD">-129191000</us-gaap:StockholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1328146" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_1002_2" unitRef="iso4217_USD">240000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1331682" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_2002_0" unitRef="iso4217_USD">135000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1333816" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_3002_1" unitRef="iso4217_USD">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1335891" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_4002_3" unitRef="iso4217_USD">559000</us-gaap:PropertyPlantAndEquipmentGross>
  <amrn:NumberOfLeasableSquareFeet contextRef="eol_PE46938---1610-K0013_STD_0_20161215_0_1410977x1379917" decimals="INF" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_3002_0" unitRef="sqft">732</amrn:NumberOfLeasableSquareFeet>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_33" unitRef="shares">328184640</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_5001_10" unitRef="iso4217_USD_per_shares">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1001_8" unitRef="iso4217_USD_per_shares">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_41" unitRef="shares">819505</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_38" unitRef="shares">269363696</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_1001_400009" unitRef="shares">4304000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_1001_400008" unitRef="shares">20513000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1001_36" unitRef="iso4217_GBP_per_shares">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_37" unitRef="shares">270183201</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_32" unitRef="shares">328184640</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_90BE5ED4-D258-4854-8051-EFE13D675464_1001_1" unitRef="shares">10143176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_1001_400007" unitRef="shares">12217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1001_7" unitRef="iso4217_USD_per_shares">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_90BE5ED4-D258-4854-8051-EFE13D675464_1001_0" unitRef="shares">21188014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1001_6" unitRef="iso4217_USD_per_shares">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_0AC5B06E-B14F-4F41-9937-D7F4F158C725_1002_3" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1001_31" unitRef="iso4217_GBP_per_shares">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_82DF7DED-D95A-423B-AF12-ED70CB1C46FC_1_0" unitRef="iso4217_USD">1500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_42" unitRef="iso4217_USD">-1204004000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PurchaseObligation contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_C8813EE9-DDDF-4058-90B9-30561F4443BD_1_0" unitRef="iso4217_USD">44600000</us-gaap:PurchaseObligation>
  <us-gaap:PreferredStockValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_30" unitRef="iso4217_USD">24364000</us-gaap:PreferredStockValue>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_26" unitRef="iso4217_USD">710000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_54015BAD-E9F2-426F-B86F-D4126AB003E9_1001_2" unitRef="iso4217_USD">126000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_54015BAD-E9F2-426F-B86F-D4126AB003E9_1001_4" unitRef="iso4217_USD">654000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:LongTermDebtFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_733CA625-F48C-477B-9F8A-7D7C24CF622E_1_0" unitRef="iso4217_USD">90500000</us-gaap:LongTermDebtFairValue>
  <us-gaap:Liabilities contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_27" unitRef="iso4217_USD">176057000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_44" unitRef="iso4217_USD">166999000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_1_0" unitRef="iso4217_USD">6611000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_19" unitRef="iso4217_USD">1172000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_11" unitRef="iso4217_USD">1050000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:AccruedMarketingCostsCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_1_2" unitRef="iso4217_USD">2821000</us-gaap:AccruedMarketingCostsCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_15" unitRef="iso4217_USD">6062000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_43" unitRef="iso4217_USD">-9058000</us-gaap:StockholdersEquity>
  <us-gaap:SeniorNotesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_17" unitRef="iso4217_USD">15351000</us-gaap:SeniorNotesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_54015BAD-E9F2-426F-B86F-D4126AB003E9_1001_1" unitRef="iso4217_USD">528000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_23" unitRef="iso4217_USD">85155000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_25" unitRef="iso4217_USD">13943000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_83F7472A-6D2E-41A2-AEB5-3A48E9712AEA_1001_1" unitRef="iso4217_USD">15100000</us-gaap:DeferredRevenue>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_35" unitRef="iso4217_USD">207166000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_39" unitRef="iso4217_USD">964914000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_1_5" unitRef="iso4217_USD">755000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_5005_11" unitRef="iso4217_USD">27198000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_1001_5" unitRef="iso4217_USD">1633000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_6C54A6F1-3A2F-4549-9723-849CFCBCB726_1001_0" unitRef="iso4217_USD">25100000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_1_4" unitRef="iso4217_USD">5800000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8806C2A6-AC61-451D-BAC9-3F0D08A2930A_1001_2" unitRef="iso4217_USD">2852000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_27EA26E1-15BA-4CFE-BED3-2272FCF4FFC1_2_3" unitRef="iso4217_USD">11500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_28" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_16" unitRef="iso4217_USD">37720000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_18" unitRef="iso4217_USD">15944000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebt contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_A00EE401-47FD-4EC3-B5CB-84A7095C9A61_1_0" unitRef="iso4217_USD">85155000</us-gaap:LongTermDebt>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_20" unitRef="iso4217_USD">76249000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_7" unitRef="iso4217_USD">109274000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_7" unitRef="iso4217_USD">146326000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_5" unitRef="iso4217_USD">2437000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_FF91E523-634F-44E5-AF0A-0D812403EAD3_1_1" unitRef="iso4217_USD">10716000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_8" unitRef="iso4217_USD">78000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_ACBECB57-E24A-44E3-9A30-77391F7D0693_1001_2" unitRef="iso4217_USD">7159000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_2" unitRef="iso4217_USD">98251000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_1" unitRef="iso4217_USD">88345000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_4" unitRef="iso4217_USD">6893000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_12" unitRef="iso4217_USD">11082000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_9" unitRef="iso4217_USD">11082000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_7AB4542F-BD5F-446A-93C0-D1577BF3217B_1001_0" unitRef="iso4217_USD">11800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5847AA63-51E9-4875-9856-4B2876CE03B4_1001_0" unitRef="iso4217_USD">646000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5847AA63-51E9-4875-9856-4B2876CE03B4_1001_3" unitRef="iso4217_USD">646000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_5" unitRef="iso4217_USD">20507000</us-gaap:InventoryNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_ACBECB57-E24A-44E3-9A30-77391F7D0693_1001_3" unitRef="iso4217_USD">16396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_4" unitRef="iso4217_USD">19985000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:ConstructionInProgressGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_1_6" unitRef="iso4217_USD">12000</us-gaap:ConstructionInProgressGross>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_2" unitRef="iso4217_USD">23731000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_1_4" unitRef="iso4217_USD">821000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_3" unitRef="iso4217_USD">600000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableGrossCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_1_0" unitRef="iso4217_USD">24127000</us-gaap:AccountsReceivableGrossCurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_12" unitRef="iso4217_USD">166999000</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_6" unitRef="iso4217_USD">121406000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_8" unitRef="iso4217_USD">12132000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_11" unitRef="iso4217_USD">8772000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8806C2A6-AC61-451D-BAC9-3F0D08A2930A_1001_1" unitRef="iso4217_USD">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5847AA63-51E9-4875-9856-4B2876CE03B4_1001_5" unitRef="iso4217_USD">5542000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5847AA63-51E9-4875-9856-4B2876CE03B4_1001_4" unitRef="iso4217_USD">646000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5847AA63-51E9-4875-9856-4B2876CE03B4_1001_2" unitRef="iso4217_USD">646000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_5847AA63-51E9-4875-9856-4B2876CE03B4_1001_1" unitRef="iso4217_USD">646000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_FF91E523-634F-44E5-AF0A-0D812403EAD3_1_0" unitRef="iso4217_USD">4430000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_FF91E523-634F-44E5-AF0A-0D812403EAD3_1_2" unitRef="iso4217_USD">5361000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_10" unitRef="iso4217_USD">741000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_6" unitRef="iso4217_USD">6983000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_ACBECB57-E24A-44E3-9A30-77391F7D0693_1001_1" unitRef="iso4217_USD">17018000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_40" unitRef="iso4217_USD">1498000</us-gaap:TreasuryStockValue>
  <amrn:OperatingLeasesFutureMinimumPaymentsDueInThreeYearsAndThereafter contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_54015BAD-E9F2-426F-B86F-D4126AB003E9_1001_3" unitRef="iso4217_USD">0</amrn:OperatingLeasesFutureMinimumPaymentsDueInThreeYearsAndThereafter>
  <amrn:AccruedLiabilitiesSalesAllowancesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_1_3" unitRef="iso4217_USD">22195000</amrn:AccruedLiabilitiesSalesAllowancesCurrent>
  <amrn:ResearchAndDevelopmentAccruedExpenseCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_0E66D60D-7927-41CC-A2A9-F2C27A63D0B2_1_1" unitRef="iso4217_USD">293000</amrn:ResearchAndDevelopmentAccruedExpenseCurrent>
  <amrn:WriteOffsOfAccountsReceivables contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_F2ADEBEC-AEBD-4D73-8152-D322BA0670FE_3001_2" unitRef="iso4217_USD">0</amrn:WriteOffsOfAccountsReceivables>
  <amrn:DeferredTaxLiabilitiesDepreciationAndAmortization contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-3" id="id_6322976_8BE8FF90-0C31-4B8A-9540-BE291C9CC18B_1_10" unitRef="iso4217_USD">1050000</amrn:DeferredTaxLiabilitiesDepreciationAndAmortization>
  <amrn:DeferredTaxLiabilitiesSubjectToExpiration contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_FFBB9AB1-7988-4A46-BD2E-435FD95549D6_1_0" unitRef="iso4217_USD">59000</amrn:DeferredTaxLiabilitiesSubjectToExpiration>
  <amrn:DeferredTaxAssetsOperatingLossCarryforwardsChangeInAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_1_1" unitRef="iso4217_USD">8100000</amrn:DeferredTaxAssetsOperatingLossCarryforwardsChangeInAmount>
  <amrn:CashDiscountPercent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="2" id="id_6322976_03F545B9-751E-426F-A616-364E9AD33027_1001_0" unitRef="pure">0.02</amrn:CashDiscountPercent>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="INF" id="id_6322976_B6C15057-6381-427A-B10F-FDCF733A3CDB_1_34" unitRef="shares">32818464</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <amrn:ConvertibleDebtCarryingValueExchanged contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0" decimals="-5" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_5001_1" unitRef="iso4217_USD">127300000</amrn:ConvertibleDebtCarryingValueExchanged>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324093x1330362_1333245x1332387" decimals="-5" id="id_6322976_73DC0D25-139B-40FC-943D-FD3BD5032179_1001_0" unitRef="iso4217_USD">900000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324093x1330362_1333245x1332387" decimals="-5" id="id_6322976_73DC0D25-139B-40FC-943D-FD3BD5032179_1001_1" unitRef="iso4217_USD">900000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324093x1528669" decimals="-3" id="id_6322976_54C02A66-6CFD-4E96-9A43-0156861E1AC2_1002_1" unitRef="iso4217_USD">1639000</us-gaap:ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324093x1528669" decimals="-5" id="id_6322976_47E8988A-2C12-4A5E-82BD-84328C41C118_4001_1" unitRef="iso4217_USD">1600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324199x1331109" decimals="2" id="id_6322976_90BE5ED4-D258-4854-8051-EFE13D675464_2001_2" unitRef="pure">0.06</amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_5001_10" unitRef="shares">10143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324199x1335583" decimals="2" id="id_6322976_90BE5ED4-D258-4854-8051-EFE13D675464_3001_3" unitRef="pure">0.03</amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6322976_BA80F022-C0C2-4D83-9584-E3156E41437E_1001_0" unitRef="iso4217_USD">0</us-gaap:SeniorLongTermNotes>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1001_4" unitRef="iso4217_USD">0</us-gaap:InterestPayableCurrent>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1001_0" unitRef="iso4217_USD">0</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_6001_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:SeniorNotesCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_1003_2" unitRef="iso4217_USD">15100000</us-gaap:SeniorNotesCurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_3002_5" unitRef="iso4217_USD">200000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6322976_733CA625-F48C-477B-9F8A-7D7C24CF622E_2001_1" unitRef="iso4217_USD">15174000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_6001_3" unitRef="iso4217_USD">15100000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6322976_A00EE401-47FD-4EC3-B5CB-84A7095C9A61_2001_1" unitRef="iso4217_USD">15107000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6322976_70A93DB3-5167-42EF-8C55-B01E933A158C_1001_0" unitRef="iso4217_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
  <amrn:ExcessPrincipalValueOverFairValue contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_DB673CC7-A9B8-4CE0-B5F8-0EDFA5B35F2F_3002_5" unitRef="iso4217_USD">9800000</amrn:ExcessPrincipalValueOverFairValue>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1001_4" unitRef="iso4217_USD">0</us-gaap:InterestPayableCurrent>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1001_0" unitRef="iso4217_USD">0</us-gaap:ConvertibleDebt>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1324896x1327983_1331211x1328015" decimals="-3" id="id_6322976_428E1F29-1CE0-444D-8A7E-676A1E06D364_2_1" unitRef="iso4217_USD">14238000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1325224x1331049" decimals="-5" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_6001_2" unitRef="iso4217_USD">6700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1325224x1335913" decimals="-5" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_7001_3" unitRef="iso4217_USD">1600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1325224x1438374" decimals="-5" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_8001_0" unitRef="iso4217_USD">573800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1325804x1405848" decimals="INF" id="id_6322976_3DA04E20-6F12-4945-931F-6D13BA50A336_1001_1" unitRef="shares">31500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1326002x1332009_1330125x1468605" decimals="-5" id="id_6322976_66F187C9-77F0-44BB-AE53-1C88915316D5_2001_1" unitRef="shares">900000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327036x1498782_1328480x1458944" decimals="-5" id="id_6322976_31BC1017-8868-41D8-8DA0-066C60F69DA5_1001_0" unitRef="iso4217_USD">2500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1324134" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_1001_3" unitRef="iso4217_USD">12000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_5003_11" unitRef="iso4217_USD">859000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1327217" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_2001_1" unitRef="iso4217_USD">3743000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1366356" decimals="-3" id="id_6322976_B5ADF582-13F2-42B3-9D5A-CE0B1BDB61F6_3001_2" unitRef="iso4217_USD">387000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_5004_11" unitRef="iso4217_USD">1681000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_5002_11" unitRef="iso4217_USD">20915000</us-gaap:ValuationAllowancesAndReservesBalance>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330096x1433040" decimals="INF" id="id_6322976_CE75DCA9-E1F7-487F-A995-E4421024247A_5002_5" unitRef="shares">32818464</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1325837" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12001_400033" unitRef="shares">328184640</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1325837" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12001_700033" unitRef="iso4217_USD">24364000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12008_1100033" unitRef="iso4217_USD">-1204004000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12006_900033" unitRef="iso4217_USD">964914000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1330220" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12003_600033" unitRef="shares">-819505</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1330220" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12003_1000033" unitRef="iso4217_USD">-1498000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12002_500033" unitRef="shares">270183201</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_12002_800033" unitRef="iso4217_USD">207166000</us-gaap:StockholdersEquity>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1400959" decimals="INF" id="id_6322976_5E4107FA-A547-4EC6-BD7B-F2A09C60FDD4_2001_0" unitRef="iso4217_USD_per_shares">1.50</amrn:ConversionPricePerShare>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330125x1468605_1330926x1336129" decimals="INF" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_7003_6" unitRef="iso4217_USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330125x1468605_1330926x1336129" decimals="-6" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_7003_7" unitRef="iso4217_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_4003_7" unitRef="iso4217_USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1331211x1328015" decimals="-3" id="id_6322976_428E1F29-1CE0-444D-8A7E-676A1E06D364_1_1" unitRef="iso4217_USD">14238000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609" decimals="-5" id="id_6322976_840F4586-0A15-4B21-837A-732A09F163FD_2001_0" unitRef="iso4217_USD">125600000</us-gaap:OtherCommitment>
  <us-gaap:LongTermDebt contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609" decimals="-5" id="id_6322976_683733D4-8948-4A17-B5B2-26E0DCD04D2B_3001_0" unitRef="iso4217_USD">93600000</us-gaap:LongTermDebt>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609_1367440x1347115" decimals="-5" id="id_6322976_840F4586-0A15-4B21-837A-732A09F163FD_3001_2" unitRef="iso4217_USD">3800000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609_1367440x1517729" decimals="-5" id="id_6322976_D9FBB891-DCBD-4086-871A-9C9066D41E1B_1001_0" unitRef="iso4217_USD">13000000</amrn:FutureMinimumGuaranteePayments>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1335482x1328677" decimals="INF" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_1002_3" unitRef="iso4217_GBP">10000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1335482x1328677" decimals="-5" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_1001_3" unitRef="iso4217_USD">12300000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1364380" decimals="INF" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_2002_2" unitRef="iso4217_GBP">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1364380" decimals="-5" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_2001_2" unitRef="iso4217_USD">6200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1410232" decimals="INF" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_3002_0" unitRef="iso4217_GBP">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1410232" decimals="-5" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_3001_0" unitRef="iso4217_USD">9300000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1493724" decimals="INF" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_4002_1" unitRef="iso4217_GBP">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1493724" decimals="-5" id="id_6322976_55810C59-468F-4306-8DB6-FB2F00861EF6_4001_1" unitRef="iso4217_USD">6200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1333769x1451741" decimals="INF" id="id_6322976_6592E058-F868-4A60-8E6C-14C2EAD82460_2002_4" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1328146" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_1001_2" unitRef="iso4217_USD">42000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1331682" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_2001_0" unitRef="iso4217_USD">157000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1333816" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_3001_1" unitRef="iso4217_USD">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1335891" decimals="-3" id="id_6322976_F5D7814B-14F1-4AF2-B8AA-F0A481FF0B6E_4001_3" unitRef="iso4217_USD">559000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ConvertibleDebtCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_71931D4D-320A-43F5-AEDA-3A7AD090AA7D_1001_0" unitRef="iso4217_USD">100000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1461424_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_7002_11" unitRef="iso4217_USD">100000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1461424_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_7002_10" unitRef="iso4217_USD">15000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134" decimals="2" id="id_6322976_A34973B0-1674-4D59-976C-048CDF0D6CB8_3002_3" unitRef="iso4217_USD_per_shares">2.88</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_9002_13" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_9002_12" unitRef="iso4217_USD">30000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-K0013_STD_0_20170120_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134" decimals="2" id="id_6322976_A34973B0-1674-4D59-976C-048CDF0D6CB8_3001_1" unitRef="iso4217_USD_per_shares">3.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-K0013_STD_0_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_F7E2D7FC-2ACF-47F4-8E31-F7D408CAA7DF_2001_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-K0013_STD_0_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_F7E2D7FC-2ACF-47F4-8E31-F7D408CAA7DF_2001_0" unitRef="iso4217_USD">30000000</us-gaap:DebtInstrumentFaceAmount>
  <amrn:AdditionalSquareFeetLeased contextRef="eol_PE46938---1610-K0013_STD_1_20130508_0_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2006_2" unitRef="sqft">10883</amrn:AdditionalSquareFeetLeased>
  <amrn:SquareFeetVacated contextRef="eol_PE46938---1610-K0013_STD_1_20140131_0_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2007_4" unitRef="sqft">2142</amrn:SquareFeetVacated>
  <amrn:SquareFeetSubleasedToThirdParty contextRef="eol_PE46938---1610-K0013_STD_1_20150131_0_1325894x1383385_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_1009_3" unitRef="sqft">4700</amrn:SquareFeetSubleasedToThirdParty>
  <amrn:LicensingAgreementTerm contextRef="eol_PE46938---1610-K0013_STD_1_20150226_0_1512983x1440366" id="id_6322976_518D511C-1A21-4F22-9A98-C0CAEAA59F1E_2001_1">P16Y</amrn:LicensingAgreementTerm>
  <amrn:NonRefundableUpfrontPaymentsReceived contextRef="eol_PE46938---1610-K0013_STD_1_20150226_0_1512983x1440366" decimals="-5" id="id_6322976_518D511C-1A21-4F22-9A98-C0CAEAA59F1E_2001_0" unitRef="iso4217_USD">15000000</amrn:NonRefundableUpfrontPaymentsReceived>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20160201_0_1324199x1331109_1325804x1405848" id="id_6322976_3D42530A-C224-402A-9DD8-71CE7934871D_1001_3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20160201_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6322976_3D42530A-C224-402A-9DD8-71CE7934871D_1001_1" unitRef="shares">2442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20160201_0_1324199x1335583_1325804x1405848" id="id_6322976_3D42530A-C224-402A-9DD8-71CE7934871D_2001_2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20160201_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6322976_3D42530A-C224-402A-9DD8-71CE7934871D_2001_0" unitRef="shares">1607500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <amrn:SquareFeetVacated contextRef="eol_PE46938---1610-K0013_STD_1_20140430_0_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2008_4" unitRef="sqft">2000</amrn:SquareFeetVacated>
  <amrn:PrivatePlacementClosingDate contextRef="eol_PE46938---1610-K0013_STD_1_20150305_0" id="id_6322976_DF1B9592-DEF9-4DCC-86C2-ACC6D377F1FD_1_3">2015-03-30</amrn:PrivatePlacementClosingDate>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1330097x1419380" decimals="INF" id="id_6322976_DF1B9592-DEF9-4DCC-86C2-ACC6D377F1FD_2001_0" unitRef="shares">352150790</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1330097x1419380" decimals="-5" id="id_6322976_DF1B9592-DEF9-4DCC-86C2-ACC6D377F1FD_2001_4" unitRef="iso4217_USD">52800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <amrn:BeneficialOwnershipLimitationPercentage contextRef="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1335482x1328677" decimals="INF" id="id_6322976_CE75DCA9-E1F7-487F-A995-E4421024247A_1001_2" unitRef="pure">0.199</amrn:BeneficialOwnershipLimitationPercentage>
  <amrn:BeneficialOwnershipLimitationPercentage contextRef="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1335482x1331874" decimals="INF" id="id_6322976_CE75DCA9-E1F7-487F-A995-E4421024247A_2001_1" unitRef="pure">0.0499</amrn:BeneficialOwnershipLimitationPercentage>
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="eol_PE46938---1610-K0013_STD_1_20150305_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6322976_34611778-5D87-472B-8002-26FE1E9E6F41_1001_1" unitRef="iso4217_USD">-900000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_1_20150330_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6322976_34611778-5D87-472B-8002-26FE1E9E6F41_1003_2" unitRef="iso4217_USD">1800000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <amrn:DeferredRevenueRecognitionPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20160308_0_1512983x1543436" id="id_6322976_FA532C1B-1356-4659-B4DF-E4C3926924CE_1001_0">P10Y</amrn:DeferredRevenueRecognitionPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_1001_1" unitRef="shares">5470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098" decimals="INF" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_1001_1" unitRef="shares">288657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1454011" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_2001_5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1454011" decimals="INF" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_2001_3" unitRef="shares">121506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1487759" decimals="INF" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_3001_7" unitRef="shares">167151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1336123x1429469" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_2001_4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1336123x1429469" decimals="INF" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_2001_3" unitRef="shares">3670000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_3001_2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_3001_0" unitRef="shares">1455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098" decimals="INF" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_4001_0" unitRef="shares">413500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1454011" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_5001_4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1454011" decimals="INF" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_5001_2" unitRef="shares">283500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1487759" decimals="INF" id="id_6322976_66E76560-2E80-4F03-A350-938697CF04FF_6001_6" unitRef="shares">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1456480_1325804x1405848_1336123x1425353" decimals="INF" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_5001_5" unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20150710_0_1330096x1335797_1330097x1403450_1330125x1482162" decimals="INF" id="id_6322976_25D5318D-B3F2-425A-838A-089551683DA0_1001_0" unitRef="shares">38867180</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20150710_0_1330096x1335797_1330097x1419380_1330125x1482162" decimals="INF" id="id_6322976_60F1AF73-1E22-447E-81D7-B829AE5F8696_1001_1" unitRef="shares">38867180</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20150710_0_1330096x1335797_1330097x1419380_1330125x1482162" decimals="-5" id="id_6322976_60F1AF73-1E22-447E-81D7-B829AE5F8696_1001_0" unitRef="iso4217_USD">5800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20160711_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6322976_52497088-76B7-4A0B-A6E4-676A38CD9F38_1001_1" unitRef="shares">208340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20160711_0_1324199x1335583_1325804x1405848" id="id_6322976_52497088-76B7-4A0B-A6E4-676A38CD9F38_2001_2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20160711_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6322976_52497088-76B7-4A0B-A6E4-676A38CD9F38_2001_0" unitRef="shares">148403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_1001_12">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_2001_6">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1328615x1330534_1330125x1468605" decimals="-5" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_3001_9" unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1328615x1330534_1330125x1468605" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_3001_10" unitRef="pure">1</amrn:AmericanDepositorySharesToSharesRatio>
  <amrn:ValueOfBridgeNotesConvertedIntoCommonStock contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1328615x1330534_1330125x1468605" decimals="-5" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_3001_2" unitRef="iso4217_USD">3600000</amrn:ValueOfBridgeNotesConvertedIntoCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1330125x1468605" decimals="-5" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_4001_3" unitRef="shares">66400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1330125x1468605" decimals="-5" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_4001_1" unitRef="iso4217_USD">62300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1330125x1468605" decimals="-5" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_4001_0" unitRef="iso4217_USD">70000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1330125x1468605" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_4001_4" unitRef="pure">1</amrn:AmericanDepositorySharesToSharesRatio>
  <amrn:EquityIssuancePerShareAmount1 contextRef="eol_PE46938---1610-K0013_STD_1_20091016_0_1330125x1468605" decimals="INF" id="id_6322976_C4E70A13-B9B2-4A7C-871F-FF834151BE10_4001_5" unitRef="iso4217_USD_per_shares">1.00</amrn:EquityIssuancePerShareAmount1>
  <amrn:SquareFeetSubleasedToThirdParty contextRef="eol_PE46938---1610-K0013_STD_1_20150630_0_1325894x1383385_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_1010_3" unitRef="sqft">2500</amrn:SquareFeetSubleasedToThirdParty>
  <amrn:AdditionalSquareFeetLeased contextRef="eol_PE46938---1610-K0013_STD_1_20111206_0_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2004_2" unitRef="sqft">2142</amrn:AdditionalSquareFeetLeased>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE46938---1610-K0013_STD_1_20121206_0_1333242x1356609" decimals="-5" id="id_6322976_6989EFA7-2ED1-44CB-B043-D648378A2922_1001_0" unitRef="iso4217_USD">100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <amrn:AdditionalSquareFeetLeased contextRef="eol_PE46938---1610-K0013_STD_1_20121215_0_1410977x1379917" decimals="0" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2005_2" unitRef="sqft">2601</amrn:AdditionalSquareFeetLeased>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1331109_1325804x1405848" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_1001_3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_1001_1" unitRef="shares">1622500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1335583_1325804x1405848" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_2001_2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_2001_0" unitRef="shares">2564251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1423313_1325804x1405848" decimals="INF" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_4001_4" unitRef="shares">5455500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-K0013_STD_1_20170119_0_1324529x1461424_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_E769C2A1-FE68-4B8D-94A3-D7CDD6EB1BEC_1001_0" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_1_20170119_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_4002_14">2047</amrn:DebtInstrumentMaturityDateYear>
  <amrn:DebtInstrumentConvertiblePremiumOnConversionPricePercentage contextRef="eol_PE46938---1610-K0013_STD_1_20170119_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="2" id="id_6322976_A34973B0-1674-4D59-976C-048CDF0D6CB8_2002_2" unitRef="pure">0.35</amrn:DebtInstrumentConvertiblePremiumOnConversionPricePercentage>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1461424_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_DE3C4B16-D3CE-4A83-82CF-E902DD5CBAE7_1001_1" unitRef="iso4217_USD">15000000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134" decimals="INF" id="id_6322976_A34973B0-1674-4D59-976C-048CDF0D6CB8_1001_4" unitRef="pure">7716048</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134" decimals="4" id="id_6322976_A34973B0-1674-4D59-976C-048CDF0D6CB8_1001_0" unitRef="pure">257.2016</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_DDCF90EF-D691-469E-8E01-FF5F8D006AF9_1001_1">2017-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentRedemptionPeriodEndDate contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_94B4C251-30B3-49D5-9477-AB24F560FC33_1001_0">2047-01-15</us-gaap:DebtInstrumentRedemptionPeriodEndDate>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_94B4C251-30B3-49D5-9477-AB24F560FC33_1001_2">P20D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_DDCF90EF-D691-469E-8E01-FF5F8D006AF9_1001_0">Payable semi-annually in arrears on January 15 and  July 15 of each year, beginning on July 15, 2017</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_F7E2D7FC-2ACF-47F4-8E31-F7D408CAA7DF_1001_3" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_94B4C251-30B3-49D5-9477-AB24F560FC33_1001_3" unitRef="D">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_DDCF90EF-D691-469E-8E01-FF5F8D006AF9_1001_2">2047-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="INF" id="id_6322976_94B4C251-30B3-49D5-9477-AB24F560FC33_1001_1" unitRef="pure">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" decimals="-5" id="id_6322976_DE3C4B16-D3CE-4A83-82CF-E902DD5CBAE7_2001_0" unitRef="iso4217_USD">28900000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134" id="id_6322976_F7E2D7FC-2ACF-47F4-8E31-F7D408CAA7DF_1001_2">2047</amrn:DebtInstrumentMaturityDateYear>
  <amrn:LicensingAgreementTerm contextRef="eol_PE46938---1610-K0013_STD_23_20160331_0_1333954x1528901_1512983x1440366" id="id_6322976_518D511C-1A21-4F22-9A98-C0CAEAA59F1E_1003_3">P4Y</amrn:LicensingAgreementTerm>
  <amrn:NonrefundableMilestonePayment contextRef="eol_PE46938---1610-K0013_STD_23_20160331_0_1333954x1528901_1512983x1440366" decimals="-5" id="id_6322976_518D511C-1A21-4F22-9A98-C0CAEAA59F1E_1003_2" unitRef="iso4217_USD">1000000</amrn:NonrefundableMilestonePayment>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_CAA30D32-129B-4270-9878-6EAB2F874F85_1001_4" unitRef="iso4217_USD">15900000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_CAA30D32-129B-4270-9878-6EAB2F874F85_2001_0" unitRef="iso4217_USD">31300000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_CAA30D32-129B-4270-9878-6EAB2F874F85_2001_3" unitRef="iso4217_USD">27500000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865" id="id_6322976_CAA30D32-129B-4270-9878-6EAB2F874F85_2001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865_1330096x1419380" decimals="INF" id="id_6322976_9C5EA559-9344-4180-877A-803988BE8DB7_1001_2" unitRef="shares">12025385</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865_1330096x1419380" decimals="4" id="id_6322976_9C5EA559-9344-4180-877A-803988BE8DB7_1001_1" unitRef="pure">384.6154</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380" decimals="-3" id="id_6322976_08C25418-58F7-4A7A-907F-EB398EA80385_1001_4" unitRef="iso4217_USD">64613000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <amrn:PublicOfferingOverAllotmentOptionExercisePeriod contextRef="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380" id="id_6322976_08C25418-58F7-4A7A-907F-EB398EA80385_1001_1">P30D</amrn:PublicOfferingOverAllotmentOptionExercisePeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380_1330125x1328958" decimals="INF" id="id_6322976_08C25418-58F7-4A7A-907F-EB398EA80385_2001_2" unitRef="shares">3165000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380_1330125x1334812" decimals="INF" id="id_6322976_08C25418-58F7-4A7A-907F-EB398EA80385_3001_0" unitRef="shares">21100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_BA80F022-C0C2-4D83-9584-E3156E41437E_1002_1" unitRef="iso4217_USD">118700000</us-gaap:DebtConversionOriginalDebtAmount1>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1375482_1328615x1333865" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_1003_6">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1375482_1328615x1333865_1330096x1419380" decimals="INF" id="id_6322976_4AC35609-3A40-4083-9CC4-CA097668D02B_2001_2" unitRef="shares">47739925</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_4AC35609-3A40-4083-9CC4-CA097668D02B_3001_1" unitRef="iso4217_USD">31300000</us-gaap:DebtConversionOriginalDebtAmount1>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1486557_1328615x1333865" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_3003_9">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1486557_1328615x1333865_1330096x1419380" decimals="INF" id="id_6322976_4AC35609-3A40-4083-9CC4-CA097668D02B_4001_3" unitRef="shares">12571263</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6322976_DB673CC7-A9B8-4CE0-B5F8-0EDFA5B35F2F_1001_3">2012-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6322976_E4B52057-6666-4C3B-948E-6C170FC8319C_1001_0" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6322976_DB673CC7-A9B8-4CE0-B5F8-0EDFA5B35F2F_1001_4">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6322976_70A93DB3-5167-42EF-8C55-B01E933A158C_1003_1">P24M</us-gaap:DebtInstrumentTerm>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_05D3E617-F753-49FC-9596-44B33AA14A0C_1001_0" unitRef="iso4217_USD">144300000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6322976_503AFAAF-7832-481D-99FC-19AF31EF79E5_1001_3">2032</amrn:DebtInstrumentMaturityDateYear>
  <amrn:AdditionalPercentageInterestRatePenalty contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865" decimals="4" id="id_6322976_F9EB896D-CF79-4842-B758-145FD3BB6965_1001_0" unitRef="pure">0.0050</amrn:AdditionalPercentageInterestRatePenalty>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865_1330096x1419380" decimals="4" id="id_6322976_DB673CC7-A9B8-4CE0-B5F8-0EDFA5B35F2F_2001_0" unitRef="pure">113.4752</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6322976_7C040AA2-60E6-490B-A339-6200DF43959B_1001_0">2014-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentRedemptionPeriodEndDate contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_1001_0">2032-01-15</us-gaap:DebtInstrumentRedemptionPeriodEndDate>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6322976_7C040AA2-60E6-490B-A339-6200DF43959B_1001_2" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_1001_3" unitRef="D">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6322976_7C040AA2-60E6-490B-A339-6200DF43959B_1001_1">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_64964F01-29CC-48A2-B42A-C4865AD381E2_1001_4" unitRef="iso4217_USD">38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_08C7B214-7267-4E54-BCA8-1C60C4FE0914_1001_3" unitRef="iso4217_USD">118700000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_64964F01-29CC-48A2-B42A-C4865AD381E2_1001_0" unitRef="iso4217_USD">-10100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6322976_08C7B214-7267-4E54-BCA8-1C60C4FE0914_1001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865_1330096x1419380" decimals="INF" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_2001_5" unitRef="shares">45666925</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865_1330096x1419380" decimals="4" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_2001_6" unitRef="pure">384.6154</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865_1335482x1331874" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_4001_2">P20D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865_1335482x1331874" decimals="INF" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_4001_1" unitRef="pure">1.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1383080_1330097x1403450_1330125x1468605" decimals="-6" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_1001_1" unitRef="shares">17000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1395733_1330097x1403450_1330125x1468605" decimals="-6" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_2001_2" unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1477553_1330097x1403450_1330125x1468605" decimals="-6" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_3001_4" unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1482069_1330097x1403450_1330125x1468605" decimals="-6" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_4001_3" unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_31_20091031_0_1330097x1403450_1330125x1468605" decimals="-5" id="id_6322976_93D151BC-B712-4328-B47E-721C9FDA865A_5001_0" unitRef="shares">36000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-K0013_STD_31_20161231_0_1324529x1461424_1328615x1333865_1330096x1419380" decimals="INF" id="id_6322976_DB673CC7-A9B8-4CE0-B5F8-0EDFA5B35F2F_2002_1" unitRef="shares">1714270</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="2" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_23" unitRef="iso4217_USD_per_shares">-0.36</us-gaap:EarningsPerShareDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_22" unitRef="iso4217_USD">-74608000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_3_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="2" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_3_5" unitRef="pure">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_26" unitRef="shares">173824000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_25" unitRef="shares">173719000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_3_2" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="2" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_3_4" unitRef="pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_3_0" unitRef="pure">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="2" id="id_6322976_37500BE5-5551-4C39-8C83-762C887B3B3F_3_0" unitRef="iso4217_USD_per_shares">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="2" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_22" unitRef="iso4217_USD_per_shares">-0.32</us-gaap:EarningsPerShareBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_3_1" unitRef="pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_709985C8-7353-4131-98D3-2FABEFB626CE_3_9" unitRef="shares">105000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_8" unitRef="iso4217_USD">-3034000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-5" id="id_6322976_37500BE5-5551-4C39-8C83-762C887B3B3F_3_1" unitRef="iso4217_USD">8100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_2" unitRef="iso4217_USD">54202000</us-gaap:Revenues>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_37" unitRef="iso4217_USD">36000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_17" unitRef="iso4217_USD">-4014000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_11" unitRef="iso4217_USD">38034000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4009_1200004" unitRef="iso4217_USD">-10100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_0" unitRef="iso4217_USD">54202000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_9" unitRef="iso4217_USD">-95955000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_17" unitRef="iso4217_USD">-56364000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_44" unitRef="iso4217_USD">10033000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_15" unitRef="iso4217_USD">-12958000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_14" unitRef="iso4217_USD">4197000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4009_1200006" unitRef="iso4217_USD">9022000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_3_3" unitRef="iso4217_USD">1067000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_33" unitRef="iso4217_USD">2480000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_13" unitRef="iso4217_USD">96000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_5" unitRef="iso4217_USD">1455000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_45" unitRef="iso4217_USD">781000</us-gaap:IncomeTaxesPaid>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_4" unitRef="iso4217_USD">33717000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_10" unitRef="iso4217_USD">13472000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4009_1200003" unitRef="iso4217_USD">307000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_14" unitRef="iso4217_USD">3727000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_20" unitRef="iso4217_USD">-56364000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_709985C8-7353-4131-98D3-2FABEFB626CE_3_6" unitRef="iso4217_USD">-63139000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_16" unitRef="iso4217_USD">1053000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_52D94783-3F82-40A8-827F-7E9F6E3F1961_3_0" unitRef="iso4217_USD">-7331000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_15" unitRef="iso4217_USD">-59201000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_709985C8-7353-4131-98D3-2FABEFB626CE_3_5" unitRef="iso4217_USD">-6775000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_5" unitRef="iso4217_USD">-3689000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_12" unitRef="iso4217_USD">-3614000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_6" unitRef="iso4217_USD">-226000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-5" id="id_6322976_40C3AD7F-B458-4952-BEE9-A9D1C610B067_3_0" unitRef="iso4217_USD">200000</us-gaap:Depreciation>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_16" unitRef="iso4217_USD">-2837000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_6" unitRef="iso4217_USD">10026000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_12" unitRef="iso4217_USD">18575000</us-gaap:InterestExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_6" unitRef="iso4217_USD">9022000</us-gaap:ShareBasedCompensation>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_3_4" unitRef="iso4217_USD">254000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4009_1200005" unitRef="iso4217_USD">2299000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_1" unitRef="iso4217_USD">660000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_3" unitRef="iso4217_USD">777000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="INF" id="id_6322976_287BE393-751E-4110-B26F-5D52DAB6627B_3_0" unitRef="iso4217_USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_3" unitRef="iso4217_USD">198000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_0" unitRef="iso4217_USD">-14786000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_19" unitRef="iso4217_USD">-1703000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-5" id="id_6322976_504D38E8-6F3B-4970-8011-3343130C7833_3_0" unitRef="iso4217_USD">1400000</us-gaap:RestrictedStockExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_6" unitRef="iso4217_USD">79346000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_8" unitRef="iso4217_USD">5863000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_8" unitRef="iso4217_USD">1073000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_20" unitRef="iso4217_USD">8811000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_18" unitRef="iso4217_USD">2420000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_38" unitRef="iso4217_USD">2633000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-5" id="id_6322976_6F037D03-4730-48BF-AF7E-194F340C34E8_3_0" unitRef="iso4217_USD">1000000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_30" unitRef="iso4217_USD">1651000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_7" unitRef="iso4217_USD">50326000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-5" id="id_6322976_B35970DA-6B46-4132-82DB-C64604549BDF_3_2" unitRef="iso4217_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_9" unitRef="iso4217_USD">646000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_39" unitRef="iso4217_USD">-71975000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_3" unitRef="iso4217_USD">20485000</us-gaap:CostOfGoodsSold>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_2" unitRef="iso4217_USD">117000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_3_7" unitRef="iso4217_USD">3335000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_1" unitRef="iso4217_USD">9493000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_2" unitRef="iso4217_USD">-3034000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_3_8" unitRef="iso4217_USD">129672000</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_31" unitRef="iso4217_USD">307000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-5" id="id_6322976_19EDCCB5-CFF5-44D9-A02D-AA11EC0A53E6_3_0" unitRef="iso4217_USD">7700000</us-gaap:StockOptionPlanExpense>
  <amrn:IncomeTaxReconciliationDerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_3" unitRef="iso4217_USD">-2706000</amrn:IncomeTaxReconciliationDerivativeLiabilities>
  <amrn:RepurchaseOfConversionOptionsOnLongTermDebt contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_51" unitRef="iso4217_USD">10100000</amrn:RepurchaseOfConversionOptionsOnLongTermDebt>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4009_1200002" unitRef="iso4217_USD">1651000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_4" unitRef="iso4217_USD">-9509000</amrn:IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt>
  <amrn:ProceedsFromRefundOfStockIssuanceCosts contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_3_32" unitRef="iso4217_USD">3191000</amrn:ProceedsFromRefundOfStockIssuanceCosts>
  <amrn:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsRefund contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4009_1200007" unitRef="iso4217_USD">3191000</amrn:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsRefund>
  <amrn:IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_3_7" unitRef="iso4217_USD">8061000</amrn:IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1324093x1528669_1333245x1332387" decimals="-5" id="id_6322976_47E8988A-2C12-4A5E-82BD-84328C41C118_2004_3" unitRef="iso4217_USD">2300000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1324093x1528669_1333245x1335616" decimals="-5" id="id_6322976_47E8988A-2C12-4A5E-82BD-84328C41C118_3004_2" unitRef="iso4217_USD">-2300000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1325224x1325185" decimals="2" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_1003_2" unitRef="pure">0.25</amrn:StatutoryTaxRate>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1325224x1325185_1328480x1515093" decimals="3" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_2003_3" unitRef="pure">0.125</amrn:StatutoryTaxRate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1328615x1333865" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_1003_2" unitRef="shares">49215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4008_1100008" unitRef="iso4217_USD">-56364000</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4006_900004" unitRef="iso4217_USD">-10100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4006_900006" unitRef="iso4217_USD">9022000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4006_900003" unitRef="iso4217_USD">114000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4006_900005" unitRef="iso4217_USD">2299000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4006_900002" unitRef="iso4217_USD">208000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsRefund contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4006_900007" unitRef="iso4217_USD">3191000</amrn:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsRefund>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4002_500003" unitRef="shares">234500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4002_800003" unitRef="iso4217_USD">193000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4002_500002" unitRef="shares">1684888</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_4002_800002" unitRef="iso4217_USD">1443000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1330098x1389060" decimals="-3" id="id_6322976_52D94783-3F82-40A8-827F-7E9F6E3F1961_1003_1" unitRef="iso4217_USD">-51870000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <amrn:ShareBasedCompensationNet contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1331645x1336129" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1003_7" unitRef="iso4217_USD">-503000</amrn:ShareBasedCompensationNet>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1333589x1330112" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_2003_0" unitRef="shares">10670000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1333589x1335583" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_3003_1" unitRef="shares">2256000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1334666x1326228" decimals="-3" id="id_6322976_8F7F819C-6050-40AD-820B-DAE744F02E7F_1003_1" unitRef="iso4217_USD">6321000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20141231_0_1334666x1332399" decimals="-3" id="id_6322976_8F7F819C-6050-40AD-820B-DAE744F02E7F_2003_0" unitRef="iso4217_USD">2701000</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_23" unitRef="iso4217_USD_per_shares">-0.83</us-gaap:EarningsPerShareDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_22" unitRef="iso4217_USD">-84021000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_2_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_2_5" unitRef="pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_26" unitRef="shares">180654000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_25" unitRef="shares">180654000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_2_2" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_2_4" unitRef="pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_2_0" unitRef="pure">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_37500BE5-5551-4C39-8C83-762C887B3B3F_2_0" unitRef="iso4217_USD_per_shares">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_22" unitRef="iso4217_USD_per_shares">-0.83</us-gaap:EarningsPerShareBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_4001_5" unitRef="iso4217_USD_per_shares">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_4001_3" unitRef="iso4217_USD_per_shares">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_2_1" unitRef="pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="INF" id="id_6322976_4AA8173D-CCAE-4FC9-8028-5ADF7E2CDA97_2_0" unitRef="shares">18020</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_4001_4" unitRef="iso4217_USD_per_shares">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_8" unitRef="iso4217_USD">8719000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4005_2" unitRef="iso4217_USD">56229000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_6A4079F6-9CC7-4B27-830B-CB3A91A893BA_2_1" unitRef="iso4217_USD">16291000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200017" unitRef="iso4217_USD">-194000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-5" id="id_6322976_37500BE5-5551-4C39-8C83-762C887B3B3F_2_1" unitRef="iso4217_USD">9100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_2" unitRef="iso4217_USD">81756000</us-gaap:Revenues>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_37" unitRef="iso4217_USD">5000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_24" unitRef="iso4217_USD">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_17" unitRef="iso4217_USD">-431000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_11" unitRef="iso4217_USD">1314000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200018" unitRef="iso4217_USD">-1300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200012" unitRef="iso4217_USD">-187000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_0" unitRef="iso4217_USD">80987000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_9" unitRef="iso4217_USD">-98222000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_17" unitRef="iso4217_USD">-115204000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_44" unitRef="iso4217_USD">12559000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_15" unitRef="iso4217_USD">5252000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_14" unitRef="iso4217_USD">5984000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200020" unitRef="iso4217_USD">13872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_2_3" unitRef="iso4217_USD">144000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_36" unitRef="iso4217_USD">194000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_33" unitRef="iso4217_USD">109000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:LicensesRevenue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_1" unitRef="iso4217_USD">769000</us-gaap:LicensesRevenue>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_13" unitRef="iso4217_USD">132000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_5" unitRef="iso4217_USD">1284000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_45" unitRef="iso4217_USD">711000</us-gaap:IncomeTaxesPaid>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_4" unitRef="iso4217_USD">53881000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_10" unitRef="iso4217_USD">-1106000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_2_1" unitRef="iso4217_USD">120000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200016" unitRef="iso4217_USD">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_34" unitRef="iso4217_USD">16145000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_14" unitRef="iso4217_USD">-228000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_20" unitRef="iso4217_USD">-149059000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_709985C8-7353-4131-98D3-2FABEFB626CE_2_6" unitRef="iso4217_USD">-149059000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_16" unitRef="iso4217_USD">519000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_52D94783-3F82-40A8-827F-7E9F6E3F1961_2_0" unitRef="iso4217_USD">-10137000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_15" unitRef="iso4217_USD">-118290000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200019" unitRef="iso4217_USD">727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_50" unitRef="iso4217_USD">4804000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_5" unitRef="iso4217_USD">-3343000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_12" unitRef="iso4217_USD">-4252000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_6" unitRef="iso4217_USD">-605000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-5" id="id_6322976_40C3AD7F-B458-4952-BEE9-A9D1C610B067_2_0" unitRef="iso4217_USD">200000</us-gaap:Depreciation>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_16" unitRef="iso4217_USD">-3086000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_6" unitRef="iso4217_USD">2248000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4004_2" unitRef="iso4217_USD">1368000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_12" unitRef="iso4217_USD">20180000</us-gaap:InterestExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_25" unitRef="iso4217_USD">-28000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_6" unitRef="iso4217_USD">13889000</us-gaap:ShareBasedCompensation>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_2_4" unitRef="iso4217_USD">439000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_1" unitRef="iso4217_USD">1053000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_3" unitRef="iso4217_USD">1166000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="INF" id="id_6322976_287BE393-751E-4110-B26F-5D52DAB6627B_2_0" unitRef="iso4217_USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_3" unitRef="iso4217_USD">166000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_0" unitRef="iso4217_USD">-29572000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_19" unitRef="iso4217_USD">14231000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_21" unitRef="iso4217_USD">-51000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_27" unitRef="iso4217_USD">57666000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_29" unitRef="iso4217_USD">27514000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-5" id="id_6322976_504D38E8-6F3B-4970-8011-3343130C7833_2_0" unitRef="iso4217_USD">6000000</us-gaap:RestrictedStockExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_6" unitRef="iso4217_USD">101041000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4005_4" unitRef="iso4217_USD">40626000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_8" unitRef="iso4217_USD">8258000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_9" unitRef="iso4217_USD">1594000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_8" unitRef="iso4217_USD">-1033000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_20" unitRef="iso4217_USD">10489000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_18" unitRef="iso4217_USD">-652000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_38" unitRef="iso4217_USD">71471000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-5" id="id_6322976_6F037D03-4730-48BF-AF7E-194F340C34E8_2_0" unitRef="iso4217_USD">800000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:PreferredStockConversionsInducements contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_19" unitRef="iso4217_USD">32987000</us-gaap:PreferredStockConversionsInducements>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_30" unitRef="iso4217_USD">2713000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_7" unitRef="iso4217_USD">51062000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B35970DA-6B46-4132-82DB-C64604549BDF_2_3" unitRef="iso4217_USD">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_2_2" unitRef="iso4217_USD">762000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_9" unitRef="iso4217_USD">646000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_39" unitRef="iso4217_USD">-12578000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_3" unitRef="iso4217_USD">27875000</us-gaap:CostOfGoodsSold>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_2" unitRef="iso4217_USD">113000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_2_7" unitRef="iso4217_USD">-9023000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_1" unitRef="iso4217_USD">8572000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_2" unitRef="iso4217_USD">8719000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_8" unitRef="iso4217_USD">152103000</us-gaap:OperatingExpenses>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_2_18" unitRef="iso4217_USD">868000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_31" unitRef="iso4217_USD">31000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-5" id="id_6322976_19EDCCB5-CFF5-44D9-A02D-AA11EC0A53E6_2_0" unitRef="iso4217_USD">7900000</us-gaap:StockOptionPlanExpense>
  <amrn:IncomeTaxReconciliationDerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_3" unitRef="iso4217_USD">187000</amrn:IncomeTaxReconciliationDerivativeLiabilities>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="INF" id="id_6322976_0AC5B06E-B14F-4F41-9937-D7F4F158C725_1_0" unitRef="shares">1844585</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4004_5" unitRef="iso4217_USD">1814000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <amrn:RepurchaseOfConversionOptionsOnLongTermDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_51" unitRef="iso4217_USD">1300000</amrn:RepurchaseOfConversionOptionsOnLongTermDebt>
  <amrn:ValuationAllowancesAndReservesChargedToEarnings contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_6A4079F6-9CC7-4B27-830B-CB3A91A893BA_2_2" unitRef="iso4217_USD">1315000</amrn:ValuationAllowancesAndReservesChargedToEarnings>
  <amrn:DerivativeLiabilitiesTransferredToEquityClassifications contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_2_48" unitRef="iso4217_USD">868000</amrn:DerivativeLiabilitiesTransferredToEquityClassifications>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200015" unitRef="iso4217_USD">2713000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_4" unitRef="iso4217_USD">-328000</amrn:IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4005_3" unitRef="iso4217_USD">-449000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4005_5" unitRef="iso4217_USD">6448000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <amrn:PreferredStockPurchaseOption contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8009_1200013" unitRef="iso4217_USD">946000</amrn:PreferredStockPurchaseOption>
  <amrn:IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_2_7" unitRef="iso4217_USD">7811000</amrn:IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount>
  <amrn:ValuationAllowancesAndReservesForeignCurrencyTranslation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-3" id="id_6322976_6A4079F6-9CC7-4B27-830B-CB3A91A893BA_2_3" unitRef="iso4217_USD">-7572000</amrn:ValuationAllowancesAndReservesForeignCurrencyTranslation>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0" decimals="-5" id="id_6322976_0AC5B06E-B14F-4F41-9937-D7F4F158C725_1_1" unitRef="iso4217_USD">2800000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324093x1528669_1333245x1332387" decimals="-5" id="id_6322976_47E8988A-2C12-4A5E-82BD-84328C41C118_2003_3" unitRef="iso4217_USD">-700000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324093x1528669_1333245x1335616" decimals="-5" id="id_6322976_47E8988A-2C12-4A5E-82BD-84328C41C118_3003_2" unitRef="iso4217_USD">700000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_4001_5" unitRef="shares">436000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_4001_3" unitRef="shares">9888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_4001_4" unitRef="shares">821000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_09ACE5E6-C7C6-4B17-B4A5-9B85B91DA62B_1003_1" unitRef="iso4217_USD">500000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1004_3" unitRef="iso4217_USD">4200000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1004_1" unitRef="iso4217_USD">10400000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865_1333110x1404455" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_2004_5" unitRef="iso4217_USD">4200000</us-gaap:InterestPaid>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865_1333245x1345793" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_3004_2" unitRef="iso4217_USD">6200000</us-gaap:InterestExpenseDebt>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_2002_2" unitRef="pure">0.256</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_2002_4" unitRef="pure">0.890</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_2002_3" unitRef="pure">0.029</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_1003_3" unitRef="iso4217_USD">1000000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1461424_1328615x1333865_1333110x1404455" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_2003_4" unitRef="iso4217_USD">1300000</us-gaap:InterestPaid>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_7B7AAF62-1B20-4A29-9916-A305547BE1A3_1003_1" unitRef="iso4217_USD">-100000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1004_3" unitRef="iso4217_USD">100000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1004_1" unitRef="iso4217_USD">200000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1486557_1328615x1333865_1333245x1345793" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_3004_2" unitRef="iso4217_USD">100000</us-gaap:InterestExpenseDebt>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1325224x1325185" decimals="2" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_1002_2" unitRef="pure">0.25</amrn:StatutoryTaxRate>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1325224x1325185_1328480x1515093" decimals="3" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_2002_3" unitRef="pure">0.125</amrn:StatutoryTaxRate>
  <amrn:PercentageOfGrossMarginPayableForPromotionAgreement contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327036x1498782" decimals="2" id="id_6322976_FBF68967-EFC9-4257-84FD-B4F1FB0E3F06_1001_0" unitRef="pure">0.15</amrn:PercentageOfGrossMarginPayableForPromotionAgreement>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4003_2" unitRef="iso4217_USD">342000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4003_3" unitRef="iso4217_USD">-205000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4003_5" unitRef="iso4217_USD">83000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4001_2" unitRef="iso4217_USD">14986000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4001_4" unitRef="iso4217_USD">10690000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4001_3" unitRef="iso4217_USD">-174000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4001_5" unitRef="iso4217_USD">2033000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4004_2" unitRef="iso4217_USD">8310000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4004_4" unitRef="iso4217_USD">7226000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4004_5" unitRef="iso4217_USD">792000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4002_2" unitRef="iso4217_USD">32591000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4002_4" unitRef="iso4217_USD">22710000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4002_3" unitRef="iso4217_USD">-70000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_4002_5" unitRef="iso4217_USD">3540000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1328615x1333865" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_1002_2" unitRef="shares">59407000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_9009_1200010" unitRef="iso4217_USD">57853000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797_1330097x1325837" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_9001_400011" unitRef="shares">391017970</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797_1330097x1325837" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_9001_700010" unitRef="iso4217_USD">29168000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_9006_900010" unitRef="iso4217_USD">28685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1433040" decimals="INF" id="id_6322976_CE75DCA9-E1F7-487F-A995-E4421024247A_3003_4" unitRef="shares">6283333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1325837" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8001_400012" unitRef="shares">-62833330</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1325837" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8001_700012" unitRef="iso4217_USD">-4804000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8008_1100021" unitRef="iso4217_USD">-115204000</us-gaap:NetIncomeLoss>
  <amrn:PreferredStockWithBeneficialConversionFeature contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8008_1100014" unitRef="iso4217_USD">-32987000</amrn:PreferredStockWithBeneficialConversionFeature>
  <amrn:PreferredStockPurchaseOption contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8008_1100013" unitRef="iso4217_USD">-868000</amrn:PreferredStockPurchaseOption>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900017" unitRef="iso4217_USD">-619000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900018" unitRef="iso4217_USD">-1300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900012" unitRef="iso4217_USD">-187000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900020" unitRef="iso4217_USD">13872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900016" unitRef="iso4217_USD">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900019" unitRef="iso4217_USD">727000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <amrn:PreferredStockWithBeneficialConversionFeature contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900014" unitRef="iso4217_USD">32987000</amrn:PreferredStockWithBeneficialConversionFeature>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900015" unitRef="iso4217_USD">1284000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <amrn:PreferredStockPurchaseOption contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8006_900013" unitRef="iso4217_USD">1814000</amrn:PreferredStockPurchaseOption>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1330220" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8003_600017" unitRef="shares">-154423</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1330220" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8003_1000017" unitRef="iso4217_USD">-194000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_500012" unitRef="shares">6283333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_500017" unitRef="shares">821376</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_500016" unitRef="shares">18020</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_800017" unitRef="iso4217_USD">619000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_800012" unitRef="iso4217_USD">4804000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_800016" unitRef="iso4217_USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_500015" unitRef="shares">1844585</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_8002_800015" unitRef="iso4217_USD">1429000</amrn:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330098x1389060" decimals="-3" id="id_6322976_52D94783-3F82-40A8-827F-7E9F6E3F1961_1002_1" unitRef="iso4217_USD">-108153000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6322976_34611778-5D87-472B-8002-26FE1E9E6F41_1002_5" unitRef="iso4217_USD">-1600000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:PreferredStockConversionsInducements contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6322976_34611778-5D87-472B-8002-26FE1E9E6F41_1002_3" unitRef="iso4217_USD">3400000</us-gaap:PreferredStockConversionsInducements>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4002_3" unitRef="iso4217_USD">-270000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4002_2" unitRef="iso4217_USD">500000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_2001_2">P7Y3M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_2001_6" unitRef="pure">0.307</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_2001_4" unitRef="pure">0.125</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_3001_1">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_3001_5" unitRef="pure">0.130</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_3001_3" unitRef="pure">0.066</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1353534" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4003_3" unitRef="iso4217_USD">-946000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1353534" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4003_2" unitRef="iso4217_USD">868000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1353534" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4003_5" unitRef="iso4217_USD">1814000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1451741" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_4001_3" unitRef="iso4217_USD">110000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:ShareBasedCompensationNet contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1451741_1331645x1336129" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_5001_4" unitRef="iso4217_USD">-9000</amrn:ShareBasedCompensationNet>
  <amrn:ShareBasedCompensationNet contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1331645x1336129" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1002_7" unitRef="iso4217_USD">-9000</amrn:ShareBasedCompensationNet>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333242x1356609" decimals="-5" id="id_6322976_1921279F-8565-462C-AF0C-56555E3481D6_1003_1" unitRef="iso4217_USD">-700000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333242x1356609_1333245x1345793" decimals="-5" id="id_6322976_683733D4-8948-4A17-B5B2-26E0DCD04D2B_1004_2" unitRef="iso4217_USD">1900000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333242x1356609_1333245x1417215" decimals="-5" id="id_6322976_683733D4-8948-4A17-B5B2-26E0DCD04D2B_2004_1" unitRef="iso4217_USD">6600000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333589x1330112" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_2002_0" unitRef="shares">17818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333589x1335583" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_3002_1" unitRef="shares">10887000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <amrn:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333769x1451741" decimals="INF" id="id_6322976_12AC26CD-35AD-453A-8100-2C49A5073DFF_1001_1" unitRef="shares">1844585</amrn:ClassOfWarrantOrRightExercisedInPeriod>
  <amrn:ClassOfWarrantOrRightExpiredInPeriod contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333769x1451741" decimals="INF" id="id_6322976_12AC26CD-35AD-453A-8100-2C49A5073DFF_1001_2" unitRef="shares">6242803</amrn:ClassOfWarrantOrRightExpiredInPeriod>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333817x1329312_1333818x1324536_1334994x1501282" decimals="2" id="id_6322976_F2ADEBEC-AEBD-4D73-8152-D322BA0670FE_1002_0" unitRef="pure">0.95</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1333817x1333518_1333818x1324536_1334994x1501282" decimals="2" id="id_6322976_F2ADEBEC-AEBD-4D73-8152-D322BA0670FE_2002_1" unitRef="pure">0.95</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1334666x1326228" decimals="-3" id="id_6322976_8F7F819C-6050-40AD-820B-DAE744F02E7F_1002_1" unitRef="iso4217_USD">10609000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1334666x1332399" decimals="-3" id="id_6322976_8F7F819C-6050-40AD-820B-DAE744F02E7F_2002_0" unitRef="iso4217_USD">3280000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_365_20151231_0_1334996x1325837" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_4002_3" unitRef="shares">32818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_091F9FD5-3F78-4553-A230-0BCFB4E84137_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
 and Cash Equivalents and Restricted Cash&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
 consist of cash, deposits with banks and short-term highly liquid
 money market instruments with remaining maturities at the date of
 purchase of 90 days or less. Restricted cash represents cash and
 cash equivalents pledged to guarantee repayment of certain expenses
 which may be incurred for business travel under corporate credit
 cards held by employees.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_88B63F94-63C2-4ACE-B53B-07FC62D2BF52_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(17)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Development, Commercialization
 and Supply Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On February&amp;#xA0;26, 2015,
 the Company entered into a Development, Commercialization and
 Supply Agreement (the &amp;#x201C;DCS Agreement&amp;#x201D;) with Eddingpharm
 (Asia) Macao Commercial Offshore Limited
 (&amp;#x201C;Eddingpharm&amp;#x201D;) related to the development and
 commercialization of Vascepa in Mainland China, Hong Kong, Macau
 and Taiwan, or the China Territory. Under the terms of the DCS
 Agreement, the Company granted to Eddingpharm an exclusive
 (including as to the Company) license with right to sublicense to
 develop and commercialize Vascepa in the China Territory for uses
 that are currently commercialized and under development by the
 Company based on the Company&amp;#x2019;s MARINE, ANCHOR and ongoing
 &lt;font style="white-space:nowrap"&gt;REDUCE-IT&lt;/font&gt; clinical trials
 of Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Under the DCS Agreement,
 Eddingpharm will be solely responsible for development and
 commercialization activities in the China Territory and associated
 expenses. The Company will provide development assistance and be
 responsible for supplying finished and later bulk drug product at
 defined prices under negotiated terms. The Company will retain all
 Vascepa manufacturing rights. Eddingpharm has agreed to certain
 restrictions regarding the commercialization of competitive
 products globally and the Company has agreed to certain
 restrictions regarding the commercialization of competitive
 products in the China Territory.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company and Eddingpharm
 agreed to form a joint development committee to oversee regulatory
 and development activities for Vascepa in the China Territory in
 accordance with a negotiated development plan and to form a
 separate joint commercialization committee to oversee Vascepa
 commercialization activities in the China Territory. Development
 costs will be paid by Eddingpharm to the extent such costs are
 incurred in connection with the negotiated development plan or
 otherwise incurred by Eddingpharm. Eddingpharm will be responsible
 for preparing and filing regulatory applications in all countries
 of the China Territory at Eddingpharm&amp;#x2019;s cost with the
 Company&amp;#x2019;s assistance. The DCS Agreement also contains
 customary provisions regarding indemnification, supply, record
 keeping, audit rights, reporting obligations, and representations
 and warranties that are customary for an arrangement of this
 type.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The term of the DCS
 Agreement expires, on a &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;product-by-product&lt;/font&gt;&lt;/font&gt; basis, upon
 the later of (i)&amp;#xA0;the date on which such product is no longer
 covered by a valid claim under a licensed patent in the China
 Territory, or (ii)&amp;#xA0;the twelfth (12th)&amp;#xA0;anniversary of the
 first commercial sale of such product in Mainland China. The DCS
 Agreement may be terminated by either party in the event of a
 bankruptcy of the other party and for material breach, subject to
 customary cure periods. In addition, at any time following the
 third anniversary of the first commercial sale of a product in
 Mainland China, Eddingpharm has the right to terminate the DCS
 Agreement for convenience with twelve months&amp;#x2019; prior notice.
 Neither party may assign or transfer the DCS Agreement without the
 prior consent of the other party, provided that the Company may
 assign the DCS Agreement in the event of a change of control
 transaction.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Upon closing of the DCS
 Agreement, the Company received a &lt;font style="white-space:nowrap"&gt;non-refundable&lt;/font&gt; $15.0&amp;#xA0;million
 &lt;font style="white-space:nowrap"&gt;up-front&lt;/font&gt; payment, which it
 will recognize as revenue over the estimated period in which the
 Company is required to provide initial and &lt;font style="white-space:nowrap"&gt;on-going&lt;/font&gt; regulatory and development
 support and clinical supply for obtaining regulatory approvals in
 the China Territory and through the estimated period in which the
 Company is required to provide commercial supply, which is
 currently estimated to be a period of approximately 16 years. In
 March 2016, Eddingpharm submitted its clinical trial application
 (&amp;#x201C;CTA&amp;#x201D;) with respect to the MARINE indication for
 Vascepa to the Chinese regulatory authority. Following the CTA
 submission, the Company received a &lt;font style="white-space:nowrap"&gt;non-refundable&lt;/font&gt; $1.0&amp;#xA0;million
 milestone payment which it will recognize as revenue over the
 estimated period in which the Company is required to provide
 &lt;font style="white-space:nowrap"&gt;on-going&lt;/font&gt; development
 support needed to support the successful approval for a new drug
 application, which is currently estimated to be a period of
 approximately four years.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In addition to the
 &lt;font style="white-space:nowrap"&gt;non-refundable,&lt;/font&gt;
 &lt;font style="white-space:nowrap"&gt;up-front&lt;/font&gt; and regulatory
 milestone payments described above, the Company is entitled to
 receive certain regulatory and sales-based milestone payments of up
 to an additional $153.0&amp;#xA0;million as well as tiered double-digit
 percentage royalties on net sales of Vascepa in the China Territory
 escalating to the high teens. The regulatory milestone events
 relate to the submission and approval of certain applications to
 the applicable regulatory authority, such as a clinical trial
 application, clinical trial exemption, or import drug license
 application. The amounts to be received upon achievement of the
 regulatory milestone events relate to the submission and approval
 for three indications, and range from $1.0&amp;#xA0;million to
 $15.0&amp;#xA0;million for a total of $33.0&amp;#xA0;million. The
 sales-based milestone events occur when annual aggregate net sales
 of Vascepa in the territory equals or exceeds certain specified
 thresholds, and range from $5.0&amp;#xA0;million to $50.0&amp;#xA0;million
 for a total of $120.0&amp;#xA0;million. Each such milestone payment
 shall be payable only once regardless of how many times the sales
 milestone event is achieved. Each such milestone payment is
 &lt;font style="white-space:nowrap"&gt;non-refundable&lt;/font&gt; and
 &lt;font style="white-space:nowrap"&gt;non-creditable&lt;/font&gt; against any
 other milestone payments. The Company recognizes contingent
 consideration from activities that is earned upon the achievement
 of a substantive milestone in the period in which the milestone is
 achieved.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On March&amp;#xA0;8, 2016, the
 Company entered into an agreement with Biologix FZCo
 (&amp;#x201C;Biologix&amp;#x201D;), a company incorporated under the laws of
 the United Arab Emirates, to register and commercialize Vascepa in
 several Middle Eastern and North African countries. Under the terms
 of the distribution agreement, the Company granted to Biologix a
 &lt;font style="white-space:nowrap"&gt;non-exclusive&lt;/font&gt; license to
 use its trademarks in connection with the importation,
 distribution, promotion, marketing and sale of Vascepa in the
 Middle East and North Africa territory. Upon closing of the
 agreement, the Company received a &lt;font style="white-space:nowrap"&gt;non-refundable&lt;/font&gt; &lt;font style="white-space:nowrap"&gt;up-front&lt;/font&gt; payment, which will be
 recognized as revenue over 10 years commencing upon first marketing
 approval of Vascepa in the territory. The Company is entitled to
 receive payments based on product sales at an agreed-upon transfer
 price, which represents a percentage of gross selling price,
 subject to a minimum floor price.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Licensing and deferred
 revenues currently consist of revenue attributable to receipt of
 &lt;font style="white-space:nowrap"&gt;up-front,&lt;/font&gt; &lt;font style="white-space:nowrap"&gt;non-refundable&lt;/font&gt; payments and milestone
 payments related to the Eddingpharm and Biologix agreements.
 &lt;font style="white-space:nowrap"&gt;Up-front&lt;/font&gt; and milestone
 payments under such agreements are typically recognized as
 licensing revenue over the estimated period in which the Company is
 required to provide regulatory and development support and clinical
 and commercial supply pursuant to the agreements. During the years
 ended December&amp;#xA0;31, 2016 and 2015, the Company recognized
 $1.1&amp;#xA0;million and $0.8&amp;#xA0;million of &lt;font style="white-space:nowrap"&gt;up-front&lt;/font&gt; and milestone payments as
 licensing revenue in connection with the Eddingpharm DCS Agreement,
 respectively, and recorded $15.1&amp;#xA0;million as deferred revenue
 as of December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_8E1A1BF1-8E80-4D5F-AEC3-2BB4F082AFE2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(9)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Commitments and
 Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Litigation&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In September and October
 2016, the Company received paragraph IV certification notices from
 four companies contending to varying degrees that certain of its
 patents are invalid, unenforceable and/or will not be infringed by
 the manufacture, use, sale or offer for sale of a generic form of
 Vascepa as described in those companies&amp;#x2019; abbreviated new drug
 applications, or ANDAs. The Company filed patent infringement
 lawsuits against three of these four ANDA applicants. In October
 2016, Amarin filed a lawsuit against Roxane Laboratories, Inc. and
 related parties (collectively, &amp;#x201C;Roxane&amp;#x201D;) in the U.S.
 District Court for the District of Nevada. The case against Roxane
 is captioned &lt;i&gt;Amarin Pharma, Inc. et al. v. Roxane Laboratories,
 Inc. et al.&lt;/i&gt;, Civ. A. No. &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2:16-cv-02525&lt;/font&gt;&lt;/font&gt; (D. Nev.). In
 November 2016, Amarin filed a lawsuit against
 Dr.&amp;#xA0;Reddy&amp;#x2019;s Laboratories, Inc. and
 Dr.&amp;#xA0;Reddy&amp;#x2019;s Laboratories, Ltd. (collectively,
 &amp;#x201C;DRL&amp;#x201D;) in the U.S. District Court for the District of
 Nevada. The case against DRL is captioned &lt;i&gt;Amarin Pharma, Inc. et
 al. v. Dr.&lt;/i&gt;&lt;i&gt;&amp;#xA0;Reddy&amp;#x2019;s Laboratories, Inc. et al.&lt;/i&gt;,
 Civ. A. No. &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2:16-cv-02562&lt;/font&gt;&lt;/font&gt; (D. Nev.). In
 November 2016, Amarin filed a lawsuit against Teva Pharmaceuticals
 USA, Inc. and Teva Pharmaceuticals Industries Limited
 (collectively, &amp;#x201C;Teva&amp;#x201D;) in the U.S. District Court for
 the District of Nevada. The case against Teva is captioned
 &lt;i&gt;Amarin Pharma, Inc. et al. v. Teva Pharmaceuticals USA, Inc. et
 al.&lt;/i&gt;, Civ. A. No. &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2:16-cv-02658.&lt;/font&gt;&lt;/font&gt; In all three
 lawsuits, Amarin is seeking, among other remedies, an order
 enjoining each defendant from marketing generic versions of Vascepa
 before the last to expire of the asserted patents in 2030. The
 three lawsuits have been consolidated for pretrial proceedings, and
 are in their early stages. As a result of the statutory stay
 associated with the filing of these lawsuits under the Hatch-Waxman
 Act, the FDA cannot grant final approval to Roxane, DRL, or
 Teva&amp;#x2019;s respective ANDA before January 2020, unless there is
 an earlier court decision holding that the subject patents are not
 infringed and/or are invalid.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fourth ANDA applicant
 referenced above is Apotex Inc. (&amp;#x201C;Apotex&amp;#x201D;), which sent
 Amarin a paragraph IV certification notice in September 2016. The
 notice reflected that Apotex made a paragraph IV notice as to some,
 but not all, of the patents listed in the Orange Book for Vascepa.
 Because Apotex did not make a paragraph IV certification as to all
 listed patents, Apotex cannot market a generic version of Vascepa
 before the last to expire of the patents for which Apotex did not
 make a paragraph IV certification, which is in 2030. At a later
 date, Apotex may elect to amend its ANDA in order to make a
 paragraph IV certification as to additional listed patents. If and
 when Apotex does make such an amendment, it would be required to
 send Amarin an additional paragraph IV certification notice, and
 Amarin would then have the ability to file a lawsuit against Apotex
 pursuant to the Hatch-Waxman Act.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company intends to
 vigorously enforce its intellectual property rights relating to
 Vascepa, but cannot predict the outcome of the &lt;i&gt;Roxane, DRL or
 Teva&lt;/i&gt; lawsuits or any subsequently filed lawsuits.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On April&amp;#xA0;26, 2016, the
 U.S. District Court for the District of New Jersey granted the
 Company&amp;#x2019;s motion to dismiss the putative consolidated class
 action lawsuit captioned &lt;i&gt;In re Amarin Corporation plc,
 Securities Litigation&lt;/i&gt;, No. &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;3:13-cv-06663&lt;/font&gt;&lt;/font&gt; (D.N.J. Nov. 1,
 2013). The class action was dismissed without prejudice with leave
 for plaintiffs to file an amended complaint. The lawsuit seeks
 unspecified monetary damages and attorneys&amp;#x2019; fees and costs
 alleging that the Company and certain of its current and former
 officers and directors made misstatements and omissions regarding
 the FDA&amp;#x2019;s willingness to approve Vascepa&amp;#x2019;s ANCHOR
 indication and related contributing factors and the potential
 relevance of data from the ongoing &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; trial to that potential
 approval. The April 2016 dismissal was the second motion to dismiss
 granted in favor of Amarin and related defendants in this
 litigation. The first motion to dismiss in this litigation was
 granted in June 2015 in response to the original complaint and
 related amendment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On May&amp;#xA0;24, 2016,
 plaintiffs notified the court that they would not file another
 amended complaint and, on May&amp;#xA0;26, 2016, filed a notice of
 appeal of the most recent dismissal to the Third Circuit Court of
 Appeals. Plaintiffs filed their appellate brief on
 September&amp;#xA0;21, 2016, the Company filed an opposition brief on
 November&amp;#xA0;29, 2016, and plaintiffs filed their reply on
 December&amp;#xA0;29, 2016. No hearing date has been set. The Company
 plans a vigorous defense to this appeal. The Company has insurance
 coverage that is anticipated to cover any significant loss exposure
 that may arise from this action.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In addition to the above,
 in the ordinary course of business, the Company is from time to
 time involved in lawsuits, claims, investigations, proceedings, and
 threats of litigation relating to intellectual property, commercial
 arrangements and other matters.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Leases&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company leases office
 space under operating leases. Future minimum lease payments under
 these leases, net of sublease rental income, as of
 December&amp;#xA0;31, 2016 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1px; WIDTH: 92pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ending
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;528&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;126&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2019-2021&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On September&amp;#xA0;30, 2011,
 the Company entered into an agreement for 320 square feet of office
 space at 2&amp;#xA0;Pembroke House, Upper Pembroke Street &lt;font style="WHITE-SPACE: nowrap"&gt;28-32&lt;/font&gt; in Dublin, Ireland. The office
 space was subsequently reduced to 270 square feet, effective
 November&amp;#xA0;1, 2013. The agreement began November&amp;#xA0;1, 2011
 and terminates on October&amp;#xA0;31, 2017 and can be extended
 automatically for successive one year periods. Monthly rent is
 approximately &amp;#x20AC;2,900 (approximately $3,100 at the time of
 filing). The agreement can be terminated by either party with three
 months prior written notice.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On July&amp;#xA0;1, 2011, the
 Company leased 9,747 square feet of office space in Bedminster, New
 Jersey. The lease, as amended, terminates on March&amp;#xA0;31, 2018,
 and may also be terminated with six months prior notice. On
 December&amp;#xA0;6, 2011 the Company leased an additional 2,142 square
 feet of space in the same location. On December&amp;#xA0;15, 2012 and
 May&amp;#xA0;8, 2013, the Company leased an additional 2,601 and 10,883
 square feet of space, respectively, in the same location. In
 January 2014 and April 2014, the Company entered into separate
 transactions with the landlord of this property to vacate
 approximately 2,142 and 2,000 square feet of space in exchange for
 discounts on contractual future rent payments. In January 2015, the
 Company executed an agreement to sublease approximately 4,700
 square feet of this property to a third party, effective
 April&amp;#xA0;1, 2015. Additionally, in June 2015, the Company
 executed an agreement to sublease approximately 2,500 square feet
 of this property to a separate third party, effective June&amp;#xA0;16,
 2015. On December&amp;#xA0;15, 2016, the Company leased an additional
 732 square feet of space in the same location, effective
 January&amp;#xA0;1, 2017.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total rent expense during
 the years ended 2016, 2015 and 2014 was approximately
 $0.6&amp;#xA0;million, $0.8&amp;#xA0;million, and $1.0&amp;#xA0;million,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Milestone
 and Supply Purchase Obligations&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company entered into
 long-term supply agreements with multiple &lt;font style="WHITE-SPACE: nowrap"&gt;FDA-approved&lt;/font&gt; API suppliers and
 encapsulators. Certain supply agreements require annual minimum
 volume commitments by the Company and certain volume shortfalls may
 require payments for such shortfalls, as detailed below.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company entered into
 its initial Vascepa API supply agreement with Nisshin Pharma, Inc
 (&amp;#x201C;Nisshin&amp;#x201D;) in 2010. In 2011, the Company entered into
 agreements with two additional suppliers, Chemport, Inc
 (&amp;#x201C;Chemport&amp;#x201D;) and BASF (formerly Equateq Limited), for
 the supply of API. In 2012, the Company agreed to terms with a
 fourth API supplier, a consortium of companies led by Slanmhor
 Pharmaceutical, Inc. (&amp;#x201C;Slanmhor&amp;#x201D;). The API supply
 agreement with BASF terminated in February 2014. In July 2014, the
 Company terminated the supply agreement with Slanmhor and
 subsequently, in June 2015, entered into a new supply agreement
 with Finorga SAS (&amp;#x201C;Novasep&amp;#x201D;). These agreements included
 requirements for the suppliers to meet certain product
 specifications and qualify their materials and facilities with
 applicable regulatory authorities including the FDA. The Company
 has incurred certain costs associated with the qualification of
 product produced by these suppliers as described below.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Nisshin, Chemport and
 Novasep are currently the three manufacturers from which the
 Company purchases API. As of December&amp;#xA0;31, 2016, the Company
 has no royalty, milestone or minimum purchase commitments with
 Nisshin.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Chemport was approved by
 the FDA to manufacture API for commercial sale in April 2013 and
 the Company began purchasing commercial supply from Chemport in
 2013. The agreement with Chemport contains a provision requiring
 the Company to pay Chemport in cash for any shortfall in the
 minimum purchase obligations. The Company began purchasing
 commercial supply from Novasep in 2015. API manufactured by Novasep
 was previously approved by the FDA in July 2014. The 2015 supply
 agreement with Novasep contains a provision requiring the Company
 to pay Novasep a cash remedy for any shortfall in the minimum
 purchase obligations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Pursuant to the supply
 agreements, there is a total of $44.6&amp;#xA0;million that is
 potentially payable over the term of such agreements based on
 minimum purchase obligations. The Company continues to meet its
 contractual purchase obligations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Under the 2004 share
 repurchase agreement with Laxdale Limited (&amp;#x201C;Laxdale&amp;#x201D;),
 upon receipt of marketing approval in Europe for the first
 indication for Vascepa (or first indication of any product
 containing Amarin Neuroscience Limited intellectual property
 acquired from Laxdale in 2004), the Company must make an aggregate
 stock or cash payment to the former shareholders of Laxdale (at the
 sole option of each of the sellers) of &amp;#xA3;7.5&amp;#xA0;million
 (approximately $9.3&amp;#xA0;million as of December&amp;#xA0;31, 2016).
 Also under the Laxdale agreement, upon receipt of a marketing
 approval in the United States or Europe for a further indication of
 Vascepa (or further indication of any other product using Amarin
 Neuroscience Limited intellectual property), the Company must make
 an aggregate stock or cash payment (at the sole option of each of
 the sellers) of &amp;#xA3;5&amp;#xA0;million (approximately
 $6.2&amp;#xA0;million as of December&amp;#xA0;31, 2016) for each of the two
 potential market approvals (i.e., &amp;#xA3;10&amp;#xA0;million maximum, or
 approximately $12.3&amp;#xA0;million as of December&amp;#xA0;31,
 2016).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has no
 provision for any of the obligations above since the amounts are
 either not probable or able to be estimated as of December&amp;#xA0;31,
 2016.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_3B2F0D66-E80B-4E74-A23E-E68F885D9DCC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;b&gt;(12)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Stock Incentive Plans and Stock
 Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 April&amp;#xA0;29, 2011 the Board, upon the recommendation of the
 Remuneration Committee, adopted the 2011 Stock Incentive Plan
 (&amp;#x201C;2011 Plan&amp;#x201D;), which was approved by the
 Company&amp;#x2019;s shareholders on July&amp;#xA0;12, 2011. The 2011 Plan
 replaced the Company&amp;#x2019;s 2002 Stock Option Plan (&amp;#x201C;2002
 Plan&amp;#x201D;), which expired on January&amp;#xA0;1, 2012. The maximum
 number of the Company&amp;#x2019;s Ordinary Shares of &amp;#xA3;0.50 each or
 any ADS&amp;#x2019;s, as to be issued under the 2011 Plan shall not
 exceed the sum of (i) 31.5&amp;#xA0;million newly authorized Shares
 available for award and (ii)&amp;#xA0;the number of Shares that
 remained available for grants under the Company&amp;#x2019;s 2002 Plan
 and (iii)&amp;#xA0;the number of Shares underlying then outstanding
 awards under the 2002 Plan that could be subsequently forfeited,
 cancelled, expire or are otherwise terminated. The award of stock
 options (both incentive and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-qualified&lt;/font&gt;&amp;#xA0;options) and restricted stock
 units, and awards of unrestricted Shares to Directors are
 permitted. The 2011 Plan is administered by the Remuneration
 Committee of the Company&amp;#x2019;s Board of Directors and expires on
 July&amp;#xA0;12, 2021.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In addition
 to the grants under the 2011 Plan, the Company grants&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-qualified&lt;/font&gt;&amp;#xA0;stock options to employees to
 purchase the Company&amp;#x2019;s ordinary shares. These grants are made
 pursuant to employment agreements on terms consistent with the 2011
 Plan.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Under the
 terms of the 2011 Plan, and grants made pursuant to employment
 agreements, options typically vest over a four-year period, expire
 after a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ten-year&lt;/font&gt;&amp;#xA0;term
 and are granted at an exercise price equal to the closing price of
 the Company&amp;#x2019;s American Depositary Shares on the grant date.
 The following table summarizes all stock option activity for the
 year ended December&amp;#xA0;31, 2016:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands (except per share amounts and
 years)&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 January&amp;#xA0;1, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;17,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3.76&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4,400&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(688&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.92&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Expired&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(165&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7.24&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(177&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;21,188&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3.37&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7.3&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;17,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Exercisable as of
 December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;12,217&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4.38&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6.3&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7,159&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Vested and expected to
 vest as of December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;20,513&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7.3&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;16,396&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Available for future
 grant as of December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4,304&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The weighted
 average grant date fair value of stock options granted during the
 years ended December&amp;#xA0;31, 2016, 2015 and 2014 was $1.62, $2.16,
 and $1.58, respectively. The total grant date fair value of options
 vested during the years ended December&amp;#xA0;31, 2016, 2015 and 2014
 was $6.5&amp;#xA0;million, $9.1&amp;#xA0;million, and $8.1&amp;#xA0;million,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;During the
 years ended December&amp;#xA0;31, 2016, 2015 and 2014, the Company
 received proceeds from the exercise of options of
 $0.3&amp;#xA0;million, $31&amp;#xA0;thousand, and $0.3&amp;#xA0;million,
 respectively. The total intrinsic value of options exercised during
 the years ended December&amp;#xA0;31, 2016, 2015 and 2014 was
 $0.2&amp;#xA0;million, $6&amp;#xA0;thousand, and $0.2&amp;#xA0;million,
 respectively, calculated as the difference between the quoted stock
 price of the Company&amp;#x2019;s common stock as of the reporting date
 and the exercise prices of the underlying awards.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;As of
 December&amp;#xA0;31, 2016, there was $11.8&amp;#xA0;million of
 unrecognized stock-based compensation expense related to unvested
 stock option share-based compensation arrangements granted under
 the Company&amp;#x2019;s stock award plans. This expense is expected to
 be recognized over a weighted-average period of approximately 2.5
 years. The Company recognizes compensation expense for the fair
 values of those awards which have graded vesting on a straight line
 basis.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The fair
 value of stock options on the date of grant was estimated using the
 Black-Scholes option pricing model. Use of a valuation model
 requires management to make certain assumptions with respect to
 selected model inputs. Expected stock price volatility was
 calculated based on the historical volatility of the
 Company&amp;#x2019;s common stock over the expected life of the option.
 The expected life was determined using the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;short-cut&lt;/font&gt;&amp;#xA0;method based on the term and
 vesting period. The risk-free interest rate is based on&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;zero-coupon&lt;/font&gt;&amp;#xA0;U.S. Treasury securities with
 a maturity term approximating the expected life of the option at
 the date of grant. No dividend yield has been assumed as the
 Company does not currently pay dividends on its common stock and
 does not anticipate doing so in the foreseeable future. Estimated
 forfeitures are based on the Company&amp;#x2019;s historical forfeiture
 activity.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Employee
 stock options generally vest over a four-year service period and
 all stock options are settled by the issuance of new shares.
 Compensation expense recognized for all option grants is net of
 estimated forfeitures and is recognized over the awards&amp;#x2019;
 respective requisite service periods. The vesting of certain stock
 options is contingent upon the attainment of performance criteria.
 The probability that such criteria will be achieved is assessed by
 management and compensation expense for such awards is only
 recorded to the extent that the attainment of the performance
 criteria is deemed to be probable. The Company recorded
 compensation expense in relation to stock options of
 $6.6&amp;#xA0;million, $7.9&amp;#xA0;million and $7.7&amp;#xA0;million for the
 years ended December&amp;#xA0;31, 2016, 2015 and 2014,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;For 2016,
 2015 and 2014, the Company used the following assumptions to
 estimate the fair value of share-based payment awards:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Risk free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.07%&amp;#xA0;-&amp;#xA0;1.70%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.37%&amp;#xA0;-&amp;#xA0;1.68%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.37%&amp;#xA0;-&amp;#xA0;1.68%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Expected dividend
 yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;0.00%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;0.00%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;0.00%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Expected option life
 (years)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Expected
 volatility&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;83%&amp;#xA0;-&amp;#xA0;86%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;86%&amp;#xA0;-&amp;#xA0;97%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;97%&amp;#xA0;-&amp;#xA0;109%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 28px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;i&gt;&lt;u&gt;Restricted Stock Units&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The 2011 Plan
 also allows for granting of restricted stock unit awards under the
 terms of the Plan. The restricted stock units vest based upon a
 time-based service condition, a performance condition, or both. The
 probability that any performance criteria will be achieved is
 assessed by management and compensation expense for such awards is
 only recorded to the extent that the attainment of the performance
 criteria is deemed to be probable. Restricted stock units are
 recorded as compensation expense based on fair value, representing
 the market value of the Company&amp;#x2019;s common stock on the date of
 grant. The fair value of restricted stock units is amortized on a
 straight-line basis through the statement of operations over the
 service period until the shares have vested. The following table
 presents the restricted stock unit activity for the years ended
 December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands (except per share
 amounts)&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Grant Date
 Fair&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 January&amp;#xA0;1, 2015&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,256&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2.03&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;9,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(821&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2.14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(436&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.45&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 December&amp;#xA0;31, 2015&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;10,887&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,756&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.47&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,853&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(647&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.74&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;10,143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2.09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 recorded compensation expense in relation to restricted stock units
 of $7.0&amp;#xA0;million, $6.0&amp;#xA0;million and $1.4&amp;#xA0;million for
 the years ended December&amp;#xA0;31, 2016, 2015 and 2014
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The following
 table presents the stock-based compensation expense related to
 stock based awards for the years ended December&amp;#xA0;31, 2016, 2015
 and 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Research and
 development&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,252&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3,280&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,701&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Selling, general and
 administrative&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;11,361&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;10,609&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6,321&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Stock-based compensation
 expense&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;13,613&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;13,889&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;9,022&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_99705C13-8B3A-476B-8077-894F65D58339_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_99705C13-8B3A-476B-8077-894F65D58339_1_3">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_99705C13-8B3A-476B-8077-894F65D58339_1_0">10-K</dei:DocumentType>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_23" unitRef="iso4217_USD_per_shares">-0.41</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_495ABAFC-CB27-4730-BB08-F5B5846A1CC0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
 per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &lt;font style="WHITE-SPACE: nowrap"&gt;&amp;#x201C;if-converted&amp;#x201D;&lt;/font&gt;
 method. In periods with reported net operating losses, all common
 stock options and warrants are deemed anti-dilutive such that basic
 net loss per share and diluted net loss per share are equal.
 However, in certain periods in which there is a gain recorded
 pursuant to the change in fair value of the warrant derivative
 liability, for diluted net loss per share purposes, the impact of
 such gains is reversed and the treasury stock method is used to
 determine diluted net loss per share.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 preferred stock is entitled to receive dividends on an &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;as-if-converted&lt;/font&gt;&lt;/font&gt; basis in the
 same form as dividends actually paid on common shares. Accordingly,
 the preferred stock is considered a participating security and the
 Company is required to apply the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method to consider the
 impact of the preferred stock on the calculation of basic and
 diluted earnings per share. The Company is currently in a net loss
 position and is therefore not required to present the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method, however, in the
 event the Company is in a net income position, the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method must be applied by
 allocating all earnings during the period to common shares and
 preferred stock based on their contractual entitlements assuming
 all earnings were distributed.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The calculation of net loss
 and the number of shares used to compute basic and diluted net loss
 per share for the years ended December&amp;#xA0;31, 2016, 2015 and 2014
 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(115,204&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock purchase
 option (see Note 10&amp;#x2014;Equity)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(868&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock beneficial
 conversion features (see Note 10&amp;#x2014;Equity)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(32,987&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss applicable to
 common shareholders&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(149,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,775&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net
 loss&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(149,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(63,139&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 share&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.32&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average shares
 outstanding&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;211,874&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;180,654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;173,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effect of dilutive
 warrants&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;105&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average shares
 outstanding&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;211,874&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;180,654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;173,824&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 share&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.36&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014, the following potentially
 dilutive securities were not included in the computation of net
 loss per share because the effect would be
 anti-dilutive:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,188&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,670&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Restricted stock and
 restricted stock units&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,887&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,256&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exchangeable senior notes
 (if converted)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,714&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;59,407&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49,215&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock (if
 converted)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400002">0000897448</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400004">Yes</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_3DC1856E-BCB2-425E-8AF3-96450CA509C6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
 Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement date.
 Fair value measurements may be classified based on the amount of
 subjectivity associated with the inputs to fair valuation of these
 assets and liabilities using the following three levels:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
 inputs that reflect the Company&amp;#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability. The Company develops these inputs based on the best
 information available, including its own data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following tables
 present information about the Company&amp;#x2019;s assets and
 liabilities as of December&amp;#xA0;31, 2016 and 2015 that are measured
 at fair value on a recurring basis and indicate the fair value
 hierarchy of the valuation techniques the Company utilized to
 determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,184&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,184&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt derivative
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts payable and accrued liabilities
 approximate fair value because of their short-term nature. The
 carrying amounts and the estimated fair values of debt instruments
 as of December&amp;#xA0;31, 2016 and 2015 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt from
 royalty-bearing instrument&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85,155&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;90,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91,512&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;87,700&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2012 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,107&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,174&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,107&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,637&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2014 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;96,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;108,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2015 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,134&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;28,448&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The estimated fair value of
 the long-term debt from royalty-bearing instrument pursuant to the
 December 2012 financing is calculated utilizing the same
 Level&amp;#xA0;3 inputs utilized in valuing the related derivative
 liability (see Long-Term Debt Redemption Features below). The
 estimated fair value of the 2012 Notes and 2014 Notes is calculated
 based on Level&amp;#xA0;1 quoted bond prices, while the estimated fair
 value of the 2015 Notes is calculated based on Level&amp;#xA0;2 quoted
 bond prices for the 2014 Notes. The carrying value of the 2012
 Notes as of December&amp;#xA0;31, 2016 and 2015 does not include a debt
 discount, as it had been fully amortized as &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt; interest expense over the
 expected term of the 2012 Notes, which was calculated to be a
 period of twenty-four months. The carrying value of the 2014 Notes
 as of December&amp;#xA0;31, 2015 includes a debt discount of
 $24.1&amp;#xA0;million, which prior to mandatory exchange was being
 amortized as &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;
 interest expense over the expected term of the 2014 Notes, through
 January 2019. The carrying value of the 2015 Notes as of
 December&amp;#xA0;31, 2015 includes a debt discount of
 $4.2&amp;#xA0;million, which prior to mandatory exchange was being
 amortized as &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;
 interest expense over the expected term of the 2015 Notes, through
 January 2019. The carrying values and related debt discounts of the
 2014 Notes and 2015 Notes as of December&amp;#xA0;31, 2015 reflect the
 retroactive reclassification of debt issuance costs per adoption of
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03&lt;/font&gt; as
 described in Note 8&amp;#x2014;Debt. The change in the estimated fair
 values of these liabilities from December&amp;#xA0;31, 2015 to
 December&amp;#xA0;31, 2016 is largely related to changes in the quoted
 bond prices and derecognition of the mandatorily exchanged
 debt.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_8DA1517C-35BD-4A5A-933F-A571BF6D4CD2_1_0">P13Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_4EBD730D-CC10-4D73-85F9-212A1976987A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(4)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Inventory&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company capitalizes its
 purchases of saleable inventory of Vascepa from suppliers that have
 been qualified by the FDA. Inventories as of December&amp;#xA0;31, 2016
 and 2015 consist of the following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="54%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,430&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,096&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in process&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,716&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,640&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,361&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,249&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total inventory&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,507&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;18,985&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_BBD9D3C0-56BF-45CF-BC42-3287A5B615AB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effective April 2016, the
 Company adopted Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;)
 &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt;
 &lt;i&gt;Inventory (Topic 330)&amp;#x2014;Simplifying the Measurement of
 Inventory&lt;/i&gt;, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost and net realizable value test and, as such, began to
 state inventories at the lower of cost or net realizable value.
 Such adoption had no impact on the carrying value of inventory.
 Cost is determined based on actual cost using the average cost
 method. An allowance is established when management determines that
 certain inventories may not be saleable. If inventory cost exceeds
 expected net realizable value due to obsolescence, damage or
 quantities in excess of expected demand, changes in price levels or
 other causes, the Company will reduce the carrying value of such
 inventory to net realizable value and recognize the difference as a
 component of cost of goods sold in the period in which it occurs.
 The Company capitalizes inventory purchases of saleable product
 from approved suppliers while inventory purchases from suppliers
 prior to regulatory approval are included as a component of
 research and development expense. The Company expenses inventory
 identified for use as marketing samples when they are packaged. The
 average cost reflects the actual purchase price of Vascepa active
 pharmaceutical ingredient, or API.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_22" unitRef="iso4217_USD">-71815000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_10A9FD89-D169-426B-A26A-7793118A1B65_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
 Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are early adopted by the Company or
 adopted as of the specified effective date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In January 2016, the
 Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt;
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;835-30):&lt;/font&gt; Simplifying the Presentation
 of Debt Issuance Costs&lt;/i&gt;, which provides guidance on simplifying
 the presentation of debt issuance costs on the balance sheet. To
 simplify presentation of debt issuance costs, the amendments in ASU
 &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03&lt;/font&gt; require
 that debt issuance costs related to a recognized debt liability be
 presented in the balance sheet as a direct deduction from the
 carrying amount of that debt liability, consistent with the
 treatment of debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this update. In accordance with ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt; the Company applied
 the new guidance on a retrospective basis, wherein the consolidated
 balance sheet of each individual period presented was adjusted to
 reflect the period-specific effects of applying the new guidance.
 See Note 8&lt;i&gt;&amp;#x2014;&lt;/i&gt;Debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2016, the Company
 adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt; &lt;i&gt;Inventory (Topic
 330): Simplifying the Measurement of Inventory&lt;/i&gt;, which
 simplifies the subsequent measurement of inventories by replacing
 the lower of cost or market test with a lower of cost or net
 realizable value test. When evidence exists that the net realizable
 value of inventory is less than its cost (due to damage, physical
 deterioration, obsolescence, changes in price levels or other
 causes), the Company will recognize the difference as a component
 of cost of goods sold in the period in which it occurs. In
 accordance with ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt; the Company applied
 the new guidance on a prospective basis with no impact on the
 carrying amount of inventory.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Also in April 2016, the
 Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital. This aspect of the
 standard was adopted prospectively, and accordingly, the provision
 for income taxes for the year ended December&amp;#xA0;31, 2016 includes
 $0.4&amp;#xA0;million of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately
 $1.6&amp;#xA0;million relating to excess tax benefits on stock-based
 compensation outstanding as of December&amp;#xA0;31, 2015, with a
 corresponding cumulative-effect adjustment to accumulated deficit.
 The new standard also amends the presentation of employee
 share-based payment-related items in the statement of cash flows by
 requiring that: (i)&amp;#xA0;excess income tax benefits and
 deficiencies be classified in cash flows from operating activities,
 and (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.7&amp;#xA0;million of excess tax benefit
 and $2.3&amp;#xA0;million of excess tax provision from cash flows
 provided by financing activities to cash flows used in operating
 activities in the consolidated statement of cash flows as of
 December&amp;#xA0;31, 2015 and 2014, respectively, to conform to the
 current year presentation. The presentation requirement for cash
 flows related to taxes paid for withheld shares had no impact to
 any of the periods presented in the consolidated statement of cash
 flows since such payments have historically been presented as a
 financing activity.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In December 2016, the
 Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-15,&lt;/font&gt; &lt;i&gt;Presentation of
 Financial Statements&amp;#x2014;Going Concern (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;205-40):&lt;/font&gt; Disclosure of Uncertainties
 about an Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;.
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-15&lt;/font&gt;
 requires management to assess an entity&amp;#x2019;s ability to continue
 as a going concern by incorporating and expanding upon certain
 principles that are currently in U.S. auditing standards.
 Specifically, the ASU (i)&amp;#xA0;provides a definition of the term
 substantial doubt, (ii)&amp;#xA0;requires an evaluation every reporting
 period including interim periods, (iii)&amp;#xA0;provides principles
 for considering the mitigating effect of management&amp;#x2019;s plans,
 (iv)&amp;#xA0;requires certain disclosures when substantial doubt is
 alleviated as a result of consideration of management&amp;#x2019;s
 plans, (v)&amp;#xA0;requires an express statement and other disclosures
 when substantial doubt is not alleviated and (vi)&amp;#xA0;requires an
 assessment for a period of one year after the date that the
 financial statements are issued (or available to be issued). The
 Company believes that its cash and cash equivalents will be
 sufficient to fund its projected operations through the results of
 the &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; study, which
 it anticipates will be available &lt;font style="WHITE-SPACE: nowrap"&gt;mid-2018.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company also considered
 the following recent accounting pronouncements which were not yet
 adopted as of December&amp;#xA0;31, 2016:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In May 2014, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09,&lt;/font&gt; Revenue from
 Contracts with Customers (Topic 606), which will replace numerous
 requirements in U.S. GAAP, including industry-specific
 requirements. This guidance provides a five step model to be
 applied to all contracts with customers, with an underlying
 principle that an entity will recognize revenue to depict the
 transfer of goods or services to customers at an amount that the
 entity expects to be entitled to in exchange for those goods or
 services. ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09&lt;/font&gt; requires extensive
 quantitative and qualitative disclosures covering the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including disclosures on significant
 judgments made when applying the guidance. This guidance is
 effective for annual reporting periods beginning after
 December&amp;#xA0;15, 2017 and interim periods therein. Early adoption
 is permitted for reporting periods and interim periods therein,
 beginning after December&amp;#xA0;15, 2016. An entity can elect to
 apply the guidance under one of the following two methods:
 (i)&amp;#xA0;retrospectively to each prior reporting period presented,
 referred to as the full retrospective method, or
 (ii)&amp;#xA0;retrospectively with the cumulative effect of initially
 applying the standard recognized at the date of initial application
 in retained earnings, referred to as the modified retrospective
 method.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has
 substantially completed an initial impact assessment of the
 potential changes from adopting ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09.&lt;/font&gt; The impact
 assessment consisted of a review of a representative sample of
 contracts, discussions with key stakeholders, and a cataloging of
 potential impacts on its financial statements, accounting policies,
 financial control, and operations. The Company anticipates that the
 adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09&lt;/font&gt; will not have a
 material impact on product revenue from distributors and may have
 an impact on contract revenues generated by its license
 agreements:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(i)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Changes in the model for
 distinct licenses of functional intellectual property which may
 result in a timing difference of revenue recognition. Whereas
 revenue from these arrangements was previously recognized over a
 period of time pursuant to the multiple element arrangement
 guidance, revenue from these arrangements may now be recognized at
 point in time under the new guidance.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(ii)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Assessments of milestone
 payments, which are linked to events that are in the
 Company&amp;#x2019;s control, will result in variable consideration that
 may be recognized at an earlier point in time under the new
 guidance, when it is probable that the milestone will be achieved
 without a significant future reversal of cumulative revenue
 expected.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has not yet
 completed its final review of the impact of this guidance; however,
 the Company anticipates applying the modified retrospective method
 when implementing this guidance. The Company plans to adopt the new
 standard effective January&amp;#xA0;1, 2018. The Company continues to
 monitor additional changes, modifications, clarifications or
 interpretations being undertaken by the FASB, which may impact its
 current conclusions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In January 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-01,&lt;/font&gt; &lt;i&gt;Financial
 Instruments&amp;#x2014;Overall (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;825-10):&lt;/font&gt; Recognition and Measurement
 of Financial Assets and Financial Liabilities&lt;/i&gt;. The new guidance
 is intended to improve the recognition and measurement of financial
 instruments by requiring separate presentation of financial assets
 and financial liabilities by measurement category and form of
 financial asset (i.e., securities or loans and receivables) within
 the balance sheet or the accompanying notes to the financial
 statements, eliminating the requirement for public business
 entities to disclose the method(s) and significant assumptions used
 to estimate the fair value that is required to be disclosed for
 financial instruments measured at amortized cost within the balance
 sheet, requiring public business entities to use the exit price
 notion when measuring the fair value of financial instruments for
 disclosure purposes, requiring equity investments (except those
 accounted for under the equity method of accounting, or those that
 result in consolidation of the investee) to be measured at fair
 value with changes in fair value recognized in net income, and
 requiring a reporting organization to present separately in other
 comprehensive income the portion of the total change in the fair
 value of a liability resulting from a change in the
 instrument-specific credit risk (also referred to as &amp;#x201C;own
 credit&amp;#x201D;) when the organization has elected to measure the
 liability at fair value in accordance with the fair value option
 for financial instruments, among others. The new guidance is
 effective for fiscal years beginning after December&amp;#xA0;15, 2017,
 including interim periods within those fiscal years. The new
 guidance permits early adoption of the own credit provision. The
 Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In February 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-02,&lt;/font&gt; &lt;i&gt;Leases (Topic
 842)&lt;/i&gt;. The new guidance will require lessees to recognize a
 &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; asset and a lease
 liability for virtually all of their leases (other than leases that
 meet the definition of a short-term lease). The liability will be
 equal to the present value of lease payments. The asset will be
 based on the liability, subject to adjustment, such as for initial
 direct costs. Under the new guidance, lessor accounting is largely
 unchanged but certain targeted improvements were made to align,
 where necessary, lessor accounting with the lessee accounting model
 and Topic 606, Revenue from Contracts with Customers. The new lease
 guidance also simplified the accounting for sale and leaseback
 transactions primarily because lessees must recognize lease assets
 and lease liabilities and therefore, will no longer be provided
 with a source of &lt;font style="WHITE-SPACE: nowrap"&gt;off-balance&lt;/font&gt; sheet financing. The new
 guidance is effective for fiscal years beginning after
 December&amp;#xA0;15, 2018, including interim periods within those
 fiscal years. Early adoption is permitted. The Company is currently
 evaluating the accounting, transition and disclosure requirements
 of the standard and cannot currently estimate the financial
 statement impact of adoption.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In March 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-08,&lt;/font&gt; &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606): Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)&lt;/i&gt;, which
 clarifies that an entity is a principal when it controls the
 specified good or service before that good or service is
 transferred to the customer, and is an agent when it does not
 control the specified good or service before it is transferred to
 the customer. The new guidance is intended to improve the
 operability and understandability of the implementation guidance on
 principal versus agent considerations. In April 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-10&lt;/font&gt;&lt;i&gt;, Revenue from
 Contracts with Customers (Topic 606): Identifying Performance
 Obligations and Licensing,&lt;/i&gt; which clarifies the following two
 aspects of Topic 606: (a)&amp;#xA0;identifying performance obligations;
 and (b)&amp;#xA0;the licensing implementation guidance. Further, in May
 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-12,&lt;/font&gt; &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606): Narrow-Scope Improvements and
 Practical Expedients,&lt;/i&gt; which provides clarifying guidance in
 certain narrow areas and adds some practical expedients. The
 amendments do not change the core principles of the guidance in
 Topic 606 and are effective for the Company&amp;#x2019;s fiscal year
 beginning January&amp;#xA0;1, 2018. Early application is permitted only
 as of annual reporting periods beginning after December&amp;#xA0;15,
 2016, including interim reporting periods within that reporting
 period. The Company is currently evaluating the accounting,
 transition and disclosure requirements of these standards and
 cannot currently estimate the financial statement impact of
 adoption.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In August 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-15,&lt;/font&gt; &lt;i&gt;Statement of Cash
 Flows (Topic 230): Classification of Certain Cash Receipts and Cash
 Payments&lt;/i&gt;, which is intended to reduce diversity in practice
 regarding how certain cash receipts and cash payments are presented
 and classified in the statement of cash flows. Specifically, it
 addresses the following eight issues: debt prepayment or debt
 extinguishment costs; settlement of &lt;font style="WHITE-SPACE: nowrap"&gt;zero-coupon&lt;/font&gt; debt instruments;
 contingent consideration payments made after a business
 combination; proceeds from the settlement of insurance claims;
 proceeds from the settlement of corporate-owned life insurance
 policies, including bank-owned life insurance policies;
 distributions received from equity method investments; beneficial
 interests in securitization transactions; and separately
 identifiable cash flows and application of the predominance
 principle. The new guidance is effective for fiscal years beginning
 after December&amp;#xA0;15, 2017, including interim periods within
 those fiscal years. Early adoption is permitted. The Company has
 evaluated the accounting, transition and disclosure requirements of
 the standard and does not expect it to have a material impact on
 the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company believes that
 the impact of other recently issued but not yet adopted accounting
 pronouncements will not have a material impact on the
 Company&amp;#x2019;s consolidated financial position, results of
 operations, and cash flows, or do not apply to the Company&amp;#x2019;s
 operations.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_88816752-10F5-409C-95FA-7A6022D76B63_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014, the following potentially
 dilutive securities were not included in the computation of net
 loss per share because the effect would be
 anti-dilutive:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,188&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,670&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Restricted stock and
 restricted stock units&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,887&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,256&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exchangeable senior notes
 (if converted)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,714&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;59,407&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49,215&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock (if
 converted)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E47A46A1-1BC4-4587-A9EE-1AFD25165291_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The (provision for) benefit
 from income taxes shown in the accompanying consolidated statements
 of operations consists of the following for fiscal 2016, 2015 and
 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Current:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Federal-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,053&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;660&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;State-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;138&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;113&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;117&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,171&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,166&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;777&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Federal-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,001&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,343&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,689&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;State-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(334&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(605&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Ireland and United
 Kingdom&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,023&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,335&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Change in valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,276&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,798&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,252&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,614&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision for (benefit
 from) income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,969&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,086&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,837&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_C9B3DE1A-FE13-4A1B-A5A0-E598C472A384_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company leases office
 space under operating leases. Future minimum lease payments under
 these leases, net of sublease rental income, as of
 December&amp;#xA0;31, 2016 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1px; WIDTH: 92pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ending
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;528&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;126&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2019-2021&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_1E1ECF1D-C6F8-41D8-BA44-197D4F891622_1_0">&lt;div&gt;
 &lt;p&gt;&lt;font size="2"&gt;The following table presents the restricted stock
 unit activity for the years ended December&amp;#xA0;31, 2016 and
 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands (except per share
 amounts)&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Grant Date
 Fair&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding as of
 January&amp;#xA0;1, 2015&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,256&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.03&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,888&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(821&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.14&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(436&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.45&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding as of
 December&amp;#xA0;31, 2015&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,887&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,756&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.47&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,853&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(647&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1.74&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding as of
 December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.09&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_3186341D-DF03-4DC5-9091-CB839E82A8E2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
 Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 selling, general and administrative costs to operations as
 incurred. Selling, general and administrative costs include costs
 of salaries, programs and infrastructure necessary for the general
 conduct of the Company&amp;#x2019;s business, including those incurred
 as a result of the commercialization of Vascepa in the United
 States as well as &lt;font style="WHITE-SPACE: nowrap"&gt;co-promotion&lt;/font&gt; fees payable to Kowa
 Pharmaceuticals America, Inc.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_1_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_1_5" unitRef="pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_1_400004" unitRef="shares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_A3E6572F-05C6-431E-8976-94F9ED085187_1_1">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1_5" unitRef="iso4217_USD_per_shares">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1_4" unitRef="iso4217_USD_per_shares">7.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_C22CA120-00E8-4B22-AE35-60954D90B651_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(2)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Significant Accounting
 Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The consolidated financial
 statements include the accounts of the Company and its wholly-owned
 subsidiaries. All intercompany accounts and transactions have been
 eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounting estimates are
 based on historical experience and other factors that are
 considered reasonable under the circumstances. Estimates are used
 in determining such items as provisions for sales returns, rebates
 and incentives, chargebacks, and other sales allowances;
 depreciable/amortizable lives; asset impairments; valuation
 allowance on deferred taxes; probabilities of achievement of
 performance conditions for certain equity awards; amounts recorded
 for licensing revenue; contingencies and accruals; and valuations
 of derivative and long-term debt instruments. Because of the
 uncertainties inherent in such estimates, actual results may differ
 from these estimates. Management periodically evaluates estimates
 used in the preparation of the consolidated financial statements
 for continued reasonableness.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Forecasted Financial Information in Accounting
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The use of forecasted
 financial information is inherent in many of the Company&amp;#x2019;s
 accounting estimates including, but not limited to, determining the
 estimated fair values of derivatives, debt instruments and
 intangible assets, evaluating the need for valuation allowances for
 deferred tax assets, and assessing the Company&amp;#x2019;s ability to
 continue as a going concern. Such forecasted financial information
 is comprised of numerous assumptions regarding the Company&amp;#x2019;s
 future revenues, cash flows, and operational results. Management
 believes that its financial forecasts are reasonable and
 appropriate based upon current facts and circumstances. Because of
 the inherent nature of forecasts, however, actual results may
 differ from these forecasts. Management regularly reviews the
 information related to these forecasts and adjusts the carrying
 amounts of the applicable assets prospectively, if and when actual
 results differ from previous estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors or its customers, that in turn
 resell Vascepa to retail pharmacies for subsequent resale to
 patients and healthcare providers. Patients are required to have a
 prescription in order to purchase Vascepa. In accordance with GAAP,
 the Company&amp;#x2019;s revenue recognition policy requires that:
 (i)&amp;#xA0;there is persuasive evidence that an arrangement exists
 between the Company and the Distributor, (ii)&amp;#xA0;delivery has
 occurred, (iii)&amp;#xA0;collectability is reasonably assured and
 (iv)&amp;#xA0;the price is fixed or determinable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contracts
 with its primary Distributors and delivery generally occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment. In order to conclude that the
 price is fixed or determinable, the Company must be able to
 (i)&amp;#xA0;calculate its gross product revenues from the sales to
 Distributors and (ii)&amp;#xA0;reasonably estimate its net product
 revenues. The Company calculates gross product revenues generally
 based on the wholesale acquisition cost that the Company charges
 its Distributors for Vascepa. The Company estimates its net product
 revenues by deducting from its gross product revenues
 (a)&amp;#xA0;trade allowances, such as invoice discounts for prompt
 payment and distributor fees, (b)&amp;#xA0;estimated government and
 private pay or rebates, chargebacks and discounts, such as Medicaid
 reimbursements, (c)&amp;#xA0;reserves for expected product returns and
 (d)&amp;#xA0;estimated costs of incentives offered to certain indirect
 customers, including patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
 Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within 30
 days while the fees for distribution services are based on
 contractual rates agreed with the respective Distributors. Based on
 judgment and experience, the Company expects its Distributors to
 earn these discounts and fees, and deducts the full amount of these
 discounts and fees from its gross product revenues and accounts
 receivable at the time such revenues are recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
 Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s contracts with these
 Third-party Payors, (ii)&amp;#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&amp;#xA0;information
 obtained from the Company&amp;#x2019;s Distributors and
 (iv)&amp;#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the &lt;font style="WHITE-SPACE: nowrap"&gt;18-month&lt;/font&gt; period beginning six months
 prior to the labeled expiration date and ending twelve months after
 the labeled expiration date. The expiration date for Vascepa is
 three years after it has been converted into capsule form, which is
 the last step in the manufacturing process for Vascepa and
 generally occurs within a few months before Vascepa is delivered to
 Distributors. The Company estimates future product returns on sales
 of Vascepa based on: (i)&amp;#xA0;data provided to the Company by its
 Distributors (including weekly reporting of Distributors&amp;#x2019;
 sales and inventory held by Distributors that provided the Company
 with visibility into the distribution channel in order to determine
 what quantities were sold to retail pharmacies and other
 providers), (ii)&amp;#xA0;information provided to the Company from
 retail pharmacies, (iii)&amp;#xA0;data provided to the Company by a
 third-party data provider which collects and publishes prescription
 data, and other third parties, (iv)&amp;#xA0;historical industry
 information regarding return rates for similar pharmaceutical
 products, (v)&amp;#xA0;the estimated remaining shelf life of Vascepa
 previously shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s
 Distributors.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
 Incentives:&lt;/i&gt; Other incentives that the Company offers to
 indirect customers include &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation programs. The
 Company&amp;#x2019;s &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt;
 mitigation program is intended to reduce each participating
 patient&amp;#x2019;s portion of the financial responsibility for
 Vascepa&amp;#x2019;s purchase price to a specified dollar amount. Based
 upon the terms of the program and information regarding programs
 provided for similar specialty pharmaceutical products, the Company
 estimates the average &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation amounts and the
 percentage of patients that it expects to participate in the
 program in order to establish its accruals for &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation rebates and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company adjusts its accruals for
 &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation rebates
 based on actual redemption activity and estimates regarding the
 portion of issued &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt;
 mitigation rebates that it estimates will be redeemed.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the net product revenue allowance
 and reserve categories described above for the years ended
 December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Chargebacks&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 January&amp;#xA0;1, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,207&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;481&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;792&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,090&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,986&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,591&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;342&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,310&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;56,229&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to prior
 period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(174&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(70&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(205&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(449&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,690&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(22,710&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(40,626&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 prior period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,540&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(792&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,448&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;4,296&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,881&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;535&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,084&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;15,796&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;22,952&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;69,370&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;583&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,696&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;104,601&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to prior
 period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(450&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(537&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(19,213&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(48,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,815&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(77,747&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 prior period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,205&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,167&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(259&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,915&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3,743&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;20,915&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;859&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,681&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;27,198&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Such net product revenue
 allowances and reserves are included within accrued expenses and
 other current liabilities within the consolidated balance sheets,
 with the exception of trade allowances and chargebacks, which are
 included within accounts receivable, net as discussed
 below.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Multiple-Element Arrangements and Licensing
 Revenue&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;When evaluating
 multiple-element arrangements, the Company identifies the
 deliverables included within the agreement and evaluates which
 deliverables represent separate units of accounting based on
 whether the delivered element has stand-alone value to the customer
 or if the arrangement includes a general right of return for
 delivered items.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The consideration received
 is allocated between each of the separable elements in the
 arrangement using the relative selling price method. The selling
 price used for each separable element will be based on vendor
 specific objective evidence (&amp;#x201C;VSOE&amp;#x201D;) if available,
 third-party evidence if VSOE is not available, or estimated selling
 price if neither VSOE nor third-party evidence is available.
 Revenue is then recognized as each of the separable elements to
 which the revenue has been allocated is delivered.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company may receive
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front,&lt;/font&gt; &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; payments when licensing
 its intellectual property in conjunction with research, development
 and commercialization agreements. In determining the units of
 accounting, management evaluates whether the license has
 stand-alone value from the undelivered elements to the
 collaborative partner based on the consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the stage of development of the license
 delivered, research and development capabilities of the partner and
 the ability of partners to develop and commercialize Vascepa
 independent of the Company.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;When management believes
 the license to its intellectual property does not have stand-alone
 value from the other deliverables to be provided in the
 arrangement, the Company generally recognizes revenue attributable
 to the license over the Company&amp;#x2019;s contractual or estimated
 performance period. Any unrecognized portion of license revenue is
 classified within deferred revenue in the accompanying consolidated
 balance sheets. When management believes the license to its
 intellectual property has stand-alone value, the Company recognizes
 revenue attributed to the license upon delivery. The periods over
 which revenue is recognized is subject to estimates by management
 and may change over the course of the agreement. Such a change
 could have a material impact on the amount of revenue the Company
 records in future periods.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Milestones&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Contingent consideration
 from activities that is earned upon the achievement of a
 substantive milestone is recognized in its entirety in the period
 in which the milestone is achieved. At the inception of each
 arrangement that includes milestone payments, the Company evaluates
 whether each milestone is substantive. This evaluation includes an
 assessment of whether: (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, clinical, regulatory,
 commercial and other risks that must be overcome to achieve the
 respective milestone, the level of effort and investment required
 and whether the milestone consideration is reasonable relative to
 all deliverables and payment terms in the arrangement in making
 this assessment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See Note
 17&amp;#x2014;Development, Commercialization and Supply Agreement for
 further information regarding licensing revenue and milestones
 primarily related to the Company&amp;#x2019;s multiple-element
 arrangement with Eddingpharm (Asia) Macao Commercial Offshore
 Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Distribution Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company records
 distribution costs related to shipping product to its customers,
 primarily through the use of common carriers or external
 distribution services, in cost of goods sold.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Cash
 and Cash Equivalents and Restricted Cash&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents
 consist of cash, deposits with banks and short-term highly liquid
 money market instruments with remaining maturities at the date of
 purchase of 90 days or less. Restricted cash represents cash and
 cash equivalents pledged to guarantee repayment of certain expenses
 which may be incurred for business travel under corporate credit
 cards held by employees.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Accounts Receivable, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable, net,
 comprised of trade receivables, are generally due within 30 days
 and are stated at amounts due from customers. The Company
 recognizes an allowance for losses on accounts receivable in an
 amount equal to the estimated probable losses net of any
 recoveries. The allowance is based primarily on assessment of
 specific identifiable customer accounts considered at risk or
 uncollectible, as well as an analysis of current receivables aging
 and expected future write-offs. The expense associated with the
 allowance for doubtful accounts is recognized as selling, general,
 and administrative expense. The Company has not historically
 experienced any credit losses.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes the impact of accounts receivable reserves on the gross
 trade accounts receivable balances as of December&amp;#xA0;31, 2016 and
 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gross trade accounts
 receivable&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;24,127&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;18,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Trade allowances&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,743&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,296&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Chargebacks&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(387&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(148&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Allowance for doubtful
 accounts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable,
 net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;19,985&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,826&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effective April 2016, the
 Company adopted Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;)
 &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt;
 &lt;i&gt;Inventory (Topic 330)&amp;#x2014;Simplifying the Measurement of
 Inventory&lt;/i&gt;, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost and net realizable value test and, as such, began to
 state inventories at the lower of cost or net realizable value.
 Such adoption had no impact on the carrying value of inventory.
 Cost is determined based on actual cost using the average cost
 method. An allowance is established when management determines that
 certain inventories may not be saleable. If inventory cost exceeds
 expected net realizable value due to obsolescence, damage or
 quantities in excess of expected demand, changes in price levels or
 other causes, the Company will reduce the carrying value of such
 inventory to net realizable value and recognize the difference as a
 component of cost of goods sold in the period in which it occurs.
 The Company capitalizes inventory purchases of saleable product
 from approved suppliers while inventory purchases from suppliers
 prior to regulatory approval are included as a component of
 research and development expense. The Company expenses inventory
 identified for use as marketing samples when they are packaged. The
 average cost reflects the actual purchase price of Vascepa active
 pharmaceutical ingredient, or API.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Property, Plant and Equipment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides for
 depreciation and amortization using the straight-line method by
 charges to operations in amounts that depreciate the cost of the
 fixed asset over its estimated useful life. The estimated useful
 lives, by asset classification, are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="WIDTH: 66pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Asset
 Classification&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;p style="WIDTH: 41pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Useful Lives&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Computer equipment and
 software&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3 -
 5&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture and
 fixtures&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5 years&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Lesser&amp;#xA0;of&amp;#xA0;useful&amp;#xA0;life&amp;#xA0;or&amp;#xA0;lease&amp;#xA0;term&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Upon retirement or sale of
 assets, the cost of the assets disposed and the related accumulated
 depreciation are removed from the consolidated balance sheet and
 any resulting gain or loss is credited or expensed to operations.
 Repairs and maintenance costs are expensed as incurred.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long-Lived Asset Impairment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company reviews its
 long-lived assets for impairment whenever events or changes in
 circumstances indicate that the carrying amount of such assets may
 not be recoverable. Recoverability of these assets is determined by
 comparing the forecasted undiscounted net cash flows of the
 operation to which the assets relate to their carrying amount. If
 impairment is indicated, the assets are written down to fair value.
 Fair value is determined based on discounted forecasted cash flows
 or appraised values, depending on the nature of the
 assets.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible asset, net
 consists of a milestone payment paid to the former shareholders of
 Laxdale Limited related to the 2004 acquisition of the rights to
 Vascepa, which is the result of Vascepa receiving marketing
 approval for the first indication and is amortized over its
 estimated useful life on a straight-line basis. See Note
 9&amp;#x2014;Commitments and Contingencies for further information
 regarding other obligations related to the acquisition of Laxdale
 Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Beneficial Conversion Features&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company issued Series A
 preference shares in a private placement transaction executed in
 two tranches that each contain a conversion feature whereby such
 shares are convertible into ordinary shares at a fixed rate. The
 conversion price on the date of issuance was less than the market
 price of the Company&amp;#x2019;s ordinary shares. It was determined
 that these discounts represent contingent beneficial conversion
 features, which were valued based on the difference between the
 conversion price and the market price of the ordinary shares on the
 date of issuance, which is the commitment date. These features are
 analogous to preference dividends and were each recorded as a
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt; return to
 preferred shareholders through accumulated deficit upon the
 earliest possible date of conversion, which occurred in the three
 months ended June&amp;#xA0;30, 2015 upon effectiveness of the related
 resale Registration Statement on Form &lt;font style="WHITE-SPACE: nowrap"&gt;S-3&lt;/font&gt; and in the three months ended
 September&amp;#xA0;30, 2015 upon shareholder approval received at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders. See Note
 10&amp;#x2014;Equity for further discussion.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Costs
 for Patent Litigation and Legal Proceedings&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Costs for patent litigation
 or other legal proceedings are expensed as incurred and included in
 selling, general and administrative expenses.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including: salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative
 Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 selling, general and administrative costs to operations as
 incurred. Selling, general and administrative costs include costs
 of salaries, programs and infrastructure necessary for the general
 conduct of the Company&amp;#x2019;s business, including those incurred
 as a result of the commercialization of Vascepa in the United
 States as well as &lt;font style="WHITE-SPACE: nowrap"&gt;co-promotion&lt;/font&gt; fees payable to Kowa
 Pharmaceuticals America, Inc.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
 Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carryforwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&amp;#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company regularly
 assesses its ability to realize deferred tax assets. Changes in
 historical earnings performance and future earnings projections,
 among other factors, may cause the Company to adjust its valuation
 allowance on deferred tax assets, which would impact the
 Company&amp;#x2019;s income tax expense in the period in which it is
 determined that these factors have changed.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2016, the Company
 adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital. This aspect of the
 standard was adopted prospectively and, accordingly, the provision
 for income taxes for the year ended December&amp;#xA0;31, 2016 includes
 $0.4&amp;#xA0;million of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately
 $1.6&amp;#xA0;million relating to excess tax benefits on stock-based
 compensation outstanding as of December&amp;#xA0;31, 2015, with a
 corresponding cumulative-effect adjustment to accumulated deficit.
 The new standard also amends the presentation of employee
 share-based payment-related items in the statement of cash flows by
 requiring that: (i)&amp;#xA0;excess income tax benefits and
 deficiencies be classified in cash flows from operating activities,
 and (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.7&amp;#xA0;million of excess tax benefit
 and $2.3&amp;#xA0;million of excess tax provision from cash flows
 provided by financing activities to cash flows used in operating
 activities in the consolidated statement of cash flows for the
 years ended December&amp;#xA0;31, 2015 and 2014, respectively, to
 conform to the current year presentation. The presentation
 requirement for cash flows related to taxes paid for withheld
 shares had no impact to any of the periods presented in the
 consolidated statement of cash flows since such payments have
 historically been presented as a financing activity.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s and its
 subsidiaries&amp;#x2019; income tax returns are periodically examined by
 various tax authorities. The Company is currently under audit by
 the United States Internal Revenue Service (IRS) for the years 2013
 to 2014. Although the outcome of tax audits is always uncertain and
 could result in significant cash tax payments, the Company does not
 believe the outcome of these audits will have a material adverse
 effect on the Company&amp;#x2019;s consolidated financial position or
 results of operations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the consolidated
 statement of operations at each period end while such instruments
 are outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital are recognized on the
 issuance of those shares. Warrants are valued using a Black-Scholes
 option pricing model. The long-term debt redemption features are
 valued using probability-weighted models incorporating management
 estimates for potential change in control, and by determining the
 fair value of the debt with and without the change in control
 provision included.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Loss
 per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic net loss per share is
 determined by dividing net loss by the weighted average shares of
 common stock outstanding during the period. Diluted net loss per
 share is determined by dividing net loss by diluted weighted
 average shares outstanding. Diluted weighted average shares
 reflects the dilutive effect, if any, of potentially dilutive
 common shares, such as common stock options and warrants calculated
 using the treasury stock method and convertible notes using the
 &lt;font style="WHITE-SPACE: nowrap"&gt;&amp;#x201C;if-converted&amp;#x201D;&lt;/font&gt;
 method. In periods with reported net operating losses, all common
 stock options and warrants are deemed anti-dilutive such that basic
 net loss per share and diluted net loss per share are equal.
 However, in certain periods in which there is a gain recorded
 pursuant to the change in fair value of the warrant derivative
 liability, for diluted net loss per share purposes, the impact of
 such gains is reversed and the treasury stock method is used to
 determine diluted net loss per share.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 preferred stock is entitled to receive dividends on an &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;as-if-converted&lt;/font&gt;&lt;/font&gt; basis in the
 same form as dividends actually paid on common shares. Accordingly,
 the preferred stock is considered a participating security and the
 Company is required to apply the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method to consider the
 impact of the preferred stock on the calculation of basic and
 diluted earnings per share. The Company is currently in a net loss
 position and is therefore not required to present the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method, however, in the
 event the Company is in a net income position, the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method must be applied by
 allocating all earnings during the period to common shares and
 preferred stock based on their contractual entitlements assuming
 all earnings were distributed.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The calculation of net loss
 and the number of shares used to compute basic and diluted net loss
 per share for the years ended December&amp;#xA0;31, 2016, 2015 and 2014
 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(115,204&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock purchase
 option (see Note 10&amp;#x2014;Equity)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(868&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock beneficial
 conversion features (see Note 10&amp;#x2014;Equity)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(32,987&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss applicable to
 common shareholders&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(149,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,775&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net
 loss&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(149,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(63,139&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 share&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.32&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average shares
 outstanding&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;211,874&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;180,654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;173,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effect of dilutive
 warrants&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;105&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average shares
 outstanding&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;211,874&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;180,654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;173,824&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 share&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.36&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014, the following potentially
 dilutive securities were not included in the computation of net
 loss per share because the effect would be
 anti-dilutive:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,188&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,670&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Restricted stock and
 restricted stock units&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,887&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,256&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exchangeable senior notes
 (if converted)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,714&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;59,407&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49,215&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock (if
 converted)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the
 consolidated statement of operations as interest expense each
 period in which such instruments are outstanding. If the Company
 issues shares to discharge the liability, the debt obligation is
 derecognized and common stock and additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital are recognized on the
 issuance of those shares. The conversion features in the 2012
 Notes, and previously the 2014 Notes and 2015 Notes prior to the
 mandatory exchange, qualify for the exception from derivative
 accounting in accordance with ASC &lt;font style="WHITE-SPACE: nowrap"&gt;815-40.&lt;/font&gt; The 2012 Notes may be put to
 the Company by their holders for repurchase in cash. The 2012 Notes
 are exchangeable under certain circumstances at the Company&amp;#x2019;s
 discretion, in any combination of ADSs or cash upon conversion and
 have been accounted for in accordance with ASC &lt;font style="WHITE-SPACE: nowrap"&gt;470-20.&lt;/font&gt; Under ASC &lt;font style="WHITE-SPACE: nowrap"&gt;470-20,&lt;/font&gt; the fair value of the
 liability component of the 2012 Notes was determined and deducted
 from the initial proceeds to determine the proceeds allocated to
 the conversion option, which has been recorded in equity. The
 difference between the initial fair value of the liability
 component and the amount repayable was fully amortized over the
 expected term of the instrument. The conversion features in the
 2014 Notes and 2015 Notes could only have been settled in ADSs upon
 conversion and were therefore accounted for as part of the debt
 host.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The conversion feature in
 the 2012 Notes, continues to be evaluated on a quarterly basis to
 determine if it still receives an exception from derivative
 accounting in accordance with ASC &lt;font style="WHITE-SPACE: nowrap"&gt;815-40.&lt;/font&gt; The 2014 Notes were recognized
 initially at fair value as part of an extinguishment of a portion
 of the 2012 Notes. As a result, the 2014 Notes were initially
 recognized at a discount of $27.9&amp;#xA0;million. The 2015 Notes were
 recognized initially at fair value as part of the issuance of new
 debt in November 2015. As a result, the 2015 Notes were initially
 recognized at a discount of $3.8&amp;#xA0;million. These discounts were
 amortized through interest expense through the date of the
 mandatory exchange. See Note 8&amp;#x2014;Debt for further
 discussion.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Stock-Based Compensation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based compensation
 cost is generally measured at the grant date, based on the fair
 value of the award, and is recognized as compensation expense over
 the requisite service period. For awards with performance
 conditions, if the achievement of the performance conditions is
 deemed probable, the Company recognizes compensation expense based
 on the fair value of the award over the estimated service period.
 The Company reassesses the probability of achievement of the
 performance conditions for such awards each reporting
 period.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Credit Risk&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Financial instruments that
 potentially subject the Company to credit risk consist primarily of
 cash and cash equivalents and accounts receivable. The Company
 maintains substantially all of its cash and cash equivalents in
 financial institutions believed to be of high-credit
 quality.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;A significant portion of
 the Company&amp;#x2019;s sales are to wholesalers in the pharmaceutical
 industry. The Company monitors the creditworthiness of customers to
 whom it grants credit terms and has not experienced any credit
 losses. The Company does not require collateral or any other
 security to support credit sales. The Company&amp;#x2019;s top three
 customers accounted for 95% of gross product sales for each of the
 years ending December&amp;#xA0;31, 2016 and 2015, and represented 96%
 and 95% of the gross accounts receivable balance as of
 December&amp;#xA0;31, 2016 and 2015, respectively. The Company has not
 experienced any write-offs of its accounts receivable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Suppliers&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contractual
 freedom to source the API for Vascepa and has entered into supply
 agreements with multiple suppliers. The Company&amp;#x2019;s supply of
 product for commercial sale and clinical trials is dependent upon
 relationships with third-party manufacturers and key suppliers, in
 particular three suppliers of API for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company cannot provide
 assurance that its efforts to procure uninterrupted supply of
 Vascepa API to meet market demand will continue to be successful or
 that it will be able to renew current API supply agreements on
 favorable terms or at all. Significant alteration to or termination
 of the Company&amp;#x2019;s current API supply chain or its failure to
 enter into new and similar agreements in a timely fashion, if
 needed, could have a material adverse effect on its business,
 condition (financial and other), prospects or results of
 operations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company currently has
 manufacturing agreements with three &lt;font style="WHITE-SPACE: nowrap"&gt;FDA-approved&lt;/font&gt; commercial API
 encapsulators for Vascepa manufacturing. Each of these companies
 has qualified its manufacturing processes and is capable of
 manufacturing Vascepa. There can be no guarantee that these or
 other suppliers with which the Company may contract in the future
 to encapsulate API will remain qualified to manufacture the product
 to its specifications or that these and any future suppliers will
 have the manufacturing capacity to meet anticipated demand for
 Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
 U.S. dollar as the functional currency. Monetary assets and
 liabilities denominated in a foreign currency are remeasured into
 U.S. dollars at &lt;font style="WHITE-SPACE: nowrap"&gt;period-end&lt;/font&gt;
 exchange rates. Gains and losses from the remeasurement are
 included in other (expense) income, net, in the consolidated
 statements of operations. For transactions settled during the
 applicable period, gains and losses are included in other (expense)
 income, net, in the consolidated statements of operations. Certain
 amounts payable pursuant to supply contracts are denominated in
 currencies other than the U.S. dollar.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Issuance Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Prior to January 2016, debt
 issuance costs were initially recorded as a deferred cost and
 amortized to interest expense using the effective interest method
 over the expected term of the related debt. Effective January 2016,
 the Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt;
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;835-30):&lt;/font&gt; Simplifying the Presentation
 of Debt Issuance Costs&lt;/i&gt;, and as such began recording debt
 issuance costs related to a recognized debt liability in the
 consolidated balance sheet as a direct deduction from the carrying
 amount of that debt liability and amortized to interest expense
 using the effective interest method over the expected term of the
 related debt. As the standard is required to be adopted on a
 retrospective basis, the Company reclassified $1.9&amp;#xA0;million of
 underwriters&amp;#x2019; fees and offering costs related to the 2014
 Notes and 2015 Notes from other &lt;font style="WHITE-SPACE: nowrap"&gt;long-term&lt;/font&gt; assets to exchangeable
 senior notes, net of discount, within the consolidated balance
 sheet as of December&amp;#xA0;31, 2015. Unamortized debt issuance costs
 related to the extinguishment of debt are expensed at the time the
 debt is extinguished and recorded in other (expense) income, net,
 in the consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Fair
 Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 disclosure of financial assets and financial liabilities that are
 carried at fair value based on the price that would be received
 upon sale of an asset or paid to transfer a liability in an orderly
 transaction between market participants at the measurement date.
 Fair value measurements may be classified based on the amount of
 subjectivity associated with the inputs to fair valuation of these
 assets and liabilities using the following three levels:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1&amp;#x2014;Inputs are
 unadjusted quoted prices in active markets for identical assets or
 liabilities that the Company has the ability to access at the
 measurement date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 2&amp;#x2014;Inputs
 include quoted prices for similar assets and liabilities in active
 markets, quoted prices for identical or similar assets or
 liabilities in markets that are not active, inputs other than
 quoted prices that are observable for the asset or liability (i.e.,
 interest rates, yield curves, etc.) and inputs that are derived
 principally from or corroborated by observable market data by
 correlation or other means (market corroborated inputs).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 3&amp;#x2014;Unobservable
 inputs that reflect the Company&amp;#x2019;s estimates of the
 assumptions that market participants would use in pricing the asset
 or liability. The Company develops these inputs based on the best
 information available, including its own data.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following tables
 present information about the Company&amp;#x2019;s assets and
 liabilities as of December&amp;#xA0;31, 2016 and 2015 that are measured
 at fair value on a recurring basis and indicate the fair value
 hierarchy of the valuation techniques the Company utilized to
 determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,184&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,184&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt derivative
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts payable and accrued liabilities
 approximate fair value because of their short-term nature. The
 carrying amounts and the estimated fair values of debt instruments
 as of December&amp;#xA0;31, 2016 and 2015 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt from
 royalty-bearing instrument&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85,155&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;90,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91,512&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;87,700&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2012 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,107&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,174&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,107&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,637&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2014 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;96,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;108,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2015 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,134&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;28,448&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The estimated fair value of
 the long-term debt from royalty-bearing instrument pursuant to the
 December 2012 financing is calculated utilizing the same
 Level&amp;#xA0;3 inputs utilized in valuing the related derivative
 liability (see Long-Term Debt Redemption Features below). The
 estimated fair value of the 2012 Notes and 2014 Notes is calculated
 based on Level&amp;#xA0;1 quoted bond prices, while the estimated fair
 value of the 2015 Notes is calculated based on Level&amp;#xA0;2 quoted
 bond prices for the 2014 Notes. The carrying value of the 2012
 Notes as of December&amp;#xA0;31, 2016 and 2015 does not include a debt
 discount, as it had been fully amortized as &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt; interest expense over the
 expected term of the 2012 Notes, which was calculated to be a
 period of twenty-four months. The carrying value of the 2014 Notes
 as of December&amp;#xA0;31, 2015 includes a debt discount of
 $24.1&amp;#xA0;million, which prior to mandatory exchange was being
 amortized as &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;
 interest expense over the expected term of the 2014 Notes, through
 January 2019. The carrying value of the 2015 Notes as of
 December&amp;#xA0;31, 2015 includes a debt discount of
 $4.2&amp;#xA0;million, which prior to mandatory exchange was being
 amortized as &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;
 interest expense over the expected term of the 2015 Notes, through
 January 2019. The carrying values and related debt discounts of the
 2014 Notes and 2015 Notes as of December&amp;#xA0;31, 2015 reflect the
 retroactive reclassification of debt issuance costs per adoption of
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03&lt;/font&gt; as
 described in Note 8&amp;#x2014;Debt. The change in the estimated fair
 values of these liabilities from December&amp;#xA0;31, 2015 to
 December&amp;#xA0;31, 2016 is largely related to changes in the quoted
 bond prices and derecognition of the mandatorily exchanged
 debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Liabilities&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Warrant
 Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s warrant
 derivative liability (discussed in Note 7&amp;#x2014;Warrants and
 Warrant Derivative Liability) was carried at fair value and was
 classified as Level&amp;#xA0;3 in the fair value hierarchy due to the
 use of significant unobservable inputs. During the year ended
 December&amp;#xA0;31, 2015 of the 8,087,388 warrants outstanding as of
 December&amp;#xA0;31, 2014, 1,844,585 warrants were exercised while the
 remaining 6,242,803 warrants expired and the related derivative
 liability was extinguished. As such, no warrants were outstanding
 as of December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Long-Term
 Debt Redemption Features&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman LP (discussed in Note 8&amp;#x2014;Debt) contains a
 redemption feature whereby, upon a change of control, the Company
 would be required to repay $150.0&amp;#xA0;million, less any previously
 repaid amount. The Company determined this redemption feature to be
 an embedded derivative, which is carried at fair value and is
 classified as Level&amp;#xA0;3 in the fair value hierarchy due to the
 use of significant unobservable inputs. The fair value of the
 embedded derivative was calculated using a probability-weighted
 model incorporating management estimates of future revenues and for
 a potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two was determined to be the fair value
 of the embedded derivative. As of December&amp;#xA0;31, 2016, the fair
 value of the derivative was determined to be nil based on current
 assumptions, and the debt was valued by comparing debt issues of
 similar companies with (i)&amp;#xA0;remaining terms of between 2.4 and
 5.0 years, (ii)&amp;#xA0;coupon rates of between 8.1% and 11.1% and
 (iii)&amp;#xA0;market yields of between 11.9% and 18.4%. As of
 December&amp;#xA0;31, 2015, the fair value of the derivative was
 determined to be $5.5&amp;#xA0;million, and the debt was valued by
 comparing debt issues of similar companies with (i)&amp;#xA0;remaining
 terms of between 2.0 and 7.3 years, (ii)&amp;#xA0;coupon rates of
 between 6.6% and 12.5% and (iii)&amp;#xA0;market yields of between
 13.0% and 30.7%. As such, the Company recognized a
 $5.5&amp;#xA0;million gain on change in fair value of derivative
 liability for the year ended December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s 2014
 Notes and 2015 Notes each contained a redemption feature whereby,
 upon occurrence of a change in control, the Company would have been
 required to repurchase the notes. The Company determined these
 redemption features to be embedded derivatives, requiring
 bifurcation in accordance with ASC 815. The derivatives were
 carried at fair value and were classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable inputs.
 The fair value of each embedded derivative was calculated using a
 probability-weighted model incorporating management estimates of
 the probability of a change in control occurring, and by
 determining the fair value of the debt with and without the change
 in control provision included. The difference between the two was
 determined to be the fair value of the embedded derivative. As of
 December&amp;#xA0;31, 2016, derivatives related to the 2014 Notes and
 2015 Notes were each derecognized, as the related debt hosts were
 exchanged into equity in September 2016. As of December&amp;#xA0;31,
 2015, the fair values of the derivatives related to the 2014 Notes
 and 2015 Notes were determined to be $2.1&amp;#xA0;million and
 $0.6&amp;#xA0;million, respectively, and the debts were valued by using
 (i)&amp;#xA0;the estimated remaining term of the notes, (ii)&amp;#xA0;a
 bond yield of 25.6%, (iii)&amp;#xA0;a risk-free interest rate of 2.9%
 and (iv)&amp;#xA0;volatility of 89.0%. As such, the Company recognized
 a gain on change in fair value of derivative liability for the 2014
 Notes and 2015 Notes of $2.1&amp;#xA0;million and $0.6&amp;#xA0;million,
 respectively, for the year ended December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Preferred
 Stock Purchase Option Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Pursuant to a &lt;font style="WHITE-SPACE: nowrap"&gt;pre-existing&lt;/font&gt; contractual right to
 participate in certain private placement transactions effected by
 the Company in connection with the subscription agreement executed
 on March&amp;#xA0;5, 2015, the Company determined that such right
 represented a derivative liability (see Note 10&amp;#x2014;Equity). This
 preferred stock purchase option derivative liability was carried at
 fair value and classified as Level&amp;#xA0;3 in the fair value
 hierarchy due to the use of significant unobservable inputs. The
 fair value of this liability was calculated using a Black-Scholes
 model and was determined to be $0.9&amp;#xA0;million at inception. On
 March&amp;#xA0;30, 2015, this right was exercised and the liability was
 marked to fair value through such date. The liability was then
 reclassified to permanent equity on such date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Any changes in the
 assumptions used to value the derivative liabilities, including the
 probability of a change in control, could result in a material
 change to the carrying value of such liabilities.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of derivative liabilities for the years ended
 December&amp;#xA0;31, 2016 and 2015 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Long-Term&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&amp;#xA0;
 Derivative&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Preferred
 Stock&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 January&amp;#xA0;1, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;119&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,400&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,519&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Record initial fair value
 of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;868&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,368&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(110&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;946&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,106&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfer derivative
 liability to equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,814&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,814&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on change in fair
 value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
 Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Operating segments are
 defined as components of an enterprise about which separate
 financial information is available that is evaluated on a regular
 basis by the chief operating decision-maker, or decision making
 group, in deciding how to allocate resources to an individual
 segment and in assessing performance of the segment. The Company
 currently operates in one business segment, which is the
 development and commercialization of Vascepa. A single management
 team that reports to the Company&amp;#x2019;s chief decision-maker, who
 is the Chief Executive Officer, comprehensively manages the
 business. Accordingly, the Company does not have separately
 reportable segments.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Recent
 Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;From time to time, new
 accounting pronouncements are issued by the Financial Accounting
 Standards Board, or FASB, and are early adopted by the Company or
 adopted as of the specified effective date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In January 2016, the
 Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt;
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;835-30):&lt;/font&gt; Simplifying the Presentation
 of Debt Issuance Costs&lt;/i&gt;, which provides guidance on simplifying
 the presentation of debt issuance costs on the balance sheet. To
 simplify presentation of debt issuance costs, the amendments in ASU
 &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03&lt;/font&gt; require
 that debt issuance costs related to a recognized debt liability be
 presented in the balance sheet as a direct deduction from the
 carrying amount of that debt liability, consistent with the
 treatment of debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this update. In accordance with ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt; the Company applied
 the new guidance on a retrospective basis, wherein the consolidated
 balance sheet of each individual period presented was adjusted to
 reflect the period-specific effects of applying the new guidance.
 See Note 8&lt;i&gt;&amp;#x2014;&lt;/i&gt;Debt.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2016, the Company
 adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt; &lt;i&gt;Inventory (Topic
 330): Simplifying the Measurement of Inventory&lt;/i&gt;, which
 simplifies the subsequent measurement of inventories by replacing
 the lower of cost or market test with a lower of cost or net
 realizable value test. When evidence exists that the net realizable
 value of inventory is less than its cost (due to damage, physical
 deterioration, obsolescence, changes in price levels or other
 causes), the Company will recognize the difference as a component
 of cost of goods sold in the period in which it occurs. In
 accordance with ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-11,&lt;/font&gt; the Company applied
 the new guidance on a prospective basis with no impact on the
 carrying amount of inventory.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Also in April 2016, the
 Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital. This aspect of the
 standard was adopted prospectively, and accordingly, the provision
 for income taxes for the year ended December&amp;#xA0;31, 2016 includes
 $0.4&amp;#xA0;million of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately
 $1.6&amp;#xA0;million relating to excess tax benefits on stock-based
 compensation outstanding as of December&amp;#xA0;31, 2015, with a
 corresponding cumulative-effect adjustment to accumulated deficit.
 The new standard also amends the presentation of employee
 share-based payment-related items in the statement of cash flows by
 requiring that: (i)&amp;#xA0;excess income tax benefits and
 deficiencies be classified in cash flows from operating activities,
 and (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.7&amp;#xA0;million of excess tax benefit
 and $2.3&amp;#xA0;million of excess tax provision from cash flows
 provided by financing activities to cash flows used in operating
 activities in the consolidated statement of cash flows as of
 December&amp;#xA0;31, 2015 and 2014, respectively, to conform to the
 current year presentation. The presentation requirement for cash
 flows related to taxes paid for withheld shares had no impact to
 any of the periods presented in the consolidated statement of cash
 flows since such payments have historically been presented as a
 financing activity.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In December 2016, the
 Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-15,&lt;/font&gt; &lt;i&gt;Presentation of
 Financial Statements&amp;#x2014;Going Concern (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;205-40):&lt;/font&gt; Disclosure of Uncertainties
 about an Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;.
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-15&lt;/font&gt;
 requires management to assess an entity&amp;#x2019;s ability to continue
 as a going concern by incorporating and expanding upon certain
 principles that are currently in U.S. auditing standards.
 Specifically, the ASU (i)&amp;#xA0;provides a definition of the term
 substantial doubt, (ii)&amp;#xA0;requires an evaluation every reporting
 period including interim periods, (iii)&amp;#xA0;provides principles
 for considering the mitigating effect of management&amp;#x2019;s plans,
 (iv)&amp;#xA0;requires certain disclosures when substantial doubt is
 alleviated as a result of consideration of management&amp;#x2019;s
 plans, (v)&amp;#xA0;requires an express statement and other disclosures
 when substantial doubt is not alleviated and (vi)&amp;#xA0;requires an
 assessment for a period of one year after the date that the
 financial statements are issued (or available to be issued). The
 Company believes that its cash and cash equivalents will be
 sufficient to fund its projected operations through the results of
 the &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; study, which
 it anticipates will be available &lt;font style="WHITE-SPACE: nowrap"&gt;mid-2018.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company also considered
 the following recent accounting pronouncements which were not yet
 adopted as of December&amp;#xA0;31, 2016:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In May 2014, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09,&lt;/font&gt; Revenue from
 Contracts with Customers (Topic 606), which will replace numerous
 requirements in U.S. GAAP, including industry-specific
 requirements. This guidance provides a five step model to be
 applied to all contracts with customers, with an underlying
 principle that an entity will recognize revenue to depict the
 transfer of goods or services to customers at an amount that the
 entity expects to be entitled to in exchange for those goods or
 services. ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09&lt;/font&gt; requires extensive
 quantitative and qualitative disclosures covering the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including disclosures on significant
 judgments made when applying the guidance. This guidance is
 effective for annual reporting periods beginning after
 December&amp;#xA0;15, 2017 and interim periods therein. Early adoption
 is permitted for reporting periods and interim periods therein,
 beginning after December&amp;#xA0;15, 2016. An entity can elect to
 apply the guidance under one of the following two methods:
 (i)&amp;#xA0;retrospectively to each prior reporting period presented,
 referred to as the full retrospective method, or
 (ii)&amp;#xA0;retrospectively with the cumulative effect of initially
 applying the standard recognized at the date of initial application
 in retained earnings, referred to as the modified retrospective
 method.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has
 substantially completed an initial impact assessment of the
 potential changes from adopting ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09.&lt;/font&gt; The impact
 assessment consisted of a review of a representative sample of
 contracts, discussions with key stakeholders, and a cataloging of
 potential impacts on its financial statements, accounting policies,
 financial control, and operations. The Company anticipates that the
 adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2014-09&lt;/font&gt; will not have a
 material impact on product revenue from distributors and may have
 an impact on contract revenues generated by its license
 agreements:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(i)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Changes in the model for
 distinct licenses of functional intellectual property which may
 result in a timing difference of revenue recognition. Whereas
 revenue from these arrangements was previously recognized over a
 period of time pursuant to the multiple element arrangement
 guidance, revenue from these arrangements may now be recognized at
 point in time under the new guidance.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(ii)&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Assessments of milestone
 payments, which are linked to events that are in the
 Company&amp;#x2019;s control, will result in variable consideration that
 may be recognized at an earlier point in time under the new
 guidance, when it is probable that the milestone will be achieved
 without a significant future reversal of cumulative revenue
 expected.&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has not yet
 completed its final review of the impact of this guidance; however,
 the Company anticipates applying the modified retrospective method
 when implementing this guidance. The Company plans to adopt the new
 standard effective January&amp;#xA0;1, 2018. The Company continues to
 monitor additional changes, modifications, clarifications or
 interpretations being undertaken by the FASB, which may impact its
 current conclusions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In January 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-01,&lt;/font&gt; &lt;i&gt;Financial
 Instruments&amp;#x2014;Overall (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;825-10):&lt;/font&gt; Recognition and Measurement
 of Financial Assets and Financial Liabilities&lt;/i&gt;. The new guidance
 is intended to improve the recognition and measurement of financial
 instruments by requiring separate presentation of financial assets
 and financial liabilities by measurement category and form of
 financial asset (i.e., securities or loans and receivables) within
 the balance sheet or the accompanying notes to the financial
 statements, eliminating the requirement for public business
 entities to disclose the method(s) and significant assumptions used
 to estimate the fair value that is required to be disclosed for
 financial instruments measured at amortized cost within the balance
 sheet, requiring public business entities to use the exit price
 notion when measuring the fair value of financial instruments for
 disclosure purposes, requiring equity investments (except those
 accounted for under the equity method of accounting, or those that
 result in consolidation of the investee) to be measured at fair
 value with changes in fair value recognized in net income, and
 requiring a reporting organization to present separately in other
 comprehensive income the portion of the total change in the fair
 value of a liability resulting from a change in the
 instrument-specific credit risk (also referred to as &amp;#x201C;own
 credit&amp;#x201D;) when the organization has elected to measure the
 liability at fair value in accordance with the fair value option
 for financial instruments, among others. The new guidance is
 effective for fiscal years beginning after December&amp;#xA0;15, 2017,
 including interim periods within those fiscal years. The new
 guidance permits early adoption of the own credit provision. The
 Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In February 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-02,&lt;/font&gt; &lt;i&gt;Leases (Topic
 842)&lt;/i&gt;. The new guidance will require lessees to recognize a
 &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; asset and a lease
 liability for virtually all of their leases (other than leases that
 meet the definition of a short-term lease). The liability will be
 equal to the present value of lease payments. The asset will be
 based on the liability, subject to adjustment, such as for initial
 direct costs. Under the new guidance, lessor accounting is largely
 unchanged but certain targeted improvements were made to align,
 where necessary, lessor accounting with the lessee accounting model
 and Topic 606, Revenue from Contracts with Customers. The new lease
 guidance also simplified the accounting for sale and leaseback
 transactions primarily because lessees must recognize lease assets
 and lease liabilities and therefore, will no longer be provided
 with a source of &lt;font style="WHITE-SPACE: nowrap"&gt;off-balance&lt;/font&gt; sheet financing. The new
 guidance is effective for fiscal years beginning after
 December&amp;#xA0;15, 2018, including interim periods within those
 fiscal years. Early adoption is permitted. The Company is currently
 evaluating the accounting, transition and disclosure requirements
 of the standard and cannot currently estimate the financial
 statement impact of adoption.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In March 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-08,&lt;/font&gt; &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606): Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)&lt;/i&gt;, which
 clarifies that an entity is a principal when it controls the
 specified good or service before that good or service is
 transferred to the customer, and is an agent when it does not
 control the specified good or service before it is transferred to
 the customer. The new guidance is intended to improve the
 operability and understandability of the implementation guidance on
 principal versus agent considerations. In April 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-10&lt;/font&gt;&lt;i&gt;, Revenue from
 Contracts with Customers (Topic 606): Identifying Performance
 Obligations and Licensing,&lt;/i&gt; which clarifies the following two
 aspects of Topic 606: (a)&amp;#xA0;identifying performance obligations;
 and (b)&amp;#xA0;the licensing implementation guidance. Further, in May
 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-12,&lt;/font&gt; &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606): Narrow-Scope Improvements and
 Practical Expedients,&lt;/i&gt; which provides clarifying guidance in
 certain narrow areas and adds some practical expedients. The
 amendments do not change the core principles of the guidance in
 Topic 606 and are effective for the Company&amp;#x2019;s fiscal year
 beginning January&amp;#xA0;1, 2018. Early application is permitted only
 as of annual reporting periods beginning after December&amp;#xA0;15,
 2016, including interim reporting periods within that reporting
 period. The Company is currently evaluating the accounting,
 transition and disclosure requirements of these standards and
 cannot currently estimate the financial statement impact of
 adoption.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In August 2016, the FASB
 issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-15,&lt;/font&gt; &lt;i&gt;Statement of Cash
 Flows (Topic 230): Classification of Certain Cash Receipts and Cash
 Payments&lt;/i&gt;, which is intended to reduce diversity in practice
 regarding how certain cash receipts and cash payments are presented
 and classified in the statement of cash flows. Specifically, it
 addresses the following eight issues: debt prepayment or debt
 extinguishment costs; settlement of &lt;font style="WHITE-SPACE: nowrap"&gt;zero-coupon&lt;/font&gt; debt instruments;
 contingent consideration payments made after a business
 combination; proceeds from the settlement of insurance claims;
 proceeds from the settlement of corporate-owned life insurance
 policies, including bank-owned life insurance policies;
 distributions received from equity method investments; beneficial
 interests in securitization transactions; and separately
 identifiable cash flows and application of the predominance
 principle. The new guidance is effective for fiscal years beginning
 after December&amp;#xA0;15, 2017, including interim periods within
 those fiscal years. Early adoption is permitted. The Company has
 evaluated the accounting, transition and disclosure requirements of
 the standard and does not expect it to have a material impact on
 the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company believes that
 the impact of other recently issued but not yet adopted accounting
 pronouncements will not have a material impact on the
 Company&amp;#x2019;s consolidated financial position, results of
 operations, and cash flows, or do not apply to the Company&amp;#x2019;s
 operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:SummaryOfIncomeTaxExaminationsTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_5A5C344E-CCBA-41BC-83CE-483D5550A29F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 files income tax returns in the United States, Ireland and United
 Kingdom, or UK. The Company remains subject to tax examinations in
 the following jurisdictions as of December&amp;#xA0;31,
 2016:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="WIDTH: 40pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Jurisdiction&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Tax&amp;#xA0;Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United
 States&amp;#x2014;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2013-2016&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United
 States&amp;#x2014;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2012-2016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Ireland&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2012-2016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United Kingdom&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2015-2016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:SummaryOfIncomeTaxExaminationsTextBlock>
  <dei:TradingSymbol contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400000">AMRN</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_26" unitRef="shares">211874000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_25" unitRef="shares">211874000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <dei:AmendmentFlag contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_99705C13-8B3A-476B-8077-894F65D58339_1_1">false</dei:AmendmentFlag>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_31C0A14D-0AE9-4640-AB91-0D880F41CDAA_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(13)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Defined Contribution
 Plan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company makes available
 a 401(k) plan for its U.S. employees. Under the 401(k) plan,
 employees may make contributions which are eligible for a
 discretionary percentage match, in cash, as defined in the 401(k)
 plan and determined by the Board of Directors. The Company
 recognized $0.5&amp;#xA0;million of related compensation expense for
 the year ended December&amp;#xA0;31, 2016. The Company did not make any
 contributions in 2015 or 2014.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_1A8C6A21-8A57-487B-AA86-87D86914AB32_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Credit Risk&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Financial instruments that
 potentially subject the Company to credit risk consist primarily of
 cash and cash equivalents and accounts receivable. The Company
 maintains substantially all of its cash and cash equivalents in
 financial institutions believed to be of high-credit
 quality.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;A significant portion of
 the Company&amp;#x2019;s sales are to wholesalers in the pharmaceutical
 industry. The Company monitors the creditworthiness of customers to
 whom it grants credit terms and has not experienced any credit
 losses. The Company does not require collateral or any other
 security to support credit sales. The Company&amp;#x2019;s top three
 customers accounted for 95% of gross product sales for each of the
 years ending December&amp;#xA0;31, 2016 and 2015, and represented 96%
 and 95% of the gross accounts receivable balance as of
 December&amp;#xA0;31, 2016 and 2015, respectively. The Company has not
 experienced any write-offs of its accounts receivable.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_1078BA37-EE4F-4F82-8BBF-E8880CCB48C6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The consolidated financial
 statements include the accounts of the Company and its wholly-owned
 subsidiaries. All intercompany accounts and transactions have been
 eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_3793B334-3BEB-4FC1-9900-5EB4656FDBA8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative financial
 liabilities are recorded at fair value, with gains and losses
 arising for changes in fair value recognized in the consolidated
 statement of operations at each period end while such instruments
 are outstanding. If the Company issues shares to discharge the
 liability, the derivative financial liability is derecognized and
 common stock and additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital are recognized on the
 issuance of those shares. Warrants are valued using a Black-Scholes
 option pricing model. The long-term debt redemption features are
 valued using probability-weighted models incorporating management
 estimates for potential change in control, and by determining the
 fair value of the debt with and without the change in control
 provision included.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;If the terms of warrants
 that initially require the warrant to be classified as a derivative
 financial liability lapse, the derivative financial liability is
 reclassified out of financial liabilities into equity at its fair
 value on that date. The cash proceeds received from exercises of
 warrants are recorded in common stock and additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_BFE481D8-5C53-461A-B00A-4995DF2EBB2B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All subsidiaries use the
 U.S. dollar as the functional currency. Monetary assets and
 liabilities denominated in a foreign currency are remeasured into
 U.S. dollars at &lt;font style="WHITE-SPACE: nowrap"&gt;period-end&lt;/font&gt;
 exchange rates. Gains and losses from the remeasurement are
 included in other (expense) income, net, in the consolidated
 statements of operations. For transactions settled during the
 applicable period, gains and losses are included in other (expense)
 income, net, in the consolidated statements of operations. Certain
 amounts payable pursuant to supply contracts are denominated in
 currencies other than the U.S. dollar.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_6CA8DE4A-F1AA-4084-9094-87599B8486D0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;b&gt;(11)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Interest and
 penalties related to any uncertain tax positions have historically
 been insignificant. The Company recognizes interest and penalties
 related to uncertain tax positions within the provision for income
 taxes. The total amount of unrecognized tax benefits that would
 affect the Company&amp;#x2019;s effective tax rate if recognized is
 $1.5&amp;#xA0;million as of December&amp;#xA0;31, 2016 and
 $1.4&amp;#xA0;million as of December&amp;#xA0;31, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The following
 is a reconciliation of the total amounts of unrecognized tax
 benefits for the years ended December&amp;#xA0;31, 2016, 2015 and
 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Beginning uncertain tax
 benefits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,550&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,674&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Prior
 year&amp;#x2014;increases&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;120&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Prior
 year&amp;#x2014;decreases&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(762&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Current
 year&amp;#x2014;increases&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;144&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Current
 year&amp;#x2014;decreases for lapses in statutes of
 limitations&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(439&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(254&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Ending uncertain tax
 benefits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,633&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,550&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 files income tax returns in the United States, Ireland and United
 Kingdom, or UK. The Company remains subject to tax examinations in
 the following jurisdictions as of December&amp;#xA0;31,
 2016:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="WIDTH: 40pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Jurisdiction&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Tax&amp;#xA0;Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United
 States&amp;#x2014;Federal&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2013-2016&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United
 States&amp;#x2014;State&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2012-2016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Ireland&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2012-2016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United Kingdom&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2015-2016&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 expects gross liabilities of $59,000 to expire in 2017 based on
 statutory lapses.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The
 components of loss from operations before taxes were as follows for
 the years ended December&amp;#xA0;31, 2016, 2015 and 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;United States&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(8,115&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(10,137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(7,331&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Ireland and United
 Kingdom&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(68,266&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(108,153&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(51,870&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(76,381&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(118,290&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(59,201&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The
 (provision for) benefit from income taxes shown in the accompanying
 consolidated statements of operations consists of the following for
 fiscal 2016, 2015 and 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Current:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Federal-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,053&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;660&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;State-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;138&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;113&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;117&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Total current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,171&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,166&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;777&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Deferred:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Federal-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(4,001&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,343&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,689&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;State-U.S.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(334&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(605&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Ireland and United
 Kingdom&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(143&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(9,023&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3,335&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Change in valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;13,276&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;8,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Total deferred&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;8,798&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(4,252&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,614&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Provision for (benefit
 from) income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;9,969&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,086&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(2,837&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The
 (provision for) benefit from income taxes differs from the amount
 computed by applying the statutory income tax rate to income before
 taxes due to the following for fiscal 2016, 2015 and
 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Benefits from taxes at
 statutory rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(19,039&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(29,572&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(14,786&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Rate
 differential&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4,667&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;8,572&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;9,493&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Change in valuation
 reserves&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;13,276&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;8,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Derivative
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(668&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;187&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(2,706&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Gain on extinguishment of
 debt&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(328&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(9,509&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Research and development
 credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,689&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,455&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Tax return to provision
 adjustments&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4,524&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,248&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;10,026&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Cumulative translation
 adjustment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7,385&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7,811&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;8,061&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Permanent and
 other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(409&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,073&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-deductible&lt;/font&gt;&amp;#xA0;interest expense&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,922&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,594&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Provision for (benefit
 from) income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;9,969&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(3,086&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(2,837&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;During 2016,
 the Company recorded adjustments to its deferred tax accounts
 related to the impact of foreign exchange rate changes and to
 reconcile the financial statement accounts to the amounts reported
 on its filed 2015 foreign tax returns, primarily for the impact of
 U.S. GAAP to local statutory adjustments. The majority of these
 adjustments were fully offset with valuation allowances based on
 the Company&amp;#x2019;s position with respect to the realizability of
 its recorded deferred tax assets. The Company is subject to
 corporate tax rate in Ireland of 25% for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-trading&lt;/font&gt;&amp;#xA0;activities and 12.5% for
 trading activities. For the years ended December&amp;#xA0;31, 2016,
 2015, and 2014, the Company applied the statutory corporate tax
 rate of 25% for Amarin Corporation plc, reflecting the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-trading&lt;/font&gt;&amp;#xA0;tax rate in Ireland. However,
 for Amarin Pharmaceuticals Ireland Limited, a wholly-owned
 subsidiary of Amarin Corporation plc, the Company applied the 12.5%
 Irish trading tax rate. In the table above, the Company used Amarin
 Corporation plc&amp;#x2019;s 25% tax rate as the starting point for the
 reconciliation since it is the parent entity of the
 business.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In November
 2015, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2015-17,&lt;/font&gt;&amp;#xA0;Income Taxes (Topic 740):
 &amp;#x201C;Balance Sheet Classification of Deferred Taxes&amp;#x201D;, which
 changes how deferred taxes are classified on organizations&amp;#x2019;
 balance sheets. The ASU eliminates the current requirement for
 organizations to present deferred tax liabilities and assets as
 current and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&amp;#xA0;in a classified balance sheet.
 Instead, organizations will be required to classify all deferred
 tax assets and liabilities as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-current.&lt;/font&gt;&amp;#xA0;The Company early adopted
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2015-17&lt;/font&gt;effective December&amp;#xA0;31,
 2015 on a prospective basis. Adoption of this ASU resulted in a
 reclassification of $0.9&amp;#xA0;million of the net current deferred
 tax asset to the net&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&amp;#xA0;deferred tax asset in the
 consolidated balance sheet as of December&amp;#xA0;31, 2015. No prior
 periods were retrospectively adjusted.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In April
 2016, the Company adopted ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;&amp;#xA0;Compensation-Stock
 Compensation (Topic 718): Improvements to Share-Based Payment
 Accounting which changes the accounting for certain aspects of
 share-based payments to employees. One aspect of the standard
 requires that excess tax benefits and deficiencies that arise upon
 vesting or exercise of share-based payments be recognized as an
 income tax benefit and expense in the income statement. Previously,
 such amounts were recognized as an increase and decrease in
 additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital. This aspect of the
 standard was adopted prospectively, and accordingly the provision
 for income taxes for the year ended December&amp;#xA0;31, 2016 includes
 $0.4&amp;#xA0;million of excess tax deficiencies arising from
 share-based payments during the period of adoption. Additionally,
 the new standard requires that historical excess tax benefits were
 not previously recognized because the related tax deduction had not
 reduced current taxes should be recognized on a modified
 retrospective basis as a cumulative-effect adjustment to retained
 earnings as of the beginning of the annual period of adoption.
 Consequently, the Company recognized deferred tax assets of
 approximately $1.6&amp;#xA0;million relating to excess tax benefits on
 stock-based compensation outstanding as of December&amp;#xA0;31, 2015,
 with a corresponding cumulative-effect adjustment to accumulated
 deficit.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The income
 tax effect of each type of temporary difference comprising the net
 deferred tax asset as of December&amp;#xA0;31, 2016 and 2015 is as
 follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Deferred tax
 assets:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Net operating
 losses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;88,345&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;88,996&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Stock based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;23,731&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;17,975&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Depreciation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;74&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Tax credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6,893&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6,030&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Other reserves and
 accrued liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,437&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;2,796&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Gross deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;121,406&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;115,871&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Less: valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(109,274&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(95,999&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Total deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;12,132&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;19,872&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Deferred tax
 liabilities:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Depreciation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Total deferred tax
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(1,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Net deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;11,082&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;19,872&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 assesses whether it is&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;that the Company will realize
 its deferred tax assets. The Company determined that it
 was&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;more-likely-than-not&lt;/font&gt;&amp;#xA0;that the Irish, UK, and
 Israeli net operating losses and the related deferred tax assets
 would not be realized in future periods and a full valuation
 allowance has been provided for all periods.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The following
 table reflects the activity in the valuation allowance for the
 years ended December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Beginning valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;95,999&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;85,965&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Increase as reflected in
 income tax expense&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;17,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;16,291&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Increase as reflected in
 retained earnings&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1,315&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Cumulative translation
 adjustment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(4,676&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(7,572&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Ending valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;109,274&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;95,999&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 has combined Irish, UK, and Israeli net operating loss
 carryforwards of $573.8&amp;#xA0;million, which do not expire. The
 total net operating loss carryforwards increased by approximately
 $8.1&amp;#xA0;million from the prior year primarily as a result of
 current year losses generated by the Company&amp;#x2019;s Irish
 subsidiaries, partially offset by the impact of foreign exchange
 rate changes and adjustments to reconcile the financial statement
 accounts to the amounts reported on the filed 2015 foreign tax
 returns. In addition, the Company has U.S. Federal tax credit
 carryforwards of $6.7&amp;#xA0;million and state tax credit
 carryforwards of $1.6&amp;#xA0;million. These amounts exclude the
 impact of any unrecognized tax benefits and valuation allowances.
 These carryforwards, which will expire starting between 2024 and
 2036 may be used to offset future taxable income, if
 any.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;As of
 December&amp;#xA0;31, 2016, earnings of $25.1&amp;#xA0;million have been
 retained indefinitely for reinvestment by foreign subsidiary or
 there is an expectation that any reinvestment can be
 recovered&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;tax-free&lt;/font&gt;&amp;#xA0;without significant cost, and
 the entity expects to ultimately use that means of recovery for
 domestic subsidiary companies; therefore, no provision has been
 made for income taxes that would be payable upon the distribution
 of such earnings and it would not be practicable to determine the
 amount of the related unrecognized deferred income tax
 liability.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The
 Company&amp;#x2019;s and its subsidiaries&amp;#x2019; income tax returns are
 periodically examined by various taxing authorities. The Company is
 currently under audit by the United States Internal Revenue Service
 (IRS) for the years 2013 to 2014. Although the outcome of tax
 audits is always uncertain and could result in significant cash tax
 payments, the Company does not believe the outcome of these audits
 will have a material adverse effect on the Company&amp;#x2019;s
 consolidated financial position or results of
 operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_26C07012-94B0-4481-9EBA-CA93DE120CBA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible asset, net
 consists of a milestone payment paid to the former shareholders of
 Laxdale Limited related to the 2004 acquisition of the rights to
 Vascepa, which is the result of Vascepa receiving marketing
 approval for the first indication and is amortized over its
 estimated useful life on a straight-line basis. See Note
 9&amp;#x2014;Commitments and Contingencies for further information
 regarding other obligations related to the acquisition of Laxdale
 Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_6C7BD9CC-1E05-4E58-8FE1-6AEA528367EC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(1)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Nature of Business and Basis of
 Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Nature
 of Business&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amarin Corporation plc
 (&amp;#x201C;Amarin&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) is a
 biopharmaceutical company with expertise in lipid science focused
 on the commercialization and development of therapeutics to improve
 cardiovascular health.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
 Company&amp;#x2019;s lead product, Vascepa&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 (icosapent ethyl) capsules, is approved by the U.S. Food and Drug
 Administration, or FDA, for use as an adjunct to diet to reduce
 triglyceride levels in adult patients with severe (TG &lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#xB3;&lt;/font&gt;500 mg/dL) hypertriglyceridemia.
 Vascepa is available in the United States by prescription only. In
 January 2013, the Company began selling and marketing &lt;font style="WHITE-SPACE: nowrap"&gt;1-gram&lt;/font&gt; size Vascepa capsules in the
 United States, and in October 2016, introduced a smaller
 &lt;font style="WHITE-SPACE: nowrap"&gt;0.5-gram&lt;/font&gt; size capsule. In
 August 2015, in addition to marketing Vascepa for severe
 hypertriglyceridemia, the Company commenced marketing Vascepa for
 use in adult patients with mixed dyslipidemia, as an adjunct to
 diet and an &lt;font style="WHITE-SPACE: nowrap"&gt;add-on&lt;/font&gt; to
 statin therapy in patients who despite statin therapy have high
 triglycerides (TGs &lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#xB3;&lt;/font&gt;200 mg/dL and &lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#xA3;&lt;/font&gt;500 mg/dL), which the Company
 also refers to as persistently high triglycerides. This expanded
 promotion of Vascepa commenced pursuant to a federal court order
 and is continuing pursuant to an agreement among the Company, the
 FDA and the U.S. government. The Company sells Vascepa principally
 to a limited number of major wholesalers, as well as selected
 regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors or its customers, that in turn
 resell Vascepa to retail pharmacies for subsequent resale to
 patients and healthcare providers. The Company markets Vascepa
 through its direct sales force of approximately 150 sales
 professionals, including sales representatives and their managers.
 In May 2014, Kowa Pharmaceuticals America, Inc. commenced
 &lt;font style="WHITE-SPACE: nowrap"&gt;co-promotion&lt;/font&gt; of Vascepa in
 accordance with a &lt;font style="WHITE-SPACE: nowrap"&gt;co-promotion&lt;/font&gt; agreement with the
 Company. Kowa Pharmaceuticals America, Inc. &lt;font style="WHITE-SPACE: nowrap"&gt;co-promotes&lt;/font&gt; Vascepa through its no
 less than 250 sales representatives who now devote a substantial
 portion of their time to promoting Vascepa in conjunction with the
 promotion of Kowa Pharmaceutical America, Inc.&amp;#x2019;s primary
 product, a branded statin for patients with high cholesterol. The
 Company operates in one business segment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company is also
 developing Vascepa for FDA approval of potential additional
 indications for use. In particular, the Company is conducting a
 cardiovascular outcomes study of Vascepa, titled &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; (Reduction of Cardiovascular
 Events with EPA&amp;#x2014;Intervention Trial). The &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; study, which commenced in
 2011 and completed patient enrollment and randomization of 8,175
 individual patients in 2016, is designed to evaluate the efficacy
 of Vascepa in reducing major cardiovascular events in a high-risk
 patient population on statin therapy.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Basis
 of Presentation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The consolidated financial
 statements included herein have been prepared by the Company in
 accordance with accounting principles generally accepted in the
 United States of America (the &amp;#x201C;U.S.&amp;#x201D; or the
 &amp;#x201C;United States&amp;#x201D;) and pursuant to the rules and
 regulations of the Securities and Exchange Commission, or the
 SEC.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The consolidated financial
 statements reflect all adjustments of a normal and recurring nature
 that, in the opinion of management, are necessary to present fairly
 the Company&amp;#x2019;s financial position, results of operations and
 cash flows for the periods indicated. The preparation of the
 Company&amp;#x2019;s consolidated financial statements in conformity
 with U.S. Generally Accepted Accounting Principles
 (&amp;#x201C;GAAP&amp;#x201D;) requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities, disclosure of contingent assets and liabilities at the
 date of the financial statements, and the reported amounts of
 revenues and expenses during the reporting period. The results of
 operations for the years ended December&amp;#xA0;31, 2016, 2015 and
 2014 are not necessarily indicative of the results for any future
 period. Certain numbers presented throughout this document may not
 add precisely to the totals provided due to rounding. Absolute and
 percentage changes are calculated using the underlying amounts in
 thousands. Certain prior year balances have been reclassified to
 conform to the current year presentation due primarily to the
 Company&amp;#x2019;s adoption of recent accounting pronouncements
 related to the presentation of debt issuance costs and excess tax
 benefits, as well as its inclusion of additional required
 disclosure related to (provision for) benefit from income taxes.
 These reclassifications do not have a material impact on the
 Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The accompanying
 consolidated financial statements of the Company and subsidiaries
 have been prepared on a basis which assumes that the Company will
 continue as a going concern, which contemplates the realization of
 assets and the satisfaction of liabilities and commitments in the
 normal course of business.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At December&amp;#xA0;31, 2016,
 the Company had current assets of $146.3&amp;#xA0;million, including
 cash and cash equivalents of $98.3&amp;#xA0;million. Cash and cash
 equivalents as of December&amp;#xA0;31, 2016 includes net proceeds of
 approximately $64.6&amp;#xA0;million resulting from the issuance of
 24,265,000 American Depositary Shares, or ADSs, as part of a public
 offering completed in August 2016 (see Note 10&amp;#x2014;Equity). The
 Company&amp;#x2019;s consolidated balance sheets also include long-term
 debt from royalty-bearing instrument and exchangeable senior notes.
 The terms of the January 2012 3.5% exchangeable senior notes due
 2032, or the 2012 Notes, are such that they may be redeemed by the
 Company on or after January&amp;#xA0;19, 2017 and may be put back to
 the Company by the holders on each of January&amp;#xA0;19, 2017, 2022
 and 2027 for cash equal to 100% of the principal amount plus any
 accrued and unpaid interest. The 2012 Notes are exchangeable under
 certain circumstances into cash, American Depositary Shares, or
 ADSs, or a combination of cash and ADSs, at the Company&amp;#x2019;s
 election. Accordingly, $15.1&amp;#xA0;million in principal amount of
 2012 Notes represents a short-term claim on the liquid assets of
 the Company as of December&amp;#xA0;31, 2016. In September 2016, the
 Company mandatorily exchanged $118.7&amp;#xA0;million in aggregate
 principal amount of May 2014 3.5% exchangeable senior notes due
 2032, or the 2014 Notes, and $31.3&amp;#xA0;million in aggregate
 principal amount of November 2015 3.5% exchangeable senior notes
 due 2032, or the 2015 Notes, into ADSs such that they were retired
 in full, and derecognized the related derivative liabilities. In
 January 2017, holders of the 2012 Notes exercised their option to
 put the 2012 Notes to the Company for cash. As a result, the
 Company repurchased approximately $15.0&amp;#xA0;million in aggregate
 principal amount of 2012 Notes, such that $0.1&amp;#xA0;million in
 principal amount of 2012 Notes currently remains outstanding. In
 contemplation of this repurchase, the Company issued
 $30.0&amp;#xA0;million in aggregate principal amount of January 2017
 3.5% exchangeable senior notes due 2047, or the 2017 Notes. The
 Company has initiated the process to redeem the remaining
 $0.1&amp;#xA0;million of 2012 Notes, which is expected to be completed
 in the first quarter of 2017. Refer to Note 8&amp;#x2014;Debt and Note
 18&amp;#x2014;Subsequent Events for further discussion.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company believes its
 cash and cash equivalents will be sufficient to fund its projected
 operations through the results of the &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; study, which we anticipate
 will be available &lt;font style="WHITE-SPACE: nowrap"&gt;mid-2018.&lt;/font&gt; Depending on the level of
 cash generated from operations, additional capital may be required
 to sustain operations, fund debt obligations or expand promotion of
 Vascepa as contemplated following anticipated successful results of
 the &lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt; study. The
 Company anticipates that annual net cash outflows in future periods
 will be variable.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_BB8A3ECD-1968-442B-9CA2-E55DA16C5847_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
 equipment as of December&amp;#xA0;31, 2016 and 2015 consist of the
 following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;157&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;135&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Computer
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture and
 fixtures&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;42&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;240&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Software&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;559&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;559&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;821&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;997&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated depreciation
 and amortization&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(755&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(754&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Construction in
 progress&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total property, plant and
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;78&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;243&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_BC4544F9-2565-4DDF-80AA-79044503A8E4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company sells Vascepa
 principally to a limited number of major wholesalers, as well as
 selected regional wholesalers and specialty pharmacy providers, or
 collectively, its Distributors or its customers, that in turn
 resell Vascepa to retail pharmacies for subsequent resale to
 patients and healthcare providers. Patients are required to have a
 prescription in order to purchase Vascepa. In accordance with GAAP,
 the Company&amp;#x2019;s revenue recognition policy requires that:
 (i)&amp;#xA0;there is persuasive evidence that an arrangement exists
 between the Company and the Distributor, (ii)&amp;#xA0;delivery has
 occurred, (iii)&amp;#xA0;collectability is reasonably assured and
 (iv)&amp;#xA0;the price is fixed or determinable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contracts
 with its primary Distributors and delivery generally occurs when a
 Distributor receives Vascepa. The Company evaluates the
 creditworthiness of each of its Distributors to determine whether
 revenues can be recognized upon delivery, subject to satisfaction
 of the other requirements, or whether recognition is required to be
 delayed until receipt of payment. In order to conclude that the
 price is fixed or determinable, the Company must be able to
 (i)&amp;#xA0;calculate its gross product revenues from the sales to
 Distributors and (ii)&amp;#xA0;reasonably estimate its net product
 revenues. The Company calculates gross product revenues generally
 based on the wholesale acquisition cost that the Company charges
 its Distributors for Vascepa. The Company estimates its net product
 revenues by deducting from its gross product revenues
 (a)&amp;#xA0;trade allowances, such as invoice discounts for prompt
 payment and distributor fees, (b)&amp;#xA0;estimated government and
 private pay or rebates, chargebacks and discounts, such as Medicaid
 reimbursements, (c)&amp;#xA0;reserves for expected product returns and
 (d)&amp;#xA0;estimated costs of incentives offered to certain indirect
 customers, including patients.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Trade
 Allowances:&lt;/i&gt; The Company generally provides invoice discounts on
 Vascepa sales to its Distributors for prompt payment and pays fees
 for distribution services, such as fees for certain data that
 Distributors provide to the Company. The payment terms for sales to
 Distributors generally include a 2% discount for payment within 30
 days while the fees for distribution services are based on
 contractual rates agreed with the respective Distributors. Based on
 judgment and experience, the Company expects its Distributors to
 earn these discounts and fees, and deducts the full amount of these
 discounts and fees from its gross product revenues and accounts
 receivable at the time such revenues are recognized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Rebates,
 Chargebacks and Discounts:&lt;/i&gt; The Company contracts with Medicaid,
 other government agencies and various private organizations, or
 collectively, Third-party Payors, so that Vascepa will be eligible
 for purchase by, or partial or full reimbursement from, such
 Third-party Payors. The Company estimates the rebates, chargebacks
 and discounts it will provide to Third-party Payors and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company estimates the rebates,
 chargebacks and discounts that it will provide to Third-party
 Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s contracts with these
 Third-party Payors, (ii)&amp;#xA0;the government-mandated discounts
 applicable to government-funded programs, (iii)&amp;#xA0;information
 obtained from the Company&amp;#x2019;s Distributors and
 (iv)&amp;#xA0;information obtained from other third parties regarding
 the payor mix for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Product
 Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the right to
 return unopened unprescribed Vascepa during the &lt;font style="WHITE-SPACE: nowrap"&gt;18-month&lt;/font&gt; period beginning six months
 prior to the labeled expiration date and ending twelve months after
 the labeled expiration date. The expiration date for Vascepa is
 three years after it has been converted into capsule form, which is
 the last step in the manufacturing process for Vascepa and
 generally occurs within a few months before Vascepa is delivered to
 Distributors. The Company estimates future product returns on sales
 of Vascepa based on: (i)&amp;#xA0;data provided to the Company by its
 Distributors (including weekly reporting of Distributors&amp;#x2019;
 sales and inventory held by Distributors that provided the Company
 with visibility into the distribution channel in order to determine
 what quantities were sold to retail pharmacies and other
 providers), (ii)&amp;#xA0;information provided to the Company from
 retail pharmacies, (iii)&amp;#xA0;data provided to the Company by a
 third-party data provider which collects and publishes prescription
 data, and other third parties, (iv)&amp;#xA0;historical industry
 information regarding return rates for similar pharmaceutical
 products, (v)&amp;#xA0;the estimated remaining shelf life of Vascepa
 previously shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s
 Distributors.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Other
 Incentives:&lt;/i&gt; Other incentives that the Company offers to
 indirect customers include &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation programs. The
 Company&amp;#x2019;s &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt;
 mitigation program is intended to reduce each participating
 patient&amp;#x2019;s portion of the financial responsibility for
 Vascepa&amp;#x2019;s purchase price to a specified dollar amount. Based
 upon the terms of the program and information regarding programs
 provided for similar specialty pharmaceutical products, the Company
 estimates the average &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation amounts and the
 percentage of patients that it expects to participate in the
 program in order to establish its accruals for &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation rebates and deducts
 these estimated amounts from its gross product revenues at the time
 the revenues are recognized. The Company adjusts its accruals for
 &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt; mitigation rebates
 based on actual redemption activity and estimates regarding the
 portion of issued &lt;font style="WHITE-SPACE: nowrap"&gt;co-pay&lt;/font&gt;
 mitigation rebates that it estimates will be redeemed.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the net product revenue allowance
 and reserve categories described above for the years ended
 December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;In
 thousands&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Chargebacks&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 January&amp;#xA0;1, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,207&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;481&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;792&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,090&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,986&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,591&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;342&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,310&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;56,229&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to prior
 period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(174&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(70&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(205&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(449&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,690&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(22,710&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(40,626&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 prior period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,540&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(792&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,448&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;4,296&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,881&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;535&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,084&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;15,796&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;22,952&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;69,370&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;583&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,696&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;104,601&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to prior
 period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(450&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(537&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(19,213&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(48,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,815&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(77,747&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 prior period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,205&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,167&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(259&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,915&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3,743&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;20,915&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;859&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,681&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;27,198&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Such net product revenue
 allowances and reserves are included within accrued expenses and
 other current liabilities within the consolidated balance sheets,
 with the exception of trade allowances and chargebacks, which are
 included within accounts receivable, net as discussed
 below.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Multiple-Element Arrangements and Licensing
 Revenue&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;When evaluating
 multiple-element arrangements, the Company identifies the
 deliverables included within the agreement and evaluates which
 deliverables represent separate units of accounting based on
 whether the delivered element has stand-alone value to the customer
 or if the arrangement includes a general right of return for
 delivered items.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The consideration received
 is allocated between each of the separable elements in the
 arrangement using the relative selling price method. The selling
 price used for each separable element will be based on vendor
 specific objective evidence (&amp;#x201C;VSOE&amp;#x201D;) if available,
 third-party evidence if VSOE is not available, or estimated selling
 price if neither VSOE nor third-party evidence is available.
 Revenue is then recognized as each of the separable elements to
 which the revenue has been allocated is delivered.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company may receive
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front,&lt;/font&gt; &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; payments when licensing
 its intellectual property in conjunction with research, development
 and commercialization agreements. In determining the units of
 accounting, management evaluates whether the license has
 stand-alone value from the undelivered elements to the
 collaborative partner based on the consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the stage of development of the license
 delivered, research and development capabilities of the partner and
 the ability of partners to develop and commercialize Vascepa
 independent of the Company.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;When management believes
 the license to its intellectual property does not have stand-alone
 value from the other deliverables to be provided in the
 arrangement, the Company generally recognizes revenue attributable
 to the license over the Company&amp;#x2019;s contractual or estimated
 performance period. Any unrecognized portion of license revenue is
 classified within deferred revenue in the accompanying consolidated
 balance sheets. When management believes the license to its
 intellectual property has stand-alone value, the Company recognizes
 revenue attributed to the license upon delivery. The periods over
 which revenue is recognized is subject to estimates by management
 and may change over the course of the agreement. Such a change
 could have a material impact on the amount of revenue the Company
 records in future periods.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Milestones&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Contingent consideration
 from activities that is earned upon the achievement of a
 substantive milestone is recognized in its entirety in the period
 in which the milestone is achieved. At the inception of each
 arrangement that includes milestone payments, the Company evaluates
 whether each milestone is substantive. This evaluation includes an
 assessment of whether: (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, clinical, regulatory,
 commercial and other risks that must be overcome to achieve the
 respective milestone, the level of effort and investment required
 and whether the milestone consideration is reasonable relative to
 all deliverables and payment terms in the arrangement in making
 this assessment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See Note
 17&amp;#x2014;Development, Commercialization and Supply Agreement for
 further information regarding licensing revenue and milestones
 primarily related to the Company&amp;#x2019;s multiple-element
 arrangement with Eddingpharm (Asia) Macao Commercial Offshore
 Limited.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_3EE7F6EC-95EE-40EE-A5A6-4E31B8B8F40B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The income tax effect of
 each type of temporary difference comprising the net deferred tax
 asset as of December&amp;#xA0;31, 2016 and 2015 is as
 follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax
 assets:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net operating
 losses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;88,345&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;88,996&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock based
 compensation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;23,731&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,975&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;74&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Tax credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,893&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,030&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other reserves and accrued
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,437&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,796&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gross deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;121,406&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;115,871&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Less: valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(109,274&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(95,999&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12,132&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;19,872&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax
 liabilities:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciation&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total deferred tax
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,050&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net deferred tax
 assets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,082&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;19,872&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_FBF26A5E-A749-49A3-8EE0-D246E94F8924_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The calculation of net loss
 and the number of shares used to compute basic and diluted net loss
 per share for the years ended December&amp;#xA0;31, 2016, 2015 and 2014
 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(115,204&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock purchase
 option (see Note 10&amp;#x2014;Equity)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(868&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock beneficial
 conversion features (see Note 10&amp;#x2014;Equity)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(32,987&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss applicable to
 common shareholders&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(149,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(56,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on warrant derivative
 liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,775&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net
 loss&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(86,350&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(149,059&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(63,139&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 share&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.32&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average shares
 outstanding&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;211,874&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;180,654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;173,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effect of dilutive
 warrants&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;105&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average shares
 outstanding&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;211,874&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;180,654&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;173,824&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
 share&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.36&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_A9CB3C44-EC02-4569-8EF9-819B64694490_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 presents the stock-based compensation expense related to stock
 based awards for the years ended December&amp;#xA0;31, 2016, 2015 and
 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and
 development&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,252&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,280&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,701&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Selling, general and
 administrative&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,361&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,609&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,321&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based compensation
 expense&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,613&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,889&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,022&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_1B9B6636-0CE5-494D-B970-8133AA67A9D3_1_0">&lt;div&gt;
 &lt;p&gt;&lt;font size="2"&gt;Inventories as of December&amp;#xA0;31, 2016 and 2015
 consist of the following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="54%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,430&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,096&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Work in process&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,716&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,640&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,361&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,249&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total inventory&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;20,507&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;18,985&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_FE0EA34E-DF0B-4CB4-8488-4FF815968663_1_0">&lt;div&gt;
 &lt;p&gt;&lt;font size="2"&gt;Estimated future amortization expense, based upon
 the Company&amp;#x2019;s intangible assets as of December&amp;#xA0;31, 2016
 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1px; WIDTH: 92pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ending
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2019&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2020&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2021&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,542&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,772&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_6B4B28FF-4DCB-4B30-916E-4A792E311A39_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The components of loss from
 operations before taxes were as follows for the years ended
 December&amp;#xA0;31, 2016, 2015 and 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;United States&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,115&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,137&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,331&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Ireland and United
 Kingdom&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(68,266&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(108,153&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(51,870&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(76,381&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(118,290&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(59,201&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_1_2" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_1_4" unitRef="pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_1_0" unitRef="pure">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_A3E6572F-05C6-431E-8976-94F9ED085187_1_2">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_1_400003" unitRef="shares">688000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_37500BE5-5551-4C39-8C83-762C887B3B3F_1_0" unitRef="iso4217_USD_per_shares">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1_3" unitRef="iso4217_USD_per_shares">1.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_BD644DC0-7646-4B9A-80C8-AC5EA1B19A74_1_2" unitRef="iso4217_USD_per_shares">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_FDCAB87F-2279-4D62-87D5-944199FE4B9D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Stock-Based Compensation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based compensation
 cost is generally measured at the grant date, based on the fair
 value of the award, and is recognized as compensation expense over
 the requisite service period. For awards with performance
 conditions, if the achievement of the performance conditions is
 deemed probable, the Company recognizes compensation expense based
 on the fair value of the award over the estimated service period.
 The Company reassesses the probability of achievement of the
 performance conditions for such awards each reporting
 period.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_C09EA767-13AA-4815-942F-2EF067E73EF5_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(8)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Debt&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Long-Term
 Debt from Royalty-Bearing Instrument&amp;#x2014;December 2012
 Financing&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On December&amp;#xA0;6, 2012,
 the Company entered into an agreement with BioPharma Secured Debt
 Fund II Holdings Cayman LP, or BioPharma. Under this agreement, the
 Company granted to BioPharma a security interest in future
 receivables associated with the Vascepa patent rights, in exchange
 for $100.0&amp;#xA0;million received at the closing of the agreement
 which occurred in December 2012. Under these terms, the Company
 continues to own all Vascepa intellectual property rights, however,
 such rights, as described below, could be used by BioPharma as
 collateral for repayment of the remaining unpaid balance under this
 agreement if the Company defaults on making required payments. In
 the agreement, the Company agreed to repay BioPharma up to
 $150.0&amp;#xA0;million with such repayment based on a portion of
 revenues and receivables generated from Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;As of December&amp;#xA0;31,
 2016, the remaining amount to be repaid to BioPharma is
 $125.6&amp;#xA0;million. During the year ended December&amp;#xA0;31, 2016,
 the Company made repayments under the agreement of
 $11.7&amp;#xA0;million to BioPharma and an additional $3.8&amp;#xA0;million
 is scheduled to be paid in February 2017 for the fourth quarter of
 2016. These payments were calculated based on the threshold
 limitation, as described below, as opposed to the scheduled
 quarterly repayments. Additional quarterly repayments, subject to
 the threshold limitation, are scheduled to be paid.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The final maximum
 contractual quarterly amount which could be due for payment, except
 upon a change of control and subject to the threshold limitation,
 is $13.0&amp;#xA0;million scheduled for payment in May 2017. All such
 payments reduce the remainder of the $150.0&amp;#xA0;million in
 aggregate payments to BioPharma. These quarterly payments are
 subject to a quarterly threshold amount whereby, if a calculated
 threshold, based on quarterly Vascepa revenues, is not achieved,
 the quarterly payment payable in that quarter can at the
 Company&amp;#x2019;s election be reduced, with the reduction carried
 forward without interest for payment in a future period. The
 payment of any carried forward amount is subject to similarly
 calculated threshold repayment amounts based on Vascepa revenue
 levels. Except upon a change of control in Amarin, the agreement
 does not expire until $150.0&amp;#xA0;million in aggregate has been
 repaid. Except in the event of the Company&amp;#x2019;s default, there
 is no compounding of interest and no scheduled cliff payment due
 under this agreement. Rather, payment will be made, subject to the
 threshold limitation, until $150.0&amp;#xA0;million in aggregate has
 been repaid, including payments made previously. The Company can
 prepay an amount equal to $150.0&amp;#xA0;million less any previously
 repaid amount.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company currently
 estimates that its Vascepa revenue levels will not be high enough
 in each quarter to support repayment to BioPharma in accordance
 with the maximum quarterly amounts in the repayment schedule. For
 each quarterly period since the inception of the debt, revenues
 were below the contractual threshold amount such that cash payments
 were calculated for each period reflecting the optional reduction
 amount as opposed to the contractual threshold payment due for each
 quarterly period. In accordance with the agreement with BioPharma,
 quarterly differences between the calculated optional reduction
 amounts and the repayment schedule amounts are rescheduled for
 payment beginning in the second quarter of 2017. Any such deferred
 repayments will remain subject to continued application of the
 quarterly ceiling in amounts due established by the calculated
 threshold limitation based on quarterly Vascepa revenues. No
 additional interest expense or liability is incurred as a result of
 such deferred repayments. These estimates will be reevaluated each
 reporting period by the Company and adjusted if necessary,
 prospectively.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company determined the
 redemption feature upon a change of control to be an embedded
 derivative requiring bifurcation. The fair value of the embedded
 derivative was calculated by determining the fair value of the debt
 with the change in control provision included and also without the
 change in control provision. The difference between the two fair
 values of the debt was determined to be the fair value of the
 embedded derivative, and upon closing the Company recorded a
 derivative liability of $14.6&amp;#xA0;million as a reduction to the
 note payable. The fair value of this derivative liability is
 remeasured at each reporting period, with changes in fair value
 recognized in the consolidated statement of operations and any
 changes in the assumptions used in measuring the fair value of the
 derivative liability could result in a material increase or
 decrease in its carrying value. Based on current assumptions
 underlying the valuation, the Company recognized a
 $5.5&amp;#xA0;million gain on change in fair value of derivative
 liability during the year ended December&amp;#xA0;31, 2016, as compared
 to a $0.7&amp;#xA0;million loss on change in fair value of derivative
 liability during the year ended December&amp;#xA0;31, 2015&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;As of December&amp;#xA0;31, 2016
 and 2015, the carrying value of the BioPharma debt, net of the
 unamortized debt discount and issuance costs, was
 $93.6&amp;#xA0;million and $91.5&amp;#xA0;million, respectively. During the
 year ended December&amp;#xA0;31, 2016, the Company recorded cash and
 &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; interest expense
 of $6.7&amp;#xA0;million and $2.1&amp;#xA0;million, respectively, in
 connection with the BioPharma debt. During the year ended
 December&amp;#xA0;31, 2015, the Company recorded $6.6&amp;#xA0;million and
 $1.9&amp;#xA0;million of cash and &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; interest expense,
 respectively, in connection with BioPharma debt. The Company will
 periodically evaluate the remaining term of the agreement and the
 effective interest rate is recalculated each period based on the
 Company&amp;#x2019;s most current estimate of repayment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;To secure the obligations
 under the agreement with BioPharma, the Company granted BioPharma a
 security interest in the Company&amp;#x2019;s patents, trademarks, trade
 names, domain names, copyrights, &lt;font style="white-space:nowrap"&gt;know-how&lt;/font&gt; and regulatory approvals
 related to the covered products, all books and records relating to
 the foregoing and all proceeds of the foregoing, referred to
 collectively as the collateral. If the Company (i)&amp;#xA0;fails to
 deliver a payment when due and does not remedy that failure within
 a specific notice period, (ii)&amp;#xA0;fails to maintain a
 first-priority perfected security interest in the collateral in the
 United States and does not remedy that failure after receiving
 notice of such failure or (iii)&amp;#xA0;becomes subject to an event of
 bankruptcy, then BioPharma may attempt to collect the maximum
 amount payable by the Company under this agreement (after deducting
 any payments the Company has already made).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Under the Purchase and Sale
 Agreement with BioPharma, the Company is restricted from paying
 dividends on its common shares, unless it has cash and cash
 equivalents in excess of a specified amount after such
 payment.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;January
 2012 Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2012, the Company
 issued $150.0&amp;#xA0;million in principal amount of 3.5% Exchangeable
 Senior Notes due 2032 (the &amp;#x201C;2012 Notes&amp;#x201D;), a portion of
 which was subsequently exchanged and a portion of which was
 extinguished (see discussion of May 2014 and November 2015
 Exchangeable Senior Notes below), such that $15.1&amp;#xA0;million in
 principal amount remains outstanding as of December&amp;#xA0;31, 2016.
 In January 2017, holders of the 2012 Notes exercised their option
 to put the 2012 Notes to the Company. As a result, the Company
 repurchased approximately $15.0&amp;#xA0;million in aggregate principal
 amount of 2012 Notes, such that $0.1&amp;#xA0;million in principal
 amount of 2012 Notes currently remains outstanding. Also in January
 2017, in contemplation of this surrender of 2012 Notes for
 repurchase, the Company and its wholly owned subsidiary, Corsicanto
 II Designated Activity Company (&amp;#x201C;Corsicanto II&amp;#x201D;)
 entered into separate, privately negotiated purchase agreements
 with certain investors pursuant to which Corsicanto II issued and
 sold $30.0&amp;#xA0;million in aggregate principal amount of 3.5%
 Exchangeable Senior Notes due 2047 (the &amp;#x201C;2017 Notes&amp;#x201D;).
 The Company has initiated the process to redeem the remaining
 $0.1&amp;#xA0;million of 2012 Notes, which is expected to be completed
 in the first quarter of 2017. See Note 18&amp;#x2014;Subsequent Events
 for further discussion of the issuance of the 2017
 Notes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The 2012 Notes were issued
 by Corsicanto Limited, an Irish limited company acquired by Amarin
 in January 2012. Corsicanto Limited is a wholly-owned subsidiary of
 Amarin. The general, unsecured, senior obligations are fully and
 unconditionally guaranteed by Amarin but not by any of the
 Company&amp;#x2019;s other subsidiaries. Corsicanto Limited has no
 assets, operations, revenues or cash flows other than those related
 to the issuance, administration and repayment of the 2012 Notes and
 2014 Notes. There are no significant restrictions on the ability of
 Amarin to obtain funds from Corsicanto Limited in the form of cash
 dividends, loans, or advances. Net proceeds to the Company, after
 payment of underwriting fees and expenses, were approximately
 $144.3&amp;#xA0;million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The 2012 Notes have a stated
 interest rate of 3.5%&amp;#xA0;per year, payable semiannually in
 arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year beginning
 on July&amp;#xA0;15, 2012, and ending upon the 2012 Notes&amp;#x2019;
 maturity on January&amp;#xA0;15, 2032. The 2012 Notes are subject to
 repurchase in cash by the Company at the option of the holders on
 each of January&amp;#xA0;19, 2017,&amp;#xA0;January&amp;#xA0;19, 2022, and
 January&amp;#xA0;19, 2027, at a price equal to 100% of the principal
 amount of the 2012 Notes to be repurchased, plus accrued and unpaid
 interest to, but excluding, the repurchase date. The 2012 Notes are
 exchangeable under certain circumstances into cash, ADSs, or a
 combination of cash and ADSs, at the Company&amp;#x2019;s election, with
 an initial exchange rate of 113.4752 ADSs per $1,000 principal
 amount of 2012 Notes (equivalent to an initial exchange price of
 approximately $8.8125 per ADS), subject to adjustment in certain
 circumstances, including adjustment if the Company pays cash
 dividends. If the Company elected physical settlement, the net
 remaining outstanding portion of the 2012 Notes would be
 exchangeable into 1,714,270 ADSs. Based on the closing price of the
 Company&amp;#x2019;s stock as of December&amp;#xA0;31, 2016, the principal
 amount of the 2012 Notes would exceed the value of the shares if
 converted on that date by $9.8&amp;#xA0;million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Additional covenants
 include: (i)&amp;#xA0;limitations on future indebtedness under certain
 circumstances, (ii)&amp;#xA0;the timely filing of documents and reports
 pursuant to Section&amp;#xA0;13 or 15(d) of the Securities Exchange Act
 of 1934 with both the SEC and the Trustee and
 (iii)&amp;#xA0;maintaining the tradability of the 2012 Notes. The
 Company is required to use commercially reasonable efforts to
 maintain the listing of the 2012 Notes on the Global Exchange
 Market operated under the supervision of the Irish Stock Exchange
 (or other recognized stock exchange as defined in the 2012 Notes
 indenture). If the 2012 Notes are not freely tradable, as a result
 of restrictions pursuant to U.S. securities law or the terms of the
 2012 Notes indenture or the 2012 Notes, the Company shall pay
 additional interest on the 2012 Notes at the rate of 0.50%&amp;#xA0;per
 annum of the principal amount of 2012 Notes outstanding for each
 day during such period for which the Company&amp;#x2019;s failure to
 file has occurred and is continuing or for which the 2012 Notes are
 not freely tradable.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company may not redeem
 the 2012 Notes prior to January&amp;#xA0;19, 2017, other than in
 connection with certain changes in the tax law of a relevant taxing
 jurisdiction that results in additional amounts becoming due with
 respect to payments and/or deliveries on the 2012 Notes. On or
 after January&amp;#xA0;19, 2017 and prior to the maturity date, the
 Company may redeem for cash all or part of the 2012 Notes at a
 redemption price equal to 100% of the principal amount of the 2012
 Notes to be redeemed, plus accrued and unpaid interest to, but
 excluding, the redemption date. There is no prepayment penalty or
 sinking fund provided for the 2012 Notes. If the Company undergoes
 a change in control, holders may require the Company to repurchase
 for cash all or part of their 2012 Notes at a repurchase price
 equal to 100% of the principal amount of the 2012 Notes to be
 repurchased, plus accrued and unpaid interest to, but excluding,
 the change in control repurchase date. The 2012 Notes are the
 Company&amp;#x2019;s senior unsecured obligations and rank senior in
 right of payment to the Company&amp;#x2019;s future indebtedness that is
 expressly subordinated in right of payment to the 2012 Notes and
 equal in right of payment to the Company&amp;#x2019;s future unsecured
 indebtedness that is not so subordinated. The 2012 Notes are
 effectively junior in right of payment to future secured
 indebtedness to the extent of the value of the assets securing such
 indebtedness.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The 2012 Notes are
 exchangeable under certain circumstances. At the time of issuance,
 the Company calculated the fair value of the liability component of
 the outstanding 2012 Notes to be $126.2&amp;#xA0;million, and the
 excess of the principal amount of the debt over the liability
 component of $23.8&amp;#xA0;million was allocated to the conversion
 option resulting in a discount on the debt and corresponding
 increase in equity as a result of the cash settlement feature. The
 discount created from allocating proceeds to the conversion option
 was amortized to interest expense using the effective interest
 method over the 2012 Notes&amp;#x2019; estimated remaining life, which
 was calculated to be a period of twenty-four months. As of both
 December&amp;#xA0;31, 2016 and 2015, the discount created from the
 allocation of the proceeds to the conversion option was fully
 amortized and the carrying amount of the conversion option was
 $11.5&amp;#xA0;million. The conversion option will not be subsequently
 remeasured as long as it continues to meet the criteria for equity
 classification.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company also recorded a
 debt discount to reflect the value of the underwriter&amp;#x2019;s
 discounts and offering costs. A portion of the debt discount from
 underwriter&amp;#x2019;s discounts and offering costs was allocated to
 the equity and liability components of the 2012 Notes in proportion
 to the proceeds allocated to each component. The portion of the
 debt discount from underwriter&amp;#x2019;s discounts and offering costs
 allocated to the liability component was amortized as interest
 expense over the estimated life of the 2012 Notes of twenty-four
 months. As of both December&amp;#xA0;31, 2016 and 2015, the debt
 discount was fully amortized and the carrying value of the 2012
 Notes was $15.1&amp;#xA0;million after an exchange and repayment of a
 portion of the 2012 Notes (see below for further discussion of the
 May 2014 Notes and November 2015 Notes). The outstanding 2012 Notes
 may be put to the Company (at the holders&amp;#x2019; option, upon
 fundamental change or an event of default), or converted by holders
 and the holders have the option to put the 2012 Notes back to the
 Company on each of January&amp;#xA0;19, 2017, 2022 and 2027 for cash
 equal to 100% of the principal amount plus accrued and unpaid
 interest. As a result, the carrying value of the 2012 Notes of
 $15.1&amp;#xA0;million is classified as a current liability as of
 December&amp;#xA0;31, 2016. During the years ended December&amp;#xA0;31,
 2016 and 2015, the Company recognized contractual coupon interest
 expense of $0.5&amp;#xA0;million and $1.0&amp;#xA0;million, respectively,
 related to the 2012 Notes. The Company made the contractual
 interest payments due on the 2012 Notes during the years ended
 December&amp;#xA0;31, 2016 and 2015 of $0.5&amp;#xA0;million and
 $1.3&amp;#xA0;million, respectively, and had accrued interest of
 $0.2&amp;#xA0;million and $0.3&amp;#xA0;million as of December&amp;#xA0;31,
 2016 and 2015, respectively, which is included in current portion
 of exchangeable senior notes, net of discount.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;May 2014
 Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In May 2014, the Company
 entered into separate, privately negotiated exchange agreements
 with certain holders of the 2012 Notes pursuant to which Corsicanto
 exchanged $118.7&amp;#xA0;million in aggregate principal amount of the
 existing 2012 Notes for $118.7&amp;#xA0;million in aggregate principal
 amount of new 3.5%&amp;#xA0;May 2014 Exchangeable Senior Notes due 2032
 (the &amp;#x201C;2014 Notes&amp;#x201D;), following which $31.3&amp;#xA0;million
 in aggregate principal amount of the 2012 Notes remained
 outstanding with terms unchanged (the 2012 Notes and 2014 Notes are
 referred to collectively as the &amp;#x201C;Notes&amp;#x201D;). In September
 2016, Corsicanto mandatorily exchanged $118.7&amp;#xA0;million of
 aggregate principal amount of the 2014 Notes for equity upon
 satisfaction of specified equity conditions as described below,
 such that no 2014 Notes remained outstanding as of
 December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The 2014 Notes indenture
 contained a provision that allowed the Company to elect at its
 option to cause all or any portion of the 2014 Notes to be
 mandatorily exchanged in whole or in part at any time prior to the
 close of business on the business day preceding January&amp;#xA0;15,
 2032 if the Daily VWAP (as defined in the 2014 Notes indenture)
 equaled or exceeded 110% of the Exchange Price then in effect for
 at least 20 VWAP Trading Days (as defined in the 2014 Notes
 indenture) in any 30 VWAP Trading Day period and upon satisfaction
 of other specified equity conditions, including that the ADSs
 issuable upon exchange of the 2014 Notes be eligible for resale
 without registration by &lt;font style="white-space:nowrap"&gt;non-affiliates&lt;/font&gt; and listed on The NASDAQ
 Global Market, its related exchanges or the New York Stock
 Exchange. In August 2016, Corsicanto gave notice to the holders of
 the 2014 Notes that the above described conditions had been
 satisfied and exercised its option to mandatorily exchange
 $118.7&amp;#xA0;million of aggregate principal amount of the 2014 Notes
 for equity with settlement in September 2016, such that all of the
 outstanding 2014 Notes were retired. In the event of physical
 settlement, the 2014 Notes were initially exchangeable into
 45,666,925 ADSs. The initial exchange rate was 384.6154 ADSs per
 $1,000 principal amount of the 2014 Notes (equivalent to an initial
 exchange price of approximately $2.60 per ADS, or the Exchange
 Price), subject to adjustment in certain circumstances, including,
 but not limited to, the payment of cash dividends or the
 Company&amp;#x2019;s exercise of its optional exchange rights.
 Consistent with the 2014 Notes indenture, the final &lt;font style="white-space:nowrap"&gt;as-adjusted&lt;/font&gt; exchange rate was 402.0746
 ADSs per $1,000 of principal amount, resulting in 47,739,925 ADSs
 being issued in exchange for the 2014 Notes. Refer to the end of
 this Note for discussion of the accounting treatment for this
 transaction.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The 2014 Notes had a stated
 interest rate of 3.5%&amp;#xA0;per year, payable semiannually in
 arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year beginning
 on July&amp;#xA0;15, 2014, and ending upon the 2014 Notes&amp;#x2019;
 maturity on January&amp;#xA0;15, 2032, had the notes not been exchanged
 early. The 2014 Notes indenture provided holders the option to
 exchange the 2014 Notes at any time after the issuance of the 2014
 Notes and prior to the close of business on the second business day
 immediately preceding January&amp;#xA0;15, 2032. If a fundamental
 change (as defined in the 2014 Notes indenture) had occurred prior
 to the 2014 Notes being exchanged, holders may have required the
 Company to repurchase all or part of their 2014 Notes for cash at a
 fundamental change repurchase price equal to 100% of the aggregate
 principal amount of the 2014 Notes to be repurchased, plus accrued
 and unpaid interest to, but not including, the fundamental change
 repurchase date. In addition, holders of the 2014 Notes may have
 required the Company to repurchase all or any portion of the 2014
 Notes on each of January&amp;#xA0;19, 2019,&amp;#xA0;January&amp;#xA0;19, 2024
 and January&amp;#xA0;19, 2029 for cash at a price equal to 100% of the
 aggregate principal amount of the 2014 Notes to be repurchased,
 plus accrued and unpaid interest to, but not including, the
 repurchase date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;As a result of the note
 exchange in 2014 (as described above), the Company assessed both
 quantitative and qualitative aspects of the features of the 2014
 Notes as compared to the 2012 Notes. Such assessment resulted in
 the conclusion that the features of the 2014 Notes represented a
 substantive modification from the 2012 Notes as the terms of the
 exchange resulted in a substantive modification to the embedded
 conversion feature within the 2012 Notes, and as such should be
 accounted for as an extinguishment of debt. In accordance with ASC
 &lt;font style="white-space:nowrap"&gt;470-20,&lt;/font&gt; the Company
 extinguished the 2012 Notes by recording a gain on extinguishment
 of the liability component of $38.0&amp;#xA0;million and repurchase of
 the conversion option in equity through a reduction to additional
 &lt;font style="white-space:nowrap"&gt;paid-in&lt;/font&gt; capital of
 $10.1&amp;#xA0;million. The 2014 Notes were recorded at fair value of
 $90.8&amp;#xA0;million representing a $27.9&amp;#xA0;million discount to
 par. In addition the Company recognized $2.5&amp;#xA0;million in
 underwriter&amp;#x2019;s fees and offering costs and initially
 classified those costs as deferred assets. Effective January 2016,
 the Company adopted ASU &lt;font style="white-space:nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt;
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic &lt;font style="white-space:nowrap"&gt;835-30):&lt;/font&gt; Simplifying the Presentation
 of Debt Issuance Costs&lt;/i&gt;, which requires that debt issuance costs
 related to a recognized debt liability be presented in the balance
 sheet as a direct deduction from the carrying amount of that debt
 liability, consistent with the treatment of debt discounts. As the
 standard is required to be adopted on a retrospective basis, the
 Company reclassified $1.8&amp;#xA0;million of underwriters&amp;#x2019; fees
 and offering costs related to the 2014 Notes from other long-term
 assets to exchangeable senior notes, net of discount, within the
 consolidated balance sheet as of December&amp;#xA0;31, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company further
 allocated $3.5&amp;#xA0;million of the $90.8&amp;#xA0;million fair value of
 the 2014 Notes to the derivative liability related to the
 fundamental change redemption feature (as described above). The
 fair value of this derivative liability was remeasured at each
 reporting period, with changes in fair value recognized in the
 consolidated statement of operations As a result of the mandatory
 exchange of the debt host, the Company derecognized the related
 derivative liability and recognized a $2.1&amp;#xA0;million gain on
 change in fair value of derivative liability in the year ended
 December&amp;#xA0;31, 2016, as compared to a $0.5&amp;#xA0;million gain on
 change in fair value of derivative liability recognized in the year
 ended December&amp;#xA0;31, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Because the conversion
 option in the 2014 Notes received an exception from derivative
 accounting and only required gross physical settlement in shares,
 the embedded option did not require separate accounting and was
 therefore accounted for as part of the debt host at amortized cost.
 The debt discount was amortized as interest expense over the
 estimated life of the 2014 Notes and was recognized in the
 consolidated statement of operations as interest expense. As of
 December&amp;#xA0;31, 2016 and 2015, the carrying value of the 2014
 Notes, net of the unamortized debt discount and issuance costs, was
 nil and $94.6&amp;#xA0;million, respectively. During the year ended
 December&amp;#xA0;31, 2016, the Company recognized aggregate interest
 expense of $7.7&amp;#xA0;million related to the 2014 Notes, of which
 $4.8&amp;#xA0;million represents &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; interest and $2.9&amp;#xA0;million
 represents contractual coupon interest. During the year ended
 December&amp;#xA0;31, 2015, the Company recognized aggregate interest
 expense of $10.4&amp;#xA0;million related to the 2014 Notes, of which
 $6.2&amp;#xA0;million represents &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; interest and $4.2&amp;#xA0;million
 represents contractual coupon interest. The Company made the
 contractual interest payments due on the 2014 Notes during the
 years ended December&amp;#xA0;31, 2016 and 2015 of $4.2&amp;#xA0;million in
 each period, and had accrued interest of nil and $1.9&amp;#xA0;million
 as of December&amp;#xA0;31, 2016 and 2015, respectively, which is
 included in current portion of exchangeable senior notes, net of
 discount.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;November
 2015 Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In November 2015, the
 Company entered into a privately negotiated subscription agreement
 with one of its existing investors (the &amp;#x201C;Investor&amp;#x201D;),
 pursuant to which the Investor agreed to purchase approximately
 $31.3&amp;#xA0;million in aggregate principal amount of new
 3.5%&amp;#xA0;November 2015 Exchangeable Senior Notes due 2032 (the
 &amp;#x201C;2015 Notes&amp;#x201D;) for approximately $27.5&amp;#xA0;million.
 Approximately $15.9&amp;#xA0;million of such proceeds were used to
 finance the repayment of a portion of the 2012 Notes with the
 remainder to be used for working capital and general corporate
 purposes. The 2015 Notes were issued by Amarin Corporation plc and
 were not guaranteed by any entity, but otherwise had substantially
 identical terms to the 2014 Notes, including the provision related
 to the Company&amp;#x2019;s optional exchange rights. In August 2016,
 the Company gave notice to the holders of the 2015 Notes that the
 Daily VWAP conditions as described above for the 2014 Notes had
 been satisfied and exercised its option to mandatorily exchange
 $31.3&amp;#xA0;million of aggregate principal amount of the 2015 Notes
 for equity with settlement in September 2016, such that all of the
 outstanding 2015 Notes were retired. In the event of physical
 settlement, the 2015 Notes were initially exchangeable into
 12,025,385 ADSs. The initial exchange rate was 384.6154 ADSs per
 $1,000 principal amount of 2015 Notes (equivalent to an initial
 exchange price of approximately $2.60 per ADS), subject to
 adjustment in certain circumstances, including, but not limited to,
 the payment of cash dividends or the Company&amp;#x2019;s exercise of
 optional exchange rights. Consistent with the terms of the 2015
 Notes, the final &lt;font style="white-space:nowrap"&gt;as-adjusted&lt;/font&gt; exchange rate was 402.0746
 ADSs per $1,000 of principal amount, resulting in 12,571,263 ADSs
 being issued in exchange for the 2015 Notes. Refer to the end of
 this Note for discussion of the accounting treatment for this
 transaction.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The 2015 Notes were recorded
 at fair value of $27.5&amp;#xA0;million representing a
 $3.8&amp;#xA0;million discount to par. In addition, the Company
 recognized $0.1&amp;#xA0;million in offering costs and initially
 classified those costs as deferred assets. As described for the
 2014 Notes above, effective January 2016, the Company adopted ASU
 &lt;font style="white-space:nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt;
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic &lt;font style="white-space:nowrap"&gt;835-30):&lt;/font&gt; Simplifying the Presentation
 of Debt Issuance Costs.&lt;/i&gt; As the standard is required to be
 adopted on a retrospective basis, the Company reclassified
 $0.1&amp;#xA0;million of underwriters&amp;#x2019; fees and offering costs
 related to the 2015 Notes from other long-term assets to
 exchangeable senior notes, net of discount, within the consolidated
 balance sheet as of December&amp;#xA0;31, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;The Company further
 allocated $0.5&amp;#xA0;million of the $27.5&amp;#xA0;million fair value of
 the 2015 Notes to the derivative liability related to the
 fundamental change redemption feature (as described under the 2014
 Notes above). The fair value of this derivative liability was
 remeasured at each reporting period, with changes in fair value
 recognized in the consolidated statement of operations. As a result
 of the mandatory exchange of the debt host, the Company
 derecognized the related derivative liability and recognized a
 $0.6&amp;#xA0;million gain on change in fair value of derivative
 liability in the year ended December&amp;#xA0;31, 2016, as compared to
 a $0.1&amp;#xA0;million loss on change in fair value of derivative
 liability recognized in the year ended December&amp;#xA0;31,
 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Because the conversion
 option in the 2015 Notes received an exception from derivative
 accounting and only required gross physical settlement in shares,
 the embedded option did not require separate accounting and was
 therefore accounted for as part of the debt host at amortized cost.
 The debt discount was amortized as interest expense over the
 estimated life of the 2015 Notes and recognized in the consolidated
 statement of operations as interest expense. As of
 December&amp;#xA0;31, 2016 and 2015, the carrying value of the 2015
 Notes, net of the unamortized debt discount and issuance costs, was
 nil and $27.0&amp;#xA0;million, respectively. During the year ended
 December&amp;#xA0;31, 2016, the Company recognized aggregate interest
 expense of $1.7&amp;#xA0;million related to the 2015 Notes, of which
 $0.9&amp;#xA0;million represents &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; interest and $0.8&amp;#xA0;million
 represents contractual coupon interest. During the year ended
 December&amp;#xA0;31, 2015, the Company recognized aggregate interest
 expense of $0.2&amp;#xA0;million related to the 2015 Notes, of which
 $0.1&amp;#xA0;million represents &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; interest and $0.1&amp;#xA0;million
 represents contractual coupon interest. The Company made the
 contractual interest payments due on the 2015 Notes during the year
 ended December&amp;#xA0;31, 2016 of $0.7&amp;#xA0;million, and had accrued
 interest of nil and $0.1&amp;#xA0;million as of December&amp;#xA0;31, 2016
 and 2015, respectively, which is included in current portion of
 exchangeable senior notes, net of discount&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Concurrent with the issuance
 of the 2015 Notes, Corsicanto Limited and the Company entered into
 separate, privately negotiated purchase agreements with certain
 holders of the 2012 Notes pursuant to which the Company purchased
 (the &amp;#x201C;2012 Notes Purchase&amp;#x201D;) approximately
 $16.2&amp;#xA0;million in aggregate principal amount of the 2012 Notes
 for $15.9&amp;#xA0;million, which included accrued but unpaid interest
 on such 2012 Notes. The 2012 Notes Purchase was funded by the
 issuance of the 2015 Notes. Following the closing of the 2012 Notes
 Purchase, Corsicanto had approximately $15.1&amp;#xA0;million in
 aggregate principal amount of 2012 Notes outstanding. The 2012
 Notes Purchase was accounted for as an extinguishment of debt and
 the Company recorded a gain of $1.3&amp;#xA0;million upon
 extinguishment during the fourth quarter of 2015, which represents
 the reacquisition of the conversion option at fair value and a
 negotiated discount on the purchase of the notes partially offset
 by legal and transaction advisory costs incurred.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;As described in the &lt;i&gt;May
 2014 Exchangeable Senior Notes&lt;/i&gt; and &lt;i&gt;November 2015
 Exchangeable Senior Notes&lt;/i&gt; sections above, the Company
 mandatorily exchanged, in total, $150.0&amp;#xA0;million in aggregate
 principal amount ($127.3&amp;#xA0;million in carrying value, net of
 unamortized debt discount and issuance costs) of outstanding 2014
 Notes and 2015 Notes resulting in the issuance of 60,311,188 ADSs
 and recognition of $40.1&amp;#xA0;million in common stock and
 $87.4&amp;#xA0;million in additional &lt;font style="white-space:nowrap"&gt;paid-in&lt;/font&gt; capital during the year ended
 December&amp;#xA0;31, 2016. Included within this $87.4&amp;#xA0;million is
 $0.8&amp;#xA0;million of accrued but unpaid interest as of the exchange
 date deemed satisfied and discharged in full upon delivery of the
 ADSs consistent with the terms of the notes and ASC &lt;font style="white-space:nowrap"&gt;470-20,&lt;/font&gt; less $0.7&amp;#xA0;million of
 transaction costs.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_CBE6A30F-E762-498F-9B6D-C5715A7A40D1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Debt instruments are
 initially recorded at fair value, with coupon interest and
 amortization of debt issuance discounts recognized in the
 consolidated statement of operations as interest expense each
 period in which such instruments are outstanding. If the Company
 issues shares to discharge the liability, the debt obligation is
 derecognized and common stock and additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital are recognized on the
 issuance of those shares. The conversion features in the 2012
 Notes, and previously the 2014 Notes and 2015 Notes prior to the
 mandatory exchange, qualify for the exception from derivative
 accounting in accordance with ASC &lt;font style="WHITE-SPACE: nowrap"&gt;815-40.&lt;/font&gt; The 2012 Notes may be put to
 the Company by their holders for repurchase in cash. The 2012 Notes
 are exchangeable under certain circumstances at the Company&amp;#x2019;s
 discretion, in any combination of ADSs or cash upon conversion and
 have been accounted for in accordance with ASC &lt;font style="WHITE-SPACE: nowrap"&gt;470-20.&lt;/font&gt; Under ASC &lt;font style="WHITE-SPACE: nowrap"&gt;470-20,&lt;/font&gt; the fair value of the
 liability component of the 2012 Notes was determined and deducted
 from the initial proceeds to determine the proceeds allocated to
 the conversion option, which has been recorded in equity. The
 difference between the initial fair value of the liability
 component and the amount repayable was fully amortized over the
 expected term of the instrument. The conversion features in the
 2014 Notes and 2015 Notes could only have been settled in ADSs upon
 conversion and were therefore accounted for as part of the debt
 host.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The conversion feature in
 the 2012 Notes, continues to be evaluated on a quarterly basis to
 determine if it still receives an exception from derivative
 accounting in accordance with ASC &lt;font style="WHITE-SPACE: nowrap"&gt;815-40.&lt;/font&gt; The 2014 Notes were recognized
 initially at fair value as part of an extinguishment of a portion
 of the 2012 Notes. As a result, the 2014 Notes were initially
 recognized at a discount of $27.9&amp;#xA0;million. The 2015 Notes were
 recognized initially at fair value as part of the issuance of new
 debt in November 2015. As a result, the 2015 Notes were initially
 recognized at a discount of $3.8&amp;#xA0;million. These discounts were
 amortized through interest expense through the date of the
 mandatory exchange. See Note 8&amp;#x2014;Debt for further
 discussion.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <dei:DocumentPeriodEndDate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_99705C13-8B3A-476B-8077-894F65D58339_1_2">2016-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_22" unitRef="iso4217_USD_per_shares">-0.41</us-gaap:EarningsPerShareBasic>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400005">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400007">Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_4570A1B9-CCD3-4BFF-B709-93EB67719D89_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(3)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Intangible Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Intangible assets consist
 of the historical acquisition cost of certain technology rights for
 Vascepa and have an estimated remaining useful life of 13.6 years.
 The carrying value as of December&amp;#xA0;31, 2016 is as
 follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Remaining
 Useful&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Life (in
 years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
 rights&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,852&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,772&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Amortization expense for
 each of the years ended December&amp;#xA0;31, 2016 and 2015 was
 $0.6&amp;#xA0;million and is included in research and development
 expense. Estimated future amortization expense, based upon the
 Company&amp;#x2019;s intangible assets as of December&amp;#xA0;31, 2016 is
 as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1px; WIDTH: 92pt; BORDER-BOTTOM: rgb(0,0,0) 1px solid; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Year Ending
 December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2019&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2020&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2021&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;646&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,542&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,772&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:LegalCostsPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_954EDAAB-AD00-4020-973A-B70E563CBB67_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Costs
 for Patent Litigation and Legal Proceedings&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Costs for patent litigation
 or other legal proceedings are expensed as incurred and included in
 selling, general and administrative expenses.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="INF" id="id_6322976_AB6714D5-9A80-4B12-A411-66FC499A212B_1_2" unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_4750870E-DEBF-4995-A300-31BD440FF620_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(5)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Property, Plant and
 Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
 equipment as of December&amp;#xA0;31, 2016 and 2015 consist of the
 following:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;157&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;135&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Computer
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;63&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture and
 fixtures&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;42&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;240&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Software&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;559&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;559&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;821&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;997&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accumulated depreciation
 and amortization&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(755&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(754&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Construction in
 progress&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total property, plant and
 equipment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;78&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;243&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Depreciation expense for
 each of the years ended December&amp;#xA0;31, 2016, 2015, and 2014 was
 $0.1&amp;#xA0;million, $0.2&amp;#xA0;million and $0.2&amp;#xA0;million,
 respectively.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_801BD7F8-CABF-4477-BC61-38D3A2AEBDFF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Accounts Receivable, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable, net,
 comprised of trade receivables, are generally due within 30 days
 and are stated at amounts due from customers. The Company
 recognizes an allowance for losses on accounts receivable in an
 amount equal to the estimated probable losses net of any
 recoveries. The allowance is based primarily on assessment of
 specific identifiable customer accounts considered at risk or
 uncollectible, as well as an analysis of current receivables aging
 and expected future write-offs. The expense associated with the
 allowance for doubtful accounts is recognized as selling, general,
 and administrative expense. The Company has not historically
 experienced any credit losses.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes the impact of accounts receivable reserves on the gross
 trade accounts receivable balances as of December&amp;#xA0;31, 2016 and
 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;In
 thousands&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gross trade accounts
 receivable&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;24,127&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;18,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Trade allowances&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,743&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,296&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Chargebacks&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(387&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(148&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Allowance for doubtful
 accounts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable,
 net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;19,985&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,826&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_8D7E05A1-CDFD-4B4E-8DC3-D9D25B4DB3E6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company charges
 research and development costs to operations as incurred. Research
 and development expenses are comprised of costs incurred by the
 Company in performing research and development activities,
 including: salary and benefits; stock-based compensation expense;
 laboratory supplies and other direct expenses; contractual
 services, including clinical trial and pharmaceutical development
 costs; commercial supply investment in its drug candidates; and
 infrastructure costs, including facilities costs and depreciation
 expense. In addition, research and development costs include the
 costs of product supply received from suppliers when such receipt
 by the Company is prior to regulatory approval of the
 supplier.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_59A43E94-5455-4C81-A301-DB94CEE94635_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The (provision for) benefit
 from income taxes differs from the amount computed by applying the
 statutory income tax rate to income before taxes due to the
 following for fiscal 2016, 2015 and 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Benefits from taxes at
 statutory rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(19,039&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(29,572&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,786&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Rate
 differential&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,667&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,572&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,493&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Change in valuation
 reserves&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,276&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Derivative
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(668&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;187&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,706&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on extinguishment of
 debt&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(328&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,509&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and development
 credits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,689&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,455&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Tax return to provision
 adjustments&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,524&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,248&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,026&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cumulative translation
 adjustment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,385&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,811&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,061&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Permanent and
 other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(409&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,073&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-deductible&lt;/font&gt; interest
 expense&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,922&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,594&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision for (benefit
 from) income taxes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,969&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,086&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,837&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_FCEB9615-7D27-4C08-AD72-815271AF38E0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The following
 table summarizes all stock option activity for the year ended
 December&amp;#xA0;31, 2016:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands (except per share amounts and
 years)&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 January&amp;#xA0;1, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;17,818&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3.76&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4,400&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(688&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.92&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Expired&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(165&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7.24&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;(177&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;1.62&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Outstanding as of
 December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;21,188&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3.37&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7.3&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;17,018&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Exercisable as of
 December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;12,217&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4.38&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;6.3&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7,159&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Vested and expected to
 vest as of December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;20,513&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;3.41&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;7.3&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;16,396&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Available for future
 grant as of December&amp;#xA0;31, 2016&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;4,304&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_0022136C-5BA9-4815-B73E-3CFC03D36060_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For 2016, 2015 and 2014,
 the Company used the following assumptions to estimate the fair
 value of share-based payment awards:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="43%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk free interest
 rate&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.07%&amp;#xA0;-&amp;#xA0;1.70%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.37%&amp;#xA0;-&amp;#xA0;1.68%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.37%&amp;#xA0;-&amp;#xA0;1.68%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected dividend
 yield&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.00%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.00%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.00%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected option life
 (years)&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected
 volatility&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;83%&amp;#xA0;-&amp;#xA0;86%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;86%&amp;#xA0;-&amp;#xA0;97%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;97%&amp;#xA0;-&amp;#xA0;109%&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_1E236563-80AA-4922-8742-D8AAB2BA2B65_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical
 Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Operating segments are
 defined as components of an enterprise about which separate
 financial information is available that is evaluated on a regular
 basis by the chief operating decision-maker, or decision making
 group, in deciding how to allocate resources to an individual
 segment and in assessing performance of the segment. The Company
 currently operates in one business segment, which is the
 development and commercialization of Vascepa. A single management
 team that reports to the Company&amp;#x2019;s chief decision-maker, who
 is the Chief Executive Officer, comprehensively manages the
 business. Accordingly, the Company does not have separately
 reportable segments.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_E1F3135C-DCDE-4CB6-8ED7-4F22BFA02C6F_1_400002" unitRef="shares">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_7001_9" unitRef="iso4217_USD_per_shares">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_7001_7" unitRef="iso4217_USD_per_shares">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="4" id="id_6322976_704FDCC2-137C-4A26-8DF3-8043DEE67457_1_1" unitRef="pure">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_5D53C8D0-E952-461B-87B1-CDBC65626159_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Distribution Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company records
 distribution costs related to shipping product to its customers,
 primarily through the use of common carriers or external
 distribution services, in cost of goods sold.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_4D13D848-6266-4E7E-84E8-84C1C6AACAFA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;b&gt;(10)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Equity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 28px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;i&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 March&amp;#xA0;5, 2015, the Company entered into a subscription
 agreement with four institutional investors (the
 &amp;#x201C;Purchasers&amp;#x201D;), including both existing and new
 investors, for the private placement of 352,150,790 restricted
 American Depositary Shares, each representing one (1)&amp;#xA0;share of
 Amarin&amp;#x2019;s Series A Convertible Preference Shares, par value
 &amp;#xA3;0.05&amp;#xA0;per share, in the capital of the Company
 (&amp;#x201C;Series A Preference Shares&amp;#x201D;), resulting in gross
 proceeds to the Company of $52.8&amp;#xA0;million. The closing of the
 private placement occurred on March&amp;#xA0;30, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;For each
 restricted American Depositary Share, the Purchasers paid a
 negotiated price of $0.15 (equating to $1.50 on an&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;as-if-converted-to-ordinary-shares&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&amp;#xA0;basis),
 resulting in $52.8&amp;#xA0;million in aggregate gross proceeds to the
 Company, before deducting estimated offering expenses of
 approximately $0.7&amp;#xA0;million. The net proceeds are reflected as
 preferred stock in the accompanying consolidated balance
 sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Each ten
 (10)&amp;#xA0;Series A Preference Shares may be consolidated and
 redesignated as one (1)&amp;#xA0;ordinary share, par value
 &amp;#xA3;0.50&amp;#xA0;per share, in the capital of the Company, each
 ordinary share to be represented by American Depositary Shares
 (&amp;#x201C;ADSs&amp;#x201D;), provided that consolidation will be
 prohibited if, as a result, the holder of such Series A Preference
 Shares and its affiliates would beneficially own more than 4.99% of
 the total number of Amarin ordinary shares or ADSs outstanding
 following such redesignation (the &amp;#x201C;Beneficial Ownership
 Limitation&amp;#x201D;). By written notice to the Company, a holder may
 from time to time increase or decrease the Beneficial Ownership
 Limitation to any other percentage not in excess of 19.9% specified
 in such notice; provided that any such increase will not be
 effective until the sixty-first (61st)&amp;#xA0;day after such notice
 is delivered to the Company. This consolidation and redesignation
 may be effected by a holder of Series A Preference Shares following
 the first to occur of the resale of the ADSs representing the
 ordinary shares being registered for resale under the Securities
 Act pursuant to an effective registration statement, following any
 sale of the ADSs representing the ordinary shares pursuant to Rule
 144 under the Securities Act, or if such ADSs representing the
 ordinary shares are eligible for sale under Rule 144, following the
 expiration of the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;one-year&lt;/font&gt;&amp;#xA0;holding requirement under Rule
 144. During the year ended December&amp;#xA0;31, 2015, at the request
 of the holders, a portion of the Series A Preference Shares were
 consolidated and redesignated, resulting in the issuance of
 6,283,333 ADSs such that a maximum of 32,818,464 ordinary shares
 remain issuable upon future consolidation and redesignation of the
 remaining Series A Preference Shares as of December&amp;#xA0;31, 2016,
 inclusive of the shares issued in July 2015 as discussed below,
 subject to certain adjustments for dilutive events.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Except as
 otherwise provided in the Series A Preference Share Terms or as
 required by applicable law, the Series A Preference Shares have no
 voting rights. However, as long as any Series A Preference Shares
 are outstanding, the Company cannot, without the approval of the
 holders of seventy-five percent (75%)&amp;#xA0;of the then outstanding
 Series A Preference Shares, alter or change adversely the powers,
 preferences or rights attaching to the Series A Preference Shares
 or enter into any agreement with respect to the
 foregoing.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Holders of
 the Series A Preference Shares are entitled to receive, and the
 Company is required to pay, dividends (other than dividends in the
 form of ordinary shares) on the Series A Preference Shares equal
 (on an&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;as-if-converted-to-ordinary-shares&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&amp;#xA0;basis)
 to and in the same form as dividends (other than dividends in the
 form of ordinary shares) actually paid on ordinary shares when, as
 and if such dividends (other than dividends in the form of ordinary
 shares) are paid on the ordinary shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The
 restricted American Depositary Shares and Series A Preference
 Shares were sold in a transaction exempt from the registration
 requirements under the Securities Act of 1933, as amended (the
 &amp;#x201C;Securities Act&amp;#x201D;) The Company filed a registration
 statement with the SEC covering the resale of the restricted
 American Depositary Shares and the ADSs representing ordinary
 shares created by the consolidation and redesignation of the Series
 A Preference Shares (the &amp;#x201C;Registrable Securities&amp;#x201D;) on
 April&amp;#xA0;9, 2015, which was declared effective by the SEC on
 May&amp;#xA0;1, 2015. In addition, the Company agreed to use its
 commercially reasonable best efforts to keep the registration, and
 any qualification, exemption or compliance under state securities
 laws which the Company determines to obtain, continuously
 effective, and to keep the Registration Statement free of any
 material misstatements or omissions, until the earlier of
 (a)&amp;#xA0;March&amp;#xA0;11, 2017 or (b)&amp;#xA0;the date on which all
 Registrable Securities held by Purchasers may be sold or
 transferred in compliance with Rule 144 under the Securities Act,
 without any volume or manner of sale restrictions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Series A
 Preference Shares contain a contingent beneficial conversion
 feature (&amp;#x201C;BCF&amp;#x201D;) because they contain a conversion
 feature at a fixed rate that was&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;in-the-money&lt;/font&gt;&lt;/font&gt;&amp;#xA0;when issued. The BCF was
 recorded in the three months ended June&amp;#xA0;30, 2015 as a result
 of the related Form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;S-3&lt;/font&gt;&amp;#xA0;Registration Statement being
 declared effective, which represents the resolution of the
 contingency to convert the Series A Preference Shares. The BCF was
 recognized in stockholders&amp;#x2019; deficit and was measured by
 allocating a portion of the proceeds equal to the intrinsic value
 of that feature to additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital. The effective
 purchase price of the ordinary shares into which the preferred
 shares are convertible was $1.50, which was used to compute the
 intrinsic value. The intrinsic value was calculated as the
 difference between the effective purchase price of the ordinary
 shares and the market value ($2.39 per share) on the date the
 preferred shares were issued, multiplied by the number of shares
 into which the preferred shares are convertible. The BCF resulting
 from the issuance of the Series A Preference Shares was determined
 to be $31.3&amp;#xA0;million. The BCF was recorded as a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;dividend to preferred
 shareholders through accumulated deficit, and was therefore
 reflected as an adjustment to net loss applicable to common
 shareholders for earnings per common share purposes in accordance
 with GAAP for the year ended December&amp;#xA0;31, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 March&amp;#xA0;30, 2015, in connection with the closing of the private
 placement, and pursuant to a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-existing&lt;/font&gt;&amp;#xA0;contractual right to
 participate in certain private placement transactions effected by
 the Company, the Company entered into a separate subscription
 agreement with an existing investor, Sofinnova Venture Partners VII
 L.P. (Sofinnova), for the purchase of an additional
 $5.8&amp;#xA0;million of restricted American Depositary Shares, each
 representing one (1)&amp;#xA0;share of the Company&amp;#x2019;s Series A
 Preference Shares, at the same price per share and otherwise on
 substantially the same terms as the initial private placement (the
 &amp;#x201C;Second Private Placement&amp;#x201D;). In accordance with
 applicable marketplace rules of the NASDAQ Stock Market, the
 consummation of the Second Private Placement was conditioned upon
 approval by the Company&amp;#x2019;s shareholders at a future meeting of
 the Company&amp;#x2019;s shareholders. Such approval was received at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders on
 July&amp;#xA0;6, 2015 and as a result, the closing of the Second
 Private Placement occurred on July&amp;#xA0;10, 2015. The Company
 issued 38,867,180 restricted ADSs, each representing one Series A
 Preference Share, which may be consolidated and redesignated from
 time to time up to a maximum of 3,886,718 ordinary shares, each
 ordinary share to be represented by one ADS. For each restricted
 ADS, Sofinnova paid a negotiated price of $0.15 (equating to $1.50
 on an&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;as-if-converted-to-ordinary-shares&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&amp;#xA0;basis)
 resulting in gross proceeds to the Company of $5.8&amp;#xA0;million. At
 the time of the transaction, Dr.&amp;#xA0;James Healy was a member of
 the Company&amp;#x2019;s Board and a managing general partner of
 Sofinnova Management VII, L.L.C., which is the general partner of
 Sofinnova. Dr.&amp;#xA0;Healy resigned as Director of the
 Company&amp;#x2019;s Board effective December&amp;#xA0;20, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The Company
 filed another registration statement with the SEC covering the
 resale of these restricted American Depositary Shares and the ADSs
 representing ordinary shares created by the consolidation and
 redesignation of the Series A Preference Shares (the
 &amp;#x201C;Sofinnova Registrable Securities&amp;#x201D;) on July&amp;#xA0;24,
 2015, which was declared effective by the SEC on August&amp;#xA0;7,
 2015. In addition, the Company agreed to use its commercially
 reasonable best efforts to keep the registration, and any
 qualification, exemption or compliance under state securities laws
 which the Company determines to obtain, continuously effective, and
 to keep the registration statement free of any material
 misstatements or omissions, until the earlier of (a)&amp;#xA0;July 10,
 2017 or (b)&amp;#xA0;the date on which all Sofinnova Registrable
 Securities held by Sofinnova may be sold or transferred in
 compliance with Rule 144 under the Securities Act, without any
 volume or manner of sale restrictions.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;The existence
 of this preferred stock purchase option was determined to be a
 derivative liability effective March&amp;#xA0;5, 2015, the date on
 which the private placement was initially subscribed. The fair
 value of this liability was calculated using a Black-Scholes model
 and was determined to be $0.9&amp;#xA0;million at inception and was
 charged to accumulated deficit as a deemed&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;dividend to Sofinnova. The
 liability was then marked to fair value as of March&amp;#xA0;30, 2015,
 the date on which the Company executed a subscription agreement
 with Sofinnova, resulting in a charge of $0.9&amp;#xA0;million through
 gain (loss) on change in fair value of derivatives. The liability
 of $1.8&amp;#xA0;million was reclassified to permanent equity
 (additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital) on such date.
 Subsequent to approval of the Second Private Placement at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders in July
 2015, the Company recorded the remaining value of the BCF related
 to this share issuance as a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;dividend to preferred
 shareholders through accumulated deficit. The value of the BCF was
 determined on the same basis as the first private placement and
 amounted to $3.4&amp;#xA0;million less $1.8&amp;#xA0;million previously
 recorded for the preferred stock purchase option for a
 net&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;charge of $1.6&amp;#xA0;million in
 the year ended December&amp;#xA0;31, 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 28px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;i&gt;&lt;u&gt;Common
 Stock&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In September
 2016, the Company mandatorily exchanged $118.7&amp;#xA0;million and
 $31.3&amp;#xA0;million of aggregate principal amount of the 2014 Notes
 and 2015 Notes, respectively, resulting in the issuance of
 47,739,925 ADSs and 12,571,263 ADSs, respectively, with each ADS
 representing one ordinary share of the Company (see Note
 8&amp;#x2014;Debt).&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In August
 2016, the Company completed a public offering of 21,100,000 ADSs,
 with each ADS representing one ordinary share of the Company.
 Amarin also granted the underwriters a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;30-day&lt;/font&gt;&amp;#xA0;option to purchase an
 additional 3,165,000 ADSs at the same price, which was exercised in
 full. The underwriters purchased the ADSs from the Company at a
 price of $2.679 per ADS after commission, resulting in net proceeds
 to the Company of approximately $64.6&amp;#xA0;million, after deducting
 estimated offering expenses payable by the Company. The Company
 currently intends to use the net proceeds from the offering to
 advance its&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;REDUCE-IT&lt;/font&gt;&amp;#xA0;cardiovascular outcomes trial
 and for general corporate and working capital purposes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 28px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;i&gt;&lt;u&gt;Incentive Equity Awards&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In March
 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Compensation&amp;#x2014;Stock
 Compensation (Topic 718): Improvements to Employee Share-Based
 Payment Accounting&lt;/i&gt;. The Company early adopted this standard
 during the quarter ended June&amp;#xA0;30, 2016, without electing to
 change its existing accounting policy of accounting for forfeitures
 based on expected vesting. The new standard requires that excess
 tax benefits and deficiencies that arise upon vesting or exercise
 of share-based payments be recognized as an income tax benefit and
 expense in the income statement, and also that historical excess
 tax benefits that were not previously recognized because the
 related tax deduction had not reduced current taxes payable should
 be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Further, the new
 standard amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&amp;#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. Refer to Note 2&amp;#x2014;Significant
 Accounting Policies above for additional discussion on the
 Company&amp;#x2019;s adoption of the new standard.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;In June 2014,
 the FASB issued guidance for accounting for share-based payments
 when the terms of an award provide that a performance target could
 be achieved after the requisite service period. The standard states
 that a performance target in a share-based payment that affects
 vesting and that could be achieved after the requisite service
 period should be accounted for as a performance condition. As such,
 the performance target should not be reflected in estimating the
 grant-date fair value of the award. The guidance became effective
 for all entities during the first quarter of fiscal 2016. The
 Company previously accounted for awards in a manner consistent with
 the new guidance and as such, adoption of the guidance did not have
 any impact on the Company&amp;#x2019;s consolidated financial
 statements.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;As of
 December&amp;#xA0;31, 2016, there were an aggregate of 21,188,014 stock
 options and 10,143,176 restricted stock units (&amp;#x201C;RSUs&amp;#x201D;)
 outstanding, representing approximately 6% and 3%, respectively, of
 outstanding shares (including common and preferred shares) on a
 fully diluted basis.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;During the
 years ended December&amp;#xA0;31, 2016 and 2015, the Company issued
 177,146 and 18,020 shares, respectively, as a result of the
 exercise of stock options, resulting in gross and net proceeds of
 $0.3&amp;#xA0;million during the year ended December&amp;#xA0;31, 2016 and
 $31&amp;#xA0;thousand during the year ended December&amp;#xA0;31,
 2015.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 July&amp;#xA0;11, 2016, the Company granted a total of 148,403 RSUs and
 208,340 stock options to members of the Company&amp;#x2019;s Board of
 Directors under the Amarin Corporation plc Stock Incentive Plan
 (the &amp;#x201C;2011 Plan&amp;#x201D;). The RSUs vest in equal installments
 over a three-year period upon the earlier of the anniversary of the
 grant date or the Company&amp;#x2019;s annual general meeting of
 shareholders in such anniversary year. The stock options vest in
 full upon the earlier of the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;one-year&lt;/font&gt;&amp;#xA0;anniversary of the grant date
 or the Company&amp;#x2019;s annual general meeting of shareholders in
 such anniversary year. Upon termination of service to the Company
 or upon a change of control, each Director shall be entitled to a
 payment equal to the fair market value of one share of Amarin
 common stock, which is required to be made in shares.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 February&amp;#xA0;1, 2016, the Company granted a total of 1,607,500
 RSUs and 2,442,000 stock options to employees under the 2011 Plan.
 The RSUs vest annually over a three-year period and the stock
 options vest monthly over a four-year period.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 July&amp;#xA0;6, 2015, the Company granted a total of 1,455,000 RSUs
 and 5,470,000 stock options to employees under the Amarin
 Corporation plc Stock Incentive Plan (the &amp;#x201C;2011 Plan&amp;#x201D;).
 The RSUs granted vest over a four-year period. Of the total stock
 options granted, 3,670,000 stock options vest over a four-year
 period while the remaining 1,800,000 stock options vest upon the
 achievement of certain performance conditions. During the year
 ended December&amp;#xA0;31, 2016, the Company issued 363,750 common
 shares related to the vesting of these RSUs, of which 173,563
 shares were retained as treasury shares as settlement of employee
 tax obligations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;Also on
 July&amp;#xA0;6, 2015, the Company granted a total of 413,500 RSUs and
 288,657 stock options to members of the Company&amp;#x2019;s Board of
 Directors under the 2011 Plan. Of the total awards granted, 283,500
 RSUs and 121,506 stock options vest in equal installments over a
 three-year period upon the earlier of the anniversary of the grant
 date or the Company&amp;#x2019;s annual general meeting of shareholders
 in such anniversary year, while the remaining 130,000 RSUs and
 167,151 stock options vest in full upon the earlier of
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;one-year&lt;/font&gt;&amp;#xA0;anniversary of the grant date
 or the Company&amp;#x2019;s annual general meeting of shareholders in
 such anniversary year. Upon termination of service to the Company
 or upon a change of control, each Director shall be entitled to a
 payment equal to the fair market value of one share of Amarin
 common stock, which is required to be made in shares.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;On
 January&amp;#xA0;29, 2015, the Company granted a total of 2,564,251
 RSUs and 1,622,500 stock options to employees under the 2011 Plan.
 The RSUs vest annually over a three year period and the stock
 options vest over a four year period. Also on January&amp;#xA0;29,
 2015, the Company granted 5,455,500 RSUs to employees under the
 2011 Plan that vest upon the achievement of certain performance
 conditions. The issuance of these performance RSUs was contingent
 upon shareholder approval to increase the aggregate number of
 shares authorized for issuance under the 2011 Plan, which was
 obtained at the Company&amp;#x2019;s Annual General Meeting of
 Shareholders held on July&amp;#xA0;6, 2015. During the year ended
 December&amp;#xA0;31, 2016, the Company issued 818,352 common shares
 related to the vesting of these RSUs, of which 270,329 shares were
 retained as treasury shares as settlement of employee tax
 obligations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;See Note
 12&amp;#x2014;Stock Incentive Plans and Stock Based Compensation for
 further information regarding the Company&amp;#x2019;s incentive equity
 awards.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 28px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;&lt;i&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;font style="FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" size="2"&gt;During the
 year ended December&amp;#xA0;31, 2015, the Company issued 1,844,585
 shares upon the exercise of warrants, resulting in gross and net
 proceeds of $2.8&amp;#xA0;million and $2.7&amp;#xA0;million, respectively.
 There was no warrant activity during the year ended
 December&amp;#xA0;31, 2016 and no warrants remained outstanding as of
 December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="INF" id="id_6322976_4AA8173D-CCAE-4FC9-8028-5ADF7E2CDA97_1_0" unitRef="shares">177146</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UseOfEstimates contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_4008B7E9-A90F-4C5C-A96B-FBB651066644_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounting estimates are
 based on historical experience and other factors that are
 considered reasonable under the circumstances. Estimates are used
 in determining such items as provisions for sales returns, rebates
 and incentives, chargebacks, and other sales allowances;
 depreciable/amortizable lives; asset impairments; valuation
 allowance on deferred taxes; probabilities of achievement of
 performance conditions for certain equity awards; amounts recorded
 for licensing revenue; contingencies and accruals; and valuations
 of derivative and long-term debt instruments. Because of the
 uncertainties inherent in such estimates, actual results may differ
 from these estimates. Management periodically evaluates estimates
 used in the preparation of the consolidated financial statements
 for continued reasonableness.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_1436A651-2D4A-4B8F-A402-29B6497C12E3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Liabilities&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Warrant
 Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s warrant
 derivative liability (discussed in Note 7&amp;#x2014;Warrants and
 Warrant Derivative Liability) was carried at fair value and was
 classified as Level&amp;#xA0;3 in the fair value hierarchy due to the
 use of significant unobservable inputs. During the year ended
 December&amp;#xA0;31, 2015 of the 8,087,388 warrants outstanding as of
 December&amp;#xA0;31, 2014, 1,844,585 warrants were exercised while the
 remaining 6,242,803 warrants expired and the related derivative
 liability was extinguished. As such, no warrants were outstanding
 as of December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Long-Term
 Debt Redemption Features&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s
 December 2012 financing agreement with BioPharma Secured Debt Fund
 II Holdings Cayman LP (discussed in Note 8&amp;#x2014;Debt) contains a
 redemption feature whereby, upon a change of control, the Company
 would be required to repay $150.0&amp;#xA0;million, less any previously
 repaid amount. The Company determined this redemption feature to be
 an embedded derivative, which is carried at fair value and is
 classified as Level&amp;#xA0;3 in the fair value hierarchy due to the
 use of significant unobservable inputs. The fair value of the
 embedded derivative was calculated using a probability-weighted
 model incorporating management estimates of future revenues and for
 a potential change in control, and by determining the fair value of
 the debt with and without the change in control provision included.
 The difference between the two was determined to be the fair value
 of the embedded derivative. As of December&amp;#xA0;31, 2016, the fair
 value of the derivative was determined to be nil based on current
 assumptions, and the debt was valued by comparing debt issues of
 similar companies with (i)&amp;#xA0;remaining terms of between 2.4 and
 5.0 years, (ii)&amp;#xA0;coupon rates of between 8.1% and 11.1% and
 (iii)&amp;#xA0;market yields of between 11.9% and 18.4%. As of
 December&amp;#xA0;31, 2015, the fair value of the derivative was
 determined to be $5.5&amp;#xA0;million, and the debt was valued by
 comparing debt issues of similar companies with (i)&amp;#xA0;remaining
 terms of between 2.0 and 7.3 years, (ii)&amp;#xA0;coupon rates of
 between 6.6% and 12.5% and (iii)&amp;#xA0;market yields of between
 13.0% and 30.7%. As such, the Company recognized a
 $5.5&amp;#xA0;million gain on change in fair value of derivative
 liability for the year ended December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s 2014
 Notes and 2015 Notes each contained a redemption feature whereby,
 upon occurrence of a change in control, the Company would have been
 required to repurchase the notes. The Company determined these
 redemption features to be embedded derivatives, requiring
 bifurcation in accordance with ASC 815. The derivatives were
 carried at fair value and were classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable inputs.
 The fair value of each embedded derivative was calculated using a
 probability-weighted model incorporating management estimates of
 the probability of a change in control occurring, and by
 determining the fair value of the debt with and without the change
 in control provision included. The difference between the two was
 determined to be the fair value of the embedded derivative. As of
 December&amp;#xA0;31, 2016, derivatives related to the 2014 Notes and
 2015 Notes were each derecognized, as the related debt hosts were
 exchanged into equity in September 2016. As of December&amp;#xA0;31,
 2015, the fair values of the derivatives related to the 2014 Notes
 and 2015 Notes were determined to be $2.1&amp;#xA0;million and
 $0.6&amp;#xA0;million, respectively, and the debts were valued by using
 (i)&amp;#xA0;the estimated remaining term of the notes, (ii)&amp;#xA0;a
 bond yield of 25.6%, (iii)&amp;#xA0;a risk-free interest rate of 2.9%
 and (iv)&amp;#xA0;volatility of 89.0%. As such, the Company recognized
 a gain on change in fair value of derivative liability for the 2014
 Notes and 2015 Notes of $2.1&amp;#xA0;million and $0.6&amp;#xA0;million,
 respectively, for the year ended December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;Preferred
 Stock Purchase Option Derivative Liability&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Pursuant to a &lt;font style="WHITE-SPACE: nowrap"&gt;pre-existing&lt;/font&gt; contractual right to
 participate in certain private placement transactions effected by
 the Company in connection with the subscription agreement executed
 on March&amp;#xA0;5, 2015, the Company determined that such right
 represented a derivative liability (see Note 10&amp;#x2014;Equity). This
 preferred stock purchase option derivative liability was carried at
 fair value and classified as Level&amp;#xA0;3 in the fair value
 hierarchy due to the use of significant unobservable inputs. The
 fair value of this liability was calculated using a Black-Scholes
 model and was determined to be $0.9&amp;#xA0;million at inception. On
 March&amp;#xA0;30, 2015, this right was exercised and the liability was
 marked to fair value through such date. The liability was then
 reclassified to permanent equity on such date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Any changes in the
 assumptions used to value the derivative liabilities, including the
 probability of a change in control, could result in a material
 change to the carrying value of such liabilities.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of derivative liabilities for the years ended
 December&amp;#xA0;31, 2016 and 2015 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Long-Term&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&amp;#xA0;
 Derivative&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Preferred
 Stock&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 January&amp;#xA0;1, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;119&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,400&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,519&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Record initial fair value
 of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;868&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,368&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(110&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;946&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,106&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfer derivative
 liability to equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,814&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,814&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on change in fair
 value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <dei:EntityRegistrantName contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400001">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E5F2C302-45B1-477D-97A1-BBDA6958DEE7_1_400006">No</dei:EntityVoluntaryFilers>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_7AB4542F-BD5F-446A-93C0-D1577BF3217B_1_1">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_91414444-0CE3-4226-8D80-607BD98D5FFF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following tables
 present information about the Company&amp;#x2019;s assets and
 liabilities as of December&amp;#xA0;31, 2016 and 2015 that are measured
 at fair value on a recurring basis and indicate the fair value
 hierarchy of the valuation techniques the Company utilized to
 determine such fair value:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,238&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Asset:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash
 equivalents&amp;#x2014;money markets&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,184&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,184&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt derivative
 liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_9CB42DCF-C98C-4CF2-823C-B7ECA00578F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Long-Lived Asset Impairment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company reviews its
 long-lived assets for impairment whenever events or changes in
 circumstances indicate that the carrying amount of such assets may
 not be recoverable. Recoverability of these assets is determined by
 comparing the forecasted undiscounted net cash flows of the
 operation to which the assets relate to their carrying amount. If
 impairment is indicated, the assets are written down to fair value.
 Fair value is determined based on discounted forecasted cash flows
 or appraised values, depending on the nature of the
 assets.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_FCF6E9E5-2E80-4AF7-B44D-3B3DCB4C5082_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Income
 Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax assets and
 liabilities are recognized for the future tax consequences of
 differences between the carrying amounts and tax bases of assets
 and liabilities and operating loss carryforwards and other
 attributes using enacted rates expected to be in effect when those
 differences reverse. Valuation allowances are provided against
 deferred tax assets that are not more likely than not to be
 realized.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides
 reserves for potential payments of tax to various tax authorities
 or does not recognize tax benefits related to uncertain tax
 positions and other issues. Tax benefits for uncertain tax
 positions are based on a determination of whether a tax benefit
 taken by the Company in its tax filings or positions is more likely
 than not to be realized, assuming that the matter in question will
 be decided based on its technical merits. The Company&amp;#x2019;s
 policy is to record interest and penalties in the provision for
 income taxes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company regularly
 assesses its ability to realize deferred tax assets. Changes in
 historical earnings performance and future earnings projections,
 among other factors, may cause the Company to adjust its valuation
 allowance on deferred tax assets, which would impact the
 Company&amp;#x2019;s income tax expense in the period in which it is
 determined that these factors have changed.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2016, the Company
 adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-09,&lt;/font&gt;
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt; capital. This aspect of the
 standard was adopted prospectively and, accordingly, the provision
 for income taxes for the year ended December&amp;#xA0;31, 2016 includes
 $0.4&amp;#xA0;million of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately
 $1.6&amp;#xA0;million relating to excess tax benefits on stock-based
 compensation outstanding as of December&amp;#xA0;31, 2015, with a
 corresponding cumulative-effect adjustment to accumulated deficit.
 The new standard also amends the presentation of employee
 share-based payment-related items in the statement of cash flows by
 requiring that: (i)&amp;#xA0;excess income tax benefits and
 deficiencies be classified in cash flows from operating activities,
 and (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.7&amp;#xA0;million of excess tax benefit
 and $2.3&amp;#xA0;million of excess tax provision from cash flows
 provided by financing activities to cash flows used in operating
 activities in the consolidated statement of cash flows for the
 years ended December&amp;#xA0;31, 2015 and 2014, respectively, to
 conform to the current year presentation. The presentation
 requirement for cash flows related to taxes paid for withheld
 shares had no impact to any of the periods presented in the
 consolidated statement of cash flows since such payments have
 historically been presented as a financing activity.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#x2019;s and its
 subsidiaries&amp;#x2019; income tax returns are periodically examined by
 various tax authorities. The Company is currently under audit by
 the United States Internal Revenue Service (IRS) for the years 2013
 to 2014. Although the outcome of tax audits is always uncertain and
 could result in significant cash tax payments, the Company does not
 believe the outcome of these audits will have a material adverse
 effect on the Company&amp;#x2019;s consolidated financial position or
 results of operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_AA63B411-78A3-4C47-A130-B0216F575F35_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Property, Plant and Equipment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company provides for
 depreciation and amortization using the straight-line method by
 charges to operations in amounts that depreciate the cost of the
 fixed asset over its estimated useful life. The estimated useful
 lives, by asset classification, are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="WIDTH: 66pt; BORDER-BOTTOM: #000000 1px solid"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Asset
 Classification&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;p style="WIDTH: 41pt; BORDER-BOTTOM: #000000 1px solid" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Useful Lives&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Computer equipment and
 software&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3 -
 5&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture and
 fixtures&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5 years&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Lesser&amp;#xA0;of&amp;#xA0;useful&amp;#xA0;life&amp;#xA0;or&amp;#xA0;lease&amp;#xA0;term&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Upon retirement or sale of
 assets, the cost of the assets disposed and the related accumulated
 depreciation are removed from the consolidated balance sheet and
 any resulting gain or loss is credited or expensed to operations.
 Repairs and maintenance costs are expensed as incurred.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_8B30D8D6-AE8C-495E-BD24-AD9660BF217F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(15)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Quarterly Summarized Financial
 Information (Unaudited)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="36%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="30" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fiscal years ended
 December&amp;#xA0;31, 2016 and 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;1st&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2nd&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;3rd&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;4th&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="30" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;(In thousands, except
 per share amounts)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total revenue,
 net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,543&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,933&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;33,111&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,707&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,734&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,483&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;38,696&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,633&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss applicable to
 common shareholders&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(29,771&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(31,994&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(13,354&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(62,853&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(15,772&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(32,321&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(27,453&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,891&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss per share:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.08&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.08&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_2EA88E5E-F4D7-48BE-B222-A33EC361442F_1_0">&lt;div&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;(14)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Related Party
 Transactions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;October
 2009 Private Placement&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Several of Amarin&amp;#x2019;s
 current and former directors and funds connected with them
 purchased approximately 36.0&amp;#xA0;million of its ADSs (in the form
 of common stock) in the October 2009 private placement, including:
 (i)&amp;#xA0;17&amp;#xA0;million ADSs purchased by funds managed by
 Abingworth LLP, where Dr.&amp;#xA0;Joseph Anderson, a former Director
 of Amarin, is a partner; (ii)&amp;#xA0;7&amp;#xA0;million ADSs purchased by
 Orbimed Advisors LLC, where Dr.&amp;#xA0;Carl&amp;#xA0;L. Gordon, a former
 Director of Amarin, is a General Partner; (iii)&amp;#xA0;7&amp;#xA0;million
 ADSs purchased by Sofinnova Venture Partners VII, L.P. (Sofinnova),
 where Dr.&amp;#xA0;James&amp;#xA0;I. Healy, a former Director of Amarin, is
 a Managing General Partner; and (iv)&amp;#xA0;5&amp;#xA0;million ADSs
 purchased by Fountain Healthcare Partners Fund 1, L.P. Fountain
 Healthcare Partners Ltd. is the sole General Partner of Fountain
 Healthcare Partners Fund 1, L.P. Dr.&amp;#xA0;Manus Rogan is a Managing
 Partner of Fountain Healthcare Partners Ltd. and until December
 2011 was a &lt;font style="white-space:nowrap"&gt;non-executive&lt;/font&gt;
 director of Amarin. In addition, for every ADS purchased, the
 investor received warrants to purchase 0.5 (one half) of an ADS. No
 warrants remained outstanding as of December&amp;#xA0;31, 2016.
 Therefore, the fair value of the warrants held by the current and
 former directors of the Company and their related investment funds
 amounted to zero.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;&lt;u&gt;March 2015
 Private Placement&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;On March&amp;#xA0;30, 2015, in
 connection with the closing of the initial private placement
 described in Note 10&amp;#x2014;Equity, and pursuant to a &lt;font style="white-space:nowrap"&gt;pre-existing&lt;/font&gt; contractual right to
 participate in certain private placement transactions effected by
 the Company, the Company entered into a separate subscription
 agreement with an existing investor, Sofinnova. The Company issued
 38,867,180 restricted ADSs, each representing one Series A
 Preference Share, which may be consolidated and redesignated from
 time to time up to a maximum of 3,886,718 ordinary shares, each
 ordinary share to be represented by one ADS. For each restricted
 ADS, Sofinnova paid a negotiated price of $0.15 (equating to $1.50
 on an &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;as-if-converted-to-ordinary-shares&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
 basis) resulting in gross proceeds to the Company of
 $5.8&amp;#xA0;million. The shares are owned directly by Sofinnova. At
 the time of the transaction, Dr.&amp;#xA0;James Healy was a member of
 the Company&amp;#x2019;s Board and a managing general partner of
 Sofinnova Management VII, L.L.C., which is the general partner of
 Sofinnova. Healy may be deemed to have shared voting and
 dispositive power over the shares owned by Sofinnova, but disclaims
 beneficial ownership over the shares owned by Sofinnova except to
 the extent of any pecuniary interest therein. Healy resigned as
 Director of the Company&amp;#x2019;s Board effective December&amp;#xA0;20,
 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_57C674B5-86E4-4260-A283-32E7E55BE8DC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes the impact of accounts receivable reserves on the gross
 trade accounts receivable balances as of December&amp;#xA0;31, 2016 and
 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gross trade accounts
 receivable&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;24,127&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;18,270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Trade allowances&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,743&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,296&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Chargebacks&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(387&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(148&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Allowance for doubtful
 accounts&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable,
 net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;19,985&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,826&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_DB5E9A44-69F8-478E-BD04-AADC67A3F8FC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued expenses and other
 current liabilities consist of the following as of
 December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Payroll and payroll-related
 expenses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,611&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,241&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and development
 expenses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;293&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;828&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Sales and marketing
 accruals&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,821&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,141&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued revenue
 allowances&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;22,195&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,732&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,800&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total accrued expenses and
 other current liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;37,720&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;24,226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_60C43690-497B-4460-B120-BAE139490189_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The carrying amounts of
 cash, cash equivalents, accounts payable and accrued liabilities
 approximate fair value because of their short-term nature. The
 carrying amounts and the estimated fair values of debt instruments
 as of December&amp;#xA0;31, 2016 and 2015 are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;
 Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt from
 royalty-bearing instrument&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85,155&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;90,500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91,512&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;87,700&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2012 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,107&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,174&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,107&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13,637&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2014 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;96,364&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;108,034&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2015 Notes&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;27,134&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;28,448&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_05DD070B-A61D-4C5B-87DD-B4379DF4DCCB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The change in the fair
 value of derivative liabilities for the years ended
 December&amp;#xA0;31, 2016 and 2015 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;October&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Long-Term&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Debt&amp;#xA0;
 Derivative&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Preferred
 Stock&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 January&amp;#xA0;1, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;119&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,400&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,519&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Record initial fair value
 of derivative liability&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;500&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;868&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,368&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(Gain) loss on change in
 fair value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(110&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;270&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;946&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,106&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Compensation income for
 change in fair value of warrants issued to former
 employees&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Transfer derivative
 liability to equity&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,814&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,814&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Gain on change in fair
 value of derivative liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(8,170&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_A65CB5E8-3A0E-43DE-BB18-46D1BFB3D17B_1_0">&lt;div&gt;
 &lt;p&gt;&lt;font size="2"&gt;The carrying value as of December&amp;#xA0;31, 2016
 is as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Remaining
 Useful&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Life (in
 years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Technology
 rights&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,624&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,852&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,772&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;13.6&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_75329E9A-4C2E-4240-A66A-2AB8BAA07334_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="36%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="30" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fiscal years ended
 December&amp;#xA0;31, 2016 and 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;1st&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2nd&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;3rd&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;4th&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Quarter&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="30" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;(In thousands, except
 per share amounts)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total revenue,
 net&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;25,543&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;15,933&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;33,111&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,707&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,734&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;21,483&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;38,696&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;26,633&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss applicable to
 common shareholders&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(29,771&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(31,994&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(13,354&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(62,853&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(15,772&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(32,321&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(27,453&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(21,891&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Loss per share:&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.08&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Diluted&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.16&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.07&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.35&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.08&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.18&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.12&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_700C6EDF-F919-4A41-89E7-DE13994AFAEE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following is a
 reconciliation of the total amounts of unrecognized tax benefits
 for the years ended December&amp;#xA0;31, 2016, 2015 and
 2014:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Beginning uncertain tax
 benefits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,550&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,674&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Prior
 year&amp;#x2014;increases&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;120&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Prior
 year&amp;#x2014;decreases&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(762&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Current
 year&amp;#x2014;increases&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;144&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,067&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Current
 year&amp;#x2014;decreases for lapses in statutes of
 limitations&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(439&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(254&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Ending uncertain tax
 benefits&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,633&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,550&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,487&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="2" id="id_6322976_7CE59438-0508-47BF-B878-97FD56CD0FBA_7001_8" unitRef="iso4217_USD_per_shares">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_A3E6572F-05C6-431E-8976-94F9ED085187_1_3">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_6FE0F33A-18F0-486E-A233-7BF8422BDE34_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(18)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has evaluated
 subsequent events from December&amp;#xA0;31, 2016 through the date of
 the issuance of these consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On January&amp;#xA0;19, 2017,
 holders of the 2012 Notes exercised their option to put the 2012
 Notes to the Company at a price equal to 100% of the principal
 amount of the 2012 Notes to be repurchased, plus accrued and unpaid
 interest to, but excluding, the repurchase date. As a result, the
 Company repurchased approximately $15.0&amp;#xA0;million in aggregate
 principal amount of 2012 Notes, such that $0.1&amp;#xA0;million in
 principal amount of 2012 Notes remains outstanding.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In contemplation of this
 surrender of 2012 Notes for repurchase, on January&amp;#xA0;20, 2017,
 the Company and its wholly owned subsidiary, Corsicanto II
 Designated Activity Company (&amp;#x201C;Corsicanto II&amp;#x201D;), entered
 into separate, privately negotiated purchase agreements with
 certain investors pursuant to which the Corsicanto II issued and
 sold $30.0&amp;#xA0;million in aggregate principal amount of 3.5%
 Exchangeable Senior Notes due 2047 (the &amp;#x201C;2017 Notes&amp;#x201D;),
 which are guaranteed by the Company, at an issue price of 100%. The
 transaction closed on January&amp;#xA0;25, 2017.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The 2017 Notes will be
 issued pursuant to an Indenture (the &amp;#x201C;Indenture&amp;#x201D;), to
 be entered into by the Company, Corsicanto II and Wilmington Trust,
 National Association, as trustee (the &amp;#x201C;Trustee&amp;#x201D;). The
 2017 Notes will be the senior unsecured obligations of Corsicanto
 II and will be guaranteed by the Company. The 2017 Notes will bear
 interest at a rate of 3.5% per annum from, and including,
 January&amp;#xA0;25, 2017, payable semi-annually in arrears on
 January&amp;#xA0;15 and July&amp;#xA0;15 of each year, beginning on
 July&amp;#xA0;15, 2017. The 2017 Notes will mature on January&amp;#xA0;15,
 2047, unless earlier repurchased, redeemed or exchanged.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At any time after the
 issuance of the 2017 Notes and prior to the close of business on
 the second business day immediately preceding January&amp;#xA0;15,
 2047, holders may exchange their 2017 Notes for ADSs at their
 option and at the exchange rate described below. If prior to
 January&amp;#xA0;19, 2021, a make-whole fundamental change (as defined
 in the Indenture) occurs and a holder elects to exchange its 2017
 Notes in connection with such make-whole fundamental change, such
 holder may be entitled to an increase in the exchange rate as
 described in the Indenture.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The exchange rate will
 initially be 257.2016 ADSs per $1,000 principal amount of the 2017
 Notes (equivalent to an initial exchange price of approximately
 $3.89 per ADS), subject to adjustment in certain circumstances. The
 initial exchange price for the 2017 Notes represents a premium of
 approximately 35% over the last reported sale price of $2.88 per
 share of the Company&amp;#x2019;s ADSs on The NASDAQ Global Market on
 January&amp;#xA0;19, 2017. Upon exchange, the 2017 Notes are to be
 settled in ADSs. The exchange rate is subject to adjustment from
 time to time upon the occurrence of certain events, including, but
 not limited to, the payment of cash dividends. In the event of
 physical settlement, the 2017 Notes would be exchangeable into a
 total of 7,716,048 ADSs based on the initial exchange
 rate.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Prior to January&amp;#xA0;19,
 2021, Corsicanto II may not redeem the 2017 Notes at its option
 other than in connection with certain changes in the tax law of a
 relevant taxing jurisdiction that results in additional amounts (as
 defined in the Indenture) becoming due with respect to payments
 and/or deliveries on the 2017 Notes. On or after January&amp;#xA0;19,
 2021, Corsicanto II may redeem for cash all or a portion of the
 2017 Notes at a redemption price of 100% of the aggregate principal
 amount of the 2017 Notes to be redeemed, plus accrued and unpaid
 interest to, but not including, the redemption date. If a
 Fundamental Change (as defined in the Indenture) occurs, holders
 may require Corsicanto II to repurchase all or part of their 2017
 Notes for cash at a Fundamental Change repurchase price equal to
 100% of the aggregate principal amount of the 2017 Notes to be
 repurchased, plus accrued and unpaid interest to, but not
 including, the Fundamental Change repurchase date. In addition,
 holders of the 2017 Notes may require Corsicanto II to repurchase
 all or any portion of the 2017 Notes on January&amp;#xA0;19, 2022 for
 cash at a price equal to 100% of the aggregate principal amount of
 the 2017 Notes to be repurchased, plus accrued and unpaid interest
 to, but not including, the repurchase date.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Corsicanto II may elect at
 its option to cause all or any portion of the 2017 Notes to be
 mandatorily exchanged in whole or in part at any time prior to the
 close of business on the business day preceding January&amp;#xA0;15,
 2047 if the Daily VWAP (as defined in the Indenture) equals or
 exceeds 130% of the Exchange Price then in effect for at least 20
 VWAP Trading Days (as defined in the Indenture) in any 30
 consecutive VWAP Trading Day period. Corsicanto II may only
 exercise its optional exchange rights upon satisfaction of
 specified equity conditions, including that the ADSs issuable upon
 exchange of the 2017 Notes be eligible for resale without
 registration by &lt;font style="WHITE-SPACE: nowrap"&gt;non-affiliates&lt;/font&gt; and listed on The
 NASDAQ Global Market, its related exchanges or the New York Stock
 Exchange. If Corsicanto II elects to exercise its optional exchange
 rights on or prior to January&amp;#xA0;19, 2021, each holder whose 2017
 Notes are exchanged may upon exchange receive a specified number of
 additional ADSs as set forth in the Indenture.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The net proceeds from the
 offering were approximately $28.9&amp;#xA0;million after deducting
 placement agent fees and estimated offering expenses payable by the
 Company. A portion of the net proceeds from the offering
 replenished approximately $15.0&amp;#xA0;million of cash on hand that
 the Company used to purchase substantially all of the 2012 Notes.
 The Company anticipates that it will use the remainder of the net
 proceeds from the offering for general corporate and working
 capital purposes.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has initiated
 the process to redeem the remaining $0.1&amp;#xA0;million of 2012
 Notes, which is expected to be completed in the first quarter of
 2017.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_8218C51E-0576-48AB-A3D3-CCCD9E8A105F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 reflects the activity in the valuation allowance for the years
 ended December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Beginning valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;95,999&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;85,965&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Increase as reflected in
 income tax expense&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;17,951&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,291&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Increase as reflected in
 retained earnings&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,315&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cumulative translation
 adjustment&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,676&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,572&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Ending valuation
 allowance&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;109,274&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;95,999&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
  <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_8" unitRef="iso4217_USD">13276000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7005_7" unitRef="iso4217_USD">104601000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_6A4079F6-9CC7-4B27-830B-CB3A91A893BA_1_1" unitRef="iso4217_USD">17951000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14009_1200030" unitRef="iso4217_USD">-1094000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_37500BE5-5551-4C39-8C83-762C887B3B3F_1_1" unitRef="iso4217_USD">6500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_2" unitRef="iso4217_USD">130084000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_24" unitRef="iso4217_USD">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_17" unitRef="iso4217_USD">567000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_4" unitRef="iso4217_USD">-48000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_47" unitRef="iso4217_USD">128115000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14009_1200027" unitRef="iso4217_USD">127436000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_0" unitRef="iso4217_USD">128966000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:PaymentsOfDebtRestructuringCosts contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_35" unitRef="iso4217_USD">680000</us-gaap:PaymentsOfDebtRestructuringCosts>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_9" unitRef="iso4217_USD">-65626000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_17" unitRef="iso4217_USD">-86350000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_44" unitRef="iso4217_USD">17083000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_15" unitRef="iso4217_USD">1522000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_14" unitRef="iso4217_USD">6171000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14009_1200031" unitRef="iso4217_USD">13602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_5392A7D7-BF6D-4E59-97D8-392BD3AB0C1E_1_3" unitRef="iso4217_USD">83000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_36" unitRef="iso4217_USD">1094000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:LicensesRevenue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_1" unitRef="iso4217_USD">1118000</us-gaap:LicensesRevenue>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_13" unitRef="iso4217_USD">234000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_5" unitRef="iso4217_USD">1689000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_45" unitRef="iso4217_USD">1457000</us-gaap:IncomeTaxesPaid>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_4" unitRef="iso4217_USD">95721000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_10" unitRef="iso4217_USD">8170000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14009_1200029" unitRef="iso4217_USD">287000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14009_1200025" unitRef="iso4217_USD">64613000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_14" unitRef="iso4217_USD">-482000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_20" unitRef="iso4217_USD">-86350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_709985C8-7353-4131-98D3-2FABEFB626CE_1_6" unitRef="iso4217_USD">-86350000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_16" unitRef="iso4217_USD">3831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_52D94783-3F82-40A8-827F-7E9F6E3F1961_1_0" unitRef="iso4217_USD">-8115000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_15" unitRef="iso4217_USD">-76381000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_5" unitRef="iso4217_USD">-4001000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_12" unitRef="iso4217_USD">8798000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_6" unitRef="iso4217_USD">-334000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_40C3AD7F-B458-4952-BEE9-A9D1C610B067_1_0" unitRef="iso4217_USD">100000</us-gaap:Depreciation>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_16" unitRef="iso4217_USD">9969000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_6" unitRef="iso4217_USD">4524000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:InterestExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_12" unitRef="iso4217_USD">18677000</us-gaap:InterestExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_25" unitRef="iso4217_USD">-21000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_28" unitRef="iso4217_USD">64613000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_6" unitRef="iso4217_USD">13613000</us-gaap:ShareBasedCompensation>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_1" unitRef="iso4217_USD">1033000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_3" unitRef="iso4217_USD">1171000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_287BE393-751E-4110-B26F-5D52DAB6627B_1_0" unitRef="iso4217_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_3" unitRef="iso4217_USD">138000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_0" unitRef="iso4217_USD">-19039000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_19" unitRef="iso4217_USD">884000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_21" unitRef="iso4217_USD">375000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_504D38E8-6F3B-4970-8011-3343130C7833_1_0" unitRef="iso4217_USD">7000000</us-gaap:RestrictedStockExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_6" unitRef="iso4217_USD">111372000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7005_9" unitRef="iso4217_USD">77747000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_8" unitRef="iso4217_USD">7783000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_9" unitRef="iso4217_USD">1922000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_8" unitRef="iso4217_USD">-409000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_20" unitRef="iso4217_USD">8705000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_18" unitRef="iso4217_USD">-6205000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_38" unitRef="iso4217_USD">63126000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_6F037D03-4730-48BF-AF7E-194F340C34E8_1_0" unitRef="iso4217_USD">600000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_5" unitRef="iso4217_USD">12000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_7" unitRef="iso4217_USD">49975000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_B35970DA-6B46-4132-82DB-C64604549BDF_1_2" unitRef="iso4217_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_9" unitRef="iso4217_USD">645000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_39" unitRef="iso4217_USD">-8710000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_3" unitRef="iso4217_USD">34363000</us-gaap:CostOfGoodsSold>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_2" unitRef="iso4217_USD">138000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_133FD950-1668-4338-B59F-202B03F6E9AB_1_7" unitRef="iso4217_USD">-143000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_1" unitRef="iso4217_USD">4667000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_2" unitRef="iso4217_USD">13276000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D1FF0225-1348-4482-B4EF-DAA6AB79B70E_1_8" unitRef="iso4217_USD">161347000</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_8EA20C07-164D-4813-AAC9-260C4DCDAD12_1_31" unitRef="iso4217_USD">287000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-5" id="id_6322976_19EDCCB5-CFF5-44D9-A02D-AA11EC0A53E6_1_0" unitRef="iso4217_USD">6600000</us-gaap:StockOptionPlanExpense>
  <amrn:IncomeTaxReconciliationDerivativeLiabilities contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_3" unitRef="iso4217_USD">-668000</amrn:IncomeTaxReconciliationDerivativeLiabilities>
  <amrn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_6069D610-37EC-4C9A-BC3F-952031510D36_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The estimated useful lives,
 by asset classification, are as follows:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="WIDTH: 66pt; BORDER-BOTTOM: #000000 1px solid"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Asset
 Classification&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;p style="WIDTH: 41pt; BORDER-BOTTOM: #000000 1px solid" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Useful Lives&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Computer equipment and
 software&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3 -
 5&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Furniture and
 fixtures&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5 years&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Leasehold
 improvements&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Lesser&amp;#xA0;of&amp;#xA0;useful&amp;#xA0;life&amp;#xA0;or&amp;#xA0;lease&amp;#xA0;term&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
  <amrn:DebtIssuanceCostsPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_83BDDD55-68F4-4C77-B544-D771218D65BE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Debt
 Issuance Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Prior to January 2016, debt
 issuance costs were initially recorded as a deferred cost and
 amortized to interest expense using the effective interest method
 over the expected term of the related debt. Effective January 2016,
 the Company adopted ASU &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2015-03,&lt;/font&gt;
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic &lt;font style="WHITE-SPACE: nowrap"&gt;835-30):&lt;/font&gt; Simplifying the Presentation
 of Debt Issuance Costs&lt;/i&gt;, and as such began recording debt
 issuance costs related to a recognized debt liability in the
 consolidated balance sheet as a direct deduction from the carrying
 amount of that debt liability and amortized to interest expense
 using the effective interest method over the expected term of the
 related debt. As the standard is required to be adopted on a
 retrospective basis, the Company reclassified $1.9&amp;#xA0;million of
 underwriters&amp;#x2019; fees and offering costs related to the 2014
 Notes and 2015 Notes from other &lt;font style="WHITE-SPACE: nowrap"&gt;long-term&lt;/font&gt; assets to exchangeable
 senior notes, net of discount, within the consolidated balance
 sheet as of December&amp;#xA0;31, 2015. Unamortized debt issuance costs
 related to the extinguishment of debt are expensed at the time the
 debt is extinguished and recorded in other (expense) income, net,
 in the consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:DebtIssuanceCostsPolicyTextBlock>
  <amrn:CoPromotionAgreementDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_B99CEF83-9D4F-431F-B8B2-3131590C5C4B_1_0">&lt;div&gt;
 &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;(16)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Co-Promotion&lt;/font&gt;
 Agreement&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"&gt;
 &lt;font style="font-family:Times New Roman" size="2"&gt;On
 March&amp;#xA0;31, 2014, the Company entered into a &lt;font style="white-space:nowrap"&gt;Co-Promotion&lt;/font&gt; Agreement (the Agreement)
 with Kowa Pharmaceuticals America, Inc. related to the
 commercialization of Vascepa&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
 (icosapent ethyl) capsules in the United States. Under the terms of
 the Agreement, Amarin granted to Kowa Pharmaceuticals America, Inc.
 the right to be the sole &lt;font style="white-space:nowrap"&gt;co-promoter,&lt;/font&gt; together with the Company,
 of Vascepa in the United States during the term. The initial term
 of the Agreement extends through 2018.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;During the term, Kowa
 Pharmaceuticals America, Inc. and Amarin have agreed to use
 commercially reasonable efforts to promote, detail and optimize
 sales of Vascepa in the United States. The performance requirements
 include a negotiated minimum number of details to be delivered by
 each party in the first and second position, and the use of a
 negotiated number of minimum sales representatives from each party,
 including no less than 250 Kowa Pharmaceuticals America, Inc. sales
 representatives. Kowa Pharmaceuticals America, Inc. has agreed to
 continue to bear the costs incurred for its sales force associated
 with the commercialization of Vascepa and to pay for certain
 incremental costs associated with the use of its sales force, such
 as sample costs and costs for promotional and marketing materials.
 Amarin will continue to recognize all revenue from sales of Vascepa
 and will use commercially reasonable efforts to maintain a minimum
 amount of inventory of Vascepa for use in the United
 States.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;In exchange for Kowa
 Pharmaceuticals America, Inc.&amp;#x2019;s &lt;font style="white-space:nowrap"&gt;co-promotional&lt;/font&gt; services, Kowa
 Pharmaceuticals America, Inc. is entitled to a quarterly
 &lt;font style="white-space:nowrap"&gt;co-promotion&lt;/font&gt; fee based on
 aggregate Vascepa gross margin that increases during the term. The
 percentage of aggregate Vascepa gross margin earned by Kowa
 Pharmaceuticals America, Inc. was fifteen percent (15%)&amp;#xA0;in
 2015, was nineteen percent (19%)&amp;#xA0;in 2016, and is scheduled to
 increase to low twenty percent levels in 2017 and 2018, subject to
 certain adjustments. The &lt;font style="white-space:nowrap"&gt;co-promotion&lt;/font&gt; fee also varies based on
 sales levels and whether the FDA has approved an ANCHOR indication
 labeling expansion for Vascepa or has permitted the use of data
 generated to support obtaining FDA approval of the ANCHOR
 indication in the promotion of Vascepa, in which case the
 &lt;font style="white-space:nowrap"&gt;co-promotion&lt;/font&gt; fee would be
 decreased if specified requirements are met. In certain
 circumstances, upon the earlier of the expiration or termination of
 the Agreement in accordance with its terms, Kowa Pharmaceuticals
 America, Inc. may be eligible for up to three years of &lt;font style="white-space:nowrap"&gt;co-promotion&lt;/font&gt; tail royalties equal to
 declining percentages of the &lt;font style="white-space:nowrap"&gt;co-promotion&lt;/font&gt; fee earned prior to
 agreement expiration.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;As of both December&amp;#xA0;31,
 2016 and 2015, the Company had a net payable of $2.5&amp;#xA0;million
 to Kowa Pharmaceuticals America, Inc. representing &lt;font style="white-space:nowrap"&gt;co-promotion&lt;/font&gt; fees payable to Kowa
 Pharmaceuticals America, Inc. net of reimbursable amounts incurred
 for samples and other marketing expenses.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:CoPromotionAgreementDisclosureTextBlock>
  <amrn:AccruedExpensesAndOtherLiabilitiesDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_70C09F8C-1822-42A3-8671-767A4132D0E0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(6)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Accrued Expenses and Other
 Current Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued expenses and other
 current liabilities consist of the following as of
 December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Payroll and payroll-related
 expenses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6,611&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,241&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and development
 expenses&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;293&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;828&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Sales and marketing
 accruals&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,821&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,141&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued revenue
 allowances&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;22,195&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,732&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All other&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,800&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total accrued expenses and
 other current liabilities&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;37,720&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;24,226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</amrn:AccruedExpensesAndOtherLiabilitiesDisclosureTextBlock>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7005_8" unitRef="iso4217_USD">-537000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:BeneficialConversionFeaturePolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_5BA744E4-FE2C-4F00-97F4-7AD80CD23BE3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Beneficial Conversion Features&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company issued Series A
 preference shares in a private placement transaction executed in
 two tranches that each contain a conversion feature whereby such
 shares are convertible into ordinary shares at a fixed rate. The
 conversion price on the date of issuance was less than the market
 price of the Company&amp;#x2019;s ordinary shares. It was determined
 that these discounts represent contingent beneficial conversion
 features, which were valued based on the difference between the
 conversion price and the market price of the ordinary shares on the
 date of issuance, which is the commitment date. These features are
 analogous to preference dividends and were each recorded as a
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt; return to
 preferred shareholders through accumulated deficit upon the
 earliest possible date of conversion, which occurred in the three
 months ended June&amp;#xA0;30, 2015 upon effectiveness of the related
 resale Registration Statement on Form &lt;font style="WHITE-SPACE: nowrap"&gt;S-3&lt;/font&gt; and in the three months ended
 September&amp;#xA0;30, 2015 upon shareholder approval received at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders. See Note
 10&amp;#x2014;Equity for further discussion.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:BeneficialConversionFeaturePolicyTextBlock>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7005_10" unitRef="iso4217_USD">14915000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <amrn:CashDiscountInvoiceTerms contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_03F545B9-751E-426F-A616-364E9AD33027_1_1">P30D</amrn:CashDiscountInvoiceTerms>
  <amrn:ConcentrationOfSuppliersPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_C5823C47-51B8-4A0D-8B2B-D0A92B11EF83_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Suppliers&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has contractual
 freedom to source the API for Vascepa and has entered into supply
 agreements with multiple suppliers. The Company&amp;#x2019;s supply of
 product for commercial sale and clinical trials is dependent upon
 relationships with third-party manufacturers and key suppliers, in
 particular three suppliers of API for Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company cannot provide
 assurance that its efforts to procure uninterrupted supply of
 Vascepa API to meet market demand will continue to be successful or
 that it will be able to renew current API supply agreements on
 favorable terms or at all. Significant alteration to or termination
 of the Company&amp;#x2019;s current API supply chain or its failure to
 enter into new and similar agreements in a timely fashion, if
 needed, could have a material adverse effect on its business,
 condition (financial and other), prospects or results of
 operations.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company currently has
 manufacturing agreements with three &lt;font style="WHITE-SPACE: nowrap"&gt;FDA-approved&lt;/font&gt; commercial API
 encapsulators for Vascepa manufacturing. Each of these companies
 has qualified its manufacturing processes and is capable of
 manufacturing Vascepa. There can be no guarantee that these or
 other suppliers with which the Company may contract in the future
 to encapsulate API will remain qualified to manufacture the product
 to its specifications or that these and any future suppliers will
 have the manufacturing capacity to meet anticipated demand for
 Vascepa.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:ConcentrationOfSuppliersPolicyTextBlock>
  <amrn:UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_842EDEA7-1025-4EF3-8BBD-BB89A14698F5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Use of
 Forecasted Financial Information in Accounting
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The use of forecasted
 financial information is inherent in many of the Company&amp;#x2019;s
 accounting estimates including, but not limited to, determining the
 estimated fair values of derivatives, debt instruments and
 intangible assets, evaluating the need for valuation allowances for
 deferred tax assets, and assessing the Company&amp;#x2019;s ability to
 continue as a going concern. Such forecasted financial information
 is comprised of numerous assumptions regarding the Company&amp;#x2019;s
 future revenues, cash flows, and operational results. Management
 believes that its financial forecasts are reasonable and
 appropriate based upon current facts and circumstances. Because of
 the inherent nature of forecasts, however, actual results may
 differ from these forecasts. Management regularly reviews the
 information related to these forecasts and adjusts the carrying
 amounts of the applicable assets prospectively, if and when actual
 results differ from previous estimates.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</amrn:UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock>
  <amrn:AccountsReceivableCreditPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_E56BBE09-4E91-42B4-B494-5573BA3219D4_1_0">P30D</amrn:AccountsReceivableCreditPeriod>
  <amrn:IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_DEFF8A9D-96CF-4605-939C-ADAC868EB23F_1_7" unitRef="iso4217_USD">7385000</amrn:IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount>
  <amrn:ValuationAllowancesAndReservesForeignCurrencyTranslation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="-3" id="id_6322976_6A4079F6-9CC7-4B27-830B-CB3A91A893BA_1_3" unitRef="iso4217_USD">-4676000</amrn:ValuationAllowancesAndReservesForeignCurrencyTranslation>
  <amrn:SummaryOfNetProductRevenueValuationAllowancesTableTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" id="id_6322976_5A3F00D9-581B-4019-A785-50EE31E7F310_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following table
 summarizes activity in each of the net product revenue allowance
 and reserve categories described above for the years ended
 December&amp;#xA0;31, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;&lt;i&gt;In
 thousands&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Trade&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Allowances&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Rebates,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Chargebacks&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;and&amp;#xA0;Discounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Product&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Returns&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
 &lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 January&amp;#xA0;1, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2,207&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;481&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;792&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7,090&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,986&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;32,591&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;342&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;8,310&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;56,229&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to prior
 period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(174&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(70&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(205&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(449&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,690&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(22,710&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,226&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(40,626&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 prior period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(2,033&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,540&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(83&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(792&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,448&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;4,296&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9,881&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;535&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,084&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;15,796&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;22,952&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;69,370&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;583&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;11,696&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;104,601&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Provision related to prior
 period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(450&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(537&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 current period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(19,213&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(48,719&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,815&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(77,747&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Credits/payments made for
 prior period sales&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(4,205&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(9,167&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(259&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,284&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(14,915&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Balance as of
 December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3,743&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;20,915&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;859&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1,681&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;27,198&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:SummaryOfNetProductRevenueValuationAllowancesTableTextBlock>
  <amrn:NumberOfPatientsEnrolledAndRandomizedInStudy contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0" decimals="INF" id="id_6322976_1A39C84F-6173-49FB-8BED-DF69950B7500_1_0" unitRef="Patient">8175</amrn:NumberOfPatientsEnrolledAndRandomizedInStudy>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324093x1528669" decimals="-5" id="id_6322976_54C02A66-6CFD-4E96-9A43-0156861E1AC2_1001_0" unitRef="iso4217_USD">400000</us-gaap:IncomeTaxExpenseBenefit>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324093x1528669" decimals="-5" id="id_6322976_47E8988A-2C12-4A5E-82BD-84328C41C118_1001_0" unitRef="iso4217_USD">400000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1331109" id="id_6322976_19EDCCB5-CFF5-44D9-A02D-AA11EC0A53E6_1001_1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1331109_1325804x1405848" id="id_6322976_7FE32CE0-CDF0-4CFA-B6EB-B4AA7BF6FBBE_1001_1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1331109_1325804x1405848" id="id_6322976_7FE32CE0-CDF0-4CFA-B6EB-B4AA7BF6FBBE_1001_0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_7001_9" unitRef="shares">647000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_7001_7" unitRef="shares">1756000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583" decimals="-3" id="id_6322976_9B566468-4DC2-4D8E-AD89-1CABD5867097_7001_8" unitRef="shares">1853000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583_1325804x1405848_1336123x1429469" decimals="INF" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_4002_7" unitRef="shares">173563</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583_1325804x1405848_1336123x1429469" decimals="INF" id="id_6322976_266A5A82-4DB6-4C4E-925A-73EEBF7C2956_4002_6" unitRef="shares">363750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583_1325804x1405848_1336123x1454011" decimals="INF" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_3002_6" unitRef="shares">270329</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583_1325804x1405848_1336123x1454011" decimals="INF" id="id_6322976_A64EE621-3F34-4579-97C9-8125687CE35C_3002_5" unitRef="shares">818352</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_1001_5" unitRef="iso4217_USD">2100000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1003_3" unitRef="iso4217_USD">2900000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_1003_1" unitRef="iso4217_USD">7700000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865_1333110x1404455" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_2003_5" unitRef="iso4217_USD">4200000</us-gaap:InterestPaid>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865_1333245x1345793" decimals="-5" id="id_6322976_6400A537-D257-4A3C-A422-1FB07FE20C07_3003_2" unitRef="iso4217_USD">4800000</us-gaap:InterestExpenseDebt>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_2001_2" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_1002_3" unitRef="iso4217_USD">500000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1461424_1328615x1333865" id="id_6322976_1CBB899C-7861-4D8F-B32F-6998908E7409_2001_0">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1461424_1328615x1333865_1333110x1404455" decimals="-5" id="id_6322976_F30E9A03-C827-4FFB-9FE4-23F3662FC33A_2002_4" unitRef="iso4217_USD">500000</us-gaap:InterestPaid>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_1001_5" unitRef="iso4217_USD">800000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_1001_4" unitRef="iso4217_USD">87400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_BBE8EE11-30EC-4DC1-8CFE-6FB04CDCD6A9_3001_6" unitRef="iso4217_USD">600000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1003_3" unitRef="iso4217_USD">800000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_1003_1" unitRef="iso4217_USD">1700000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865_1333110x1404455" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_2003_5" unitRef="iso4217_USD">700000</us-gaap:InterestPaid>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865_1333245x1345793" decimals="-5" id="id_6322976_A37CBC27-BB9C-483A-9828-D8FA48087D69_3003_2" unitRef="iso4217_USD">900000</us-gaap:InterestExpenseDebt>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185" decimals="2" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_1001_2" unitRef="pure">0.25</amrn:StatutoryTaxRate>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185_1328480x1515093" decimals="3" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_2001_3" unitRef="pure">0.125</amrn:StatutoryTaxRate>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185_1347414x1375306" decimals="2" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_3001_0" unitRef="pure">0.25</amrn:StatutoryTaxRate>
  <amrn:StatutoryTaxRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185_1347414x1468724" decimals="3" id="id_6322976_34F8178B-EFEA-4C84-9C9E-44F92AFF9014_4001_1" unitRef="pure">0.125</amrn:StatutoryTaxRate>
  <amrn:TaxCreditCarryforwardExpirationYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1331049_1335482x1328677" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_1002_7">2036</amrn:TaxCreditCarryforwardExpirationYear>
  <amrn:TaxCreditCarryforwardExpirationYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1331049_1335482x1331874" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_2002_6">2024</amrn:TaxCreditCarryforwardExpirationYear>
  <amrn:TaxCreditCarryforwardExpirationYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1335913_1335482x1328677" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_3002_5">2036</amrn:TaxCreditCarryforwardExpirationYear>
  <amrn:TaxCreditCarryforwardExpirationYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1335913_1335482x1331874" id="id_6322976_43013CAA-7559-44D2-AA93-03A7BA24CFAD_4002_4">2024</amrn:TaxCreditCarryforwardExpirationYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1351290_1330098x1336103_1330161x1328472" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_1002_0">2016</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1351290_1330098x1336103_1330161x1334203" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_1001_0">2013</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1407258_1330098x1336103_1330161x1328472" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_2002_1">2016</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1407258_1330098x1336103_1330161x1334203" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_2001_1">2012</us-gaap:OpenTaxYear>
  <amrn:RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782" id="id_6322976_FBF68967-EFC9-4257-84FD-B4F1FB0E3F06_1002_1">Scheduled to increase to low twenty percent levels in 2017 and  2018, subject to certain adjustments.</amrn:RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement>
  <amrn:PercentageOfGrossMarginPayableForPromotionAgreement contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782" decimals="2" id="id_6322976_FBF68967-EFC9-4257-84FD-B4F1FB0E3F06_1002_0" unitRef="pure">0.19</amrn:PercentageOfGrossMarginPayableForPromotionAgreement>
  <amrn:NumberOfSalesProfessionals contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782_1328480x1458944" decimals="INF" id="id_6322976_AB6714D5-9A80-4B12-A411-66FC499A212B_1001_0" unitRef="Employee">150</amrn:NumberOfSalesProfessionals>
  <amrn:NumberOfSalesRepresentative contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782_1328480x1458944_1335482x1331874" decimals="INF" id="id_6322976_AB6714D5-9A80-4B12-A411-66FC499A212B_2001_1" unitRef="Employee">250</amrn:NumberOfSalesRepresentative>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7003_7" unitRef="iso4217_USD">583000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327216" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7003_10" unitRef="iso4217_USD">259000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7001_7" unitRef="iso4217_USD">22952000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7001_9" unitRef="iso4217_USD">19213000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7001_8" unitRef="iso4217_USD">-87000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327217" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7001_10" unitRef="iso4217_USD">4205000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7004_7" unitRef="iso4217_USD">11696000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7004_9" unitRef="iso4217_USD">9815000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1368196" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7004_10" unitRef="iso4217_USD">1284000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7002_7" unitRef="iso4217_USD">69370000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7002_9" unitRef="iso4217_USD">48719000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7002_8" unitRef="iso4217_USD">-450000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1397499" decimals="-3" id="id_6322976_D500476A-B1C5-4A16-AF42-E321E10E1895_7002_10" unitRef="iso4217_USD">9167000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_1001_2" unitRef="shares">1714000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865" decimals="-5" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_2001_0" unitRef="iso4217_USD">150000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865_1330096x1419380" decimals="INF" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_3001_2" unitRef="shares">60311188</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:PaymentsOfDebtRestructuringCosts contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865_1330096x1419380" decimals="-5" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_3001_6" unitRef="iso4217_USD">700000</us-gaap:PaymentsOfDebtRestructuringCosts>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865_1330097x1333806" decimals="-5" id="id_6322976_596EDB80-E2D7-42C7-8FD8-1A7301CF043A_4001_3" unitRef="iso4217_USD">40100000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
  <us-gaap:PreferredStockConversionBasis contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330096x1335797" id="id_6322976_DF1B9592-DEF9-4DCC-86C2-ACC6D377F1FD_1002_1">American  Depositary Shares, each representing one (1) share of Amarin's Series A  Convertible Preference Shares</us-gaap:PreferredStockConversionBasis>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330096x1419380" decimals="INF" id="id_6322976_715D9A34-30F8-48FD-BA4C-9E7689610B5E_1002_3" unitRef="shares">24265000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330096x1419380" decimals="-3" id="id_6322976_715D9A34-30F8-48FD-BA4C-9E7689610B5E_1002_2" unitRef="iso4217_USD">64613000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1326044" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14008_1100032" unitRef="iso4217_USD">-86350000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14006_900030" unitRef="iso4217_USD">-1302000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14006_900027" unitRef="iso4217_USD">87374000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14006_900031" unitRef="iso4217_USD">13602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14006_900029" unitRef="iso4217_USD">168000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1327190" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14006_900025" unitRef="iso4217_USD">48901000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1330220" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14003_600030" unitRef="shares">-645003</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1330220" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14003_1000030" unitRef="iso4217_USD">-1087000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_500028" unitRef="shares">60311188</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_500030" unitRef="shares">1852102</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_500029" unitRef="shares">177146</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="INF" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_500026" unitRef="shares">24265000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_800030" unitRef="iso4217_USD">1295000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_800027" unitRef="iso4217_USD">40062000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_800029" unitRef="iso4217_USD">119000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806" decimals="-3" id="id_6322976_B2C9256E-354B-4EA2-BD14-7BAEC2E5EC60_14002_800025" unitRef="iso4217_USD">15712000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1325185_1330161x1328472" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_3002_2">2016</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1325185_1330161x1334203" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_3001_2">2012</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1328188_1330161x1328472" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_4002_3">2016</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1328188_1330161x1334203" id="id_6322976_C1D613DB-3831-45F0-9167-D2E5A4AB558A_4001_3">2015</us-gaap:OpenTaxYear>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1389060" decimals="-3" id="id_6322976_52D94783-3F82-40A8-827F-7E9F6E3F1961_1001_1" unitRef="iso4217_USD">-68266000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:EmbeddedDerivativeDescriptionOfHostContract contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330125x1468605_1333769x1451741" id="id_6322976_66F187C9-77F0-44BB-AE53-1C88915316D5_1001_0">The warrants issued in connection with the October 2009 financing contained a pricing variability feature which provided for an increase to the exercise price if the exchange rate between the U.S. dollar and British pound adjusts such that the warrants could be exercised at a price less than the &#xA3;0.5 par value of the common stock-that is, if the exchange rate exceeded U.S. $3.00 per &#xA3;1.0 sterling. Due to the potential variable nature of the exercise price, the warrants were not considered to be indexed to the Company&#x2019;s common stock. Accordingly, the warrants did not qualify for the exception to classify the warrants within equity and were classified as a derivative liability.</us-gaap:EmbeddedDerivativeDescriptionOfHostContract>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893" decimals="-3" id="id_6322976_98EF547D-1C10-4448-B2E8-0F69C9420F01_8002_7" unitRef="iso4217_USD">8170000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_1003_8" unitRef="iso4217_USD">5500000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1328677" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_2003_2">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_2003_6" unitRef="pure">0.184</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_2003_4" unitRef="pure">0.111</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1331874" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_3003_1">P2Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_3003_5" unitRef="pure">0.119</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6322976_8B489037-78FF-4D0F-8441-09576D1C36F0_3003_3" unitRef="pure">0.081</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1331645x1336129" id="id_6322976_EEDA4FE0-3F68-49F5-87FE-AB1DEE036947_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;(7)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Warrants and Warrant Derivative
 Liability&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On October&amp;#xA0;16, 2009,
 the Company completed a $70.0&amp;#xA0;million private placement with
 both existing and new investors resulting in $62.3&amp;#xA0;million in
 net proceeds and an additional $3.6&amp;#xA0;million from bridge notes
 converted in conjunction with the private placement. In
 consideration for the $62.3&amp;#xA0;million in net cash proceeds
 Amarin issued 66.4&amp;#xA0;million units, each unit consisting of
 (i)&amp;#xA0;one ADS (representing one ordinary share) at a purchase
 price of $1.00 and (ii)&amp;#xA0;a warrant with a five year term to
 purchase 0.5 (one half) of an ADS at an exercise price of $1.50 per
 ADS. In consideration for the conversion of $3.6&amp;#xA0;million of
 convertible bridge notes, Amarin issued 4.0&amp;#xA0;million units,
 each unit consisting of (i)&amp;#xA0;one ADS (representing one ordinary
 share) at a purchase price of $0.90 and (ii)&amp;#xA0;a warrant with a
 five year term to purchase 0.5 (one half) of an ADS at an exercise
 price of $1.50 per ADS. The total number of warrants issued in
 conjunction with the financing was 35.2&amp;#xA0;million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In conjunction with the
 October 2009 financing, the Company issued an additional
 0.9&amp;#xA0;million warrants to three former officers. The warrants
 issued in connection with the October 2009 financing contained a
 pricing variability feature which provided for an increase to the
 exercise price if the exchange rate between the U.S. dollar and
 British pound adjusts such that the warrants could be exercised at
 a price less than the &amp;#xA3;0.5 par value of the common
 stock&amp;#x2014;that is, if the exchange rate exceeded U.S. $3.00 per
 &amp;#xA3;1.0 sterling. Due to the potential variable nature of the
 exercise price, the warrants were not considered to be indexed to
 the Company&amp;#x2019;s common stock. Accordingly, the warrants did not
 qualify for the exception to classify the warrants within equity
 and were classified as a derivative liability.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of this
 warrant derivative liability was remeasured at each reporting
 period, with changes in fair value recognized in the consolidated
 statement of operations. Upon exercise, the fair value of the
 warrants exercised was remeasured and reclassified from warrant
 derivative liability to additional &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in-capital.&lt;/font&gt;&lt;/font&gt; Although the
 warrants contained a pricing variability feature, the number of
 warrants issuable remained fixed. Therefore, the maximum number of
 common shares issuable as a result of the October 2009 private
 placement was 36.1&amp;#xA0;million.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In October 2014, the
 Company and the holders of the remaining October 2009 warrants
 mutually agreed to extend the expiration date of such warrants from
 October&amp;#xA0;16, 2014 to February&amp;#xA0;27, 2015. Of the 8,087,388
 warrants outstanding as of December&amp;#xA0;31, 2014, 1,844,585
 warrants were exercised, resulting in net proceeds to the Company
 of $2.7&amp;#xA0;million, and the remaining 6,242,803 warrants expired
 and the related derivative liability was extinguished. As such, no
 warrants were outstanding as of December&amp;#xA0;31, 2016.&lt;/font&gt;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609" decimals="-5" id="id_6322976_1921279F-8565-462C-AF0C-56555E3481D6_1002_1" unitRef="iso4217_USD">5500000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:GuaranteePayments contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609" decimals="-5" id="id_6322976_840F4586-0A15-4B21-837A-732A09F163FD_1002_1" unitRef="iso4217_USD">11700000</amrn:GuaranteePayments>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609_1333245x1345793" decimals="-5" id="id_6322976_683733D4-8948-4A17-B5B2-26E0DCD04D2B_1003_2" unitRef="iso4217_USD">2100000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609_1333245x1417215" decimals="-5" id="id_6322976_683733D4-8948-4A17-B5B2-26E0DCD04D2B_2003_1" unitRef="iso4217_USD">6700000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333589x1330112" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_2001_0" unitRef="shares">21188000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333589x1335583" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_3001_1" unitRef="shares">10143000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333769x1451741" decimals="-5" id="id_6322976_6592E058-F868-4A60-8E6C-14C2EAD82460_1002_2" unitRef="iso4217_USD">2700000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333817x1329312_1333818x1324536_1334994x1501282" decimals="2" id="id_6322976_F2ADEBEC-AEBD-4D73-8152-D322BA0670FE_1001_0" unitRef="pure">0.95</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1333817x1333518_1333818x1324536_1334994x1501282" decimals="2" id="id_6322976_F2ADEBEC-AEBD-4D73-8152-D322BA0670FE_2001_1" unitRef="pure">0.96</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1334666x1326228" decimals="-3" id="id_6322976_8F7F819C-6050-40AD-820B-DAE744F02E7F_1001_1" unitRef="iso4217_USD">11361000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1334666x1332399" decimals="-3" id="id_6322976_8F7F819C-6050-40AD-820B-DAE744F02E7F_2001_0" unitRef="iso4217_USD">2252000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1334996x1325837" decimals="-3" id="id_6322976_D8F6945C-6629-45ED-B299-D0B448570127_4001_3" unitRef="shares">32818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1328146" id="id_6322976_85CBCE74-53AD-430F-9662-CD28EBE49340_1001_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1331682" id="id_6322976_85CBCE74-53AD-430F-9662-CD28EBE49340_2001_3">Lesser of useful life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1443526_1335482x1328677" id="id_6322976_85CBCE74-53AD-430F-9662-CD28EBE49340_3001_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1443526_1335482x1331874" id="id_6322976_85CBCE74-53AD-430F-9662-CD28EBE49340_4001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <amrn:EligibleMilestonePayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1328677_1512983x1440366" decimals="INF" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_1001_0" unitRef="iso4217_USD">153000000</amrn:EligibleMilestonePayment>
  <amrn:EligibleRegulatoryMilestoneEventPayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1328677_1512983x1440366" decimals="-5" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_1001_3" unitRef="iso4217_USD">15000000</amrn:EligibleRegulatoryMilestoneEventPayment>
  <amrn:EligibleSalesBasedMilestoneEventPayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1328677_1512983x1440366" decimals="-5" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_1001_6" unitRef="iso4217_USD">50000000</amrn:EligibleSalesBasedMilestoneEventPayment>
  <amrn:EligibleRegulatoryMilestoneEventPayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1331874_1512983x1440366" decimals="-5" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_2001_2" unitRef="iso4217_USD">1000000</amrn:EligibleRegulatoryMilestoneEventPayment>
  <amrn:EligibleSalesBasedMilestoneEventPayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1331874_1512983x1440366" decimals="-5" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_2001_5" unitRef="iso4217_USD">5000000</amrn:EligibleSalesBasedMilestoneEventPayment>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1410977x1363599" id="id_6322976_3367C059-7BB1-4EC0-8B00-33F82E4332A5_1001_1">2017-10-31</us-gaap:LeaseExpirationDate1>
  <amrn:RenewalOptionTermsMaximumAdditionalPeriod contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1410977x1363599" id="id_6322976_3367C059-7BB1-4EC0-8B00-33F82E4332A5_1001_2">P1Y</amrn:RenewalOptionTermsMaximumAdditionalPeriod>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1410977x1379917" id="id_6322976_2E8B911B-0338-454F-9ACE-42368C3DC4A0_2003_1">2018-03-31</us-gaap:LeaseExpirationDate1>
  <amrn:EligibleRegulatoryMilestoneEventPayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1512983x1440366" decimals="-5" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_3001_4" unitRef="iso4217_USD">33000000</amrn:EligibleRegulatoryMilestoneEventPayment>
  <amrn:EligibleSalesBasedMilestoneEventPayment contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1512983x1440366" decimals="-5" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_3001_7" unitRef="iso4217_USD">120000000</amrn:EligibleSalesBasedMilestoneEventPayment>
  <amrn:NumberOfRegulatoryMilestoneEventsIndications contextRef="eol_PE46938---1610-K0013_STD_366_20161231_0_1512983x1440366" decimals="INF" id="id_6322976_FDF955BC-820A-47F1-BECE-F38A102120C3_3001_1" unitRef="Item">3</amrn:NumberOfRegulatoryMilestoneEventsIndications>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_90_20150331_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_2_4" unitRef="iso4217_USD_per_shares">-0.18</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_90_20150331_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_2_3" unitRef="iso4217_USD_per_shares">-0.18</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_90_20150331_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_2_0" unitRef="iso4217_USD">15933000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_90_20150331_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_2_1" unitRef="iso4217_USD">-31994000</us-gaap:NetIncomeLoss>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1610-K0013_STD_90_20150331_0" decimals="-5" id="id_6322976_6A605ADE-25DB-4918-8611-C8C14672F6D5_2_2" unitRef="iso4217_USD">52800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <amrn:EquityOfferingCosts contextRef="eol_PE46938---1610-K0013_STD_90_20150331_0" decimals="-5" id="id_6322976_6A605ADE-25DB-4918-8611-C8C14672F6D5_2_3" unitRef="iso4217_USD">700000</amrn:EquityOfferingCosts>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_91_20160331_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_1_4" unitRef="iso4217_USD_per_shares">-0.16</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_91_20160331_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_1_3" unitRef="iso4217_USD_per_shares">-0.16</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_91_20160331_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_1_0" unitRef="iso4217_USD">25543000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_91_20160331_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_1_1" unitRef="iso4217_USD">-29771000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_91_20160630_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_3_4" unitRef="iso4217_USD_per_shares">-0.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_91_20160630_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_3_3" unitRef="iso4217_USD_per_shares">-0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_91_20160630_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_3_0" unitRef="iso4217_USD">33111000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_91_20160630_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_3_1" unitRef="iso4217_USD">-13354000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_91_20150630_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_4_4" unitRef="iso4217_USD_per_shares">-0.35</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_91_20150630_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_4_3" unitRef="iso4217_USD_per_shares">-0.35</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_91_20150630_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_4_0" unitRef="iso4217_USD">17707000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_91_20150630_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_4_1" unitRef="iso4217_USD">-62853000</us-gaap:NetIncomeLoss>
  <us-gaap:PreferredStockConversionsInducements contextRef="eol_PE46938---1610-K0013_STD_91_20150630_0" decimals="-5" id="id_6322976_5E4107FA-A547-4EC6-BD7B-F2A09C60FDD4_2_2" unitRef="iso4217_USD">31300000</us-gaap:PreferredStockConversionsInducements>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_92_20150930_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_6_4" unitRef="iso4217_USD_per_shares">-0.18</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_92_20150930_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_6_3" unitRef="iso4217_USD_per_shares">-0.18</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_92_20150930_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_6_0" unitRef="iso4217_USD">21483000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_92_20150930_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_6_1" unitRef="iso4217_USD">-32321000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_5_4" unitRef="iso4217_USD_per_shares">-0.08</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_5_3" unitRef="iso4217_USD_per_shares">-0.08</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_5_0" unitRef="iso4217_USD">32734000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_5_1" unitRef="iso4217_USD">-15772000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0_1324529x1375482_1328615x1333865_1330096x1419380_1330788x1448881" decimals="INF" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_3002_9" unitRef="shares">47739925</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0_1324529x1375482_1328615x1333865_1330096x1419380_1330788x1448881" decimals="4" id="id_6322976_7BEFE37C-07A4-4482-BA81-C10E31A7A0D5_3002_8" unitRef="pure">402.0746</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0_1324529x1486557_1328615x1333865_1330096x1419380_1330788x1448881" decimals="INF" id="id_6322976_9C5EA559-9344-4180-877A-803988BE8DB7_2002_5" unitRef="shares">12571263</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-K0013_STD_92_20160930_0_1324529x1486557_1328615x1333865_1330096x1419380_1330788x1448881" decimals="4" id="id_6322976_9C5EA559-9344-4180-877A-803988BE8DB7_2002_4" unitRef="pure">402.0746</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_92_20151231_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_8_4" unitRef="iso4217_USD_per_shares">-0.12</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_92_20151231_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_8_3" unitRef="iso4217_USD_per_shares">-0.12</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_92_20151231_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_8_0" unitRef="iso4217_USD">26633000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_92_20151231_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_8_1" unitRef="iso4217_USD">-21891000</us-gaap:NetIncomeLoss>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-K0013_STD_92_20151231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6322976_1405686B-53A5-42B2-9EE6-25D8F3C0EA56_1002_3" unitRef="iso4217_USD">1300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-K0013_STD_92_20161231_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_7_4" unitRef="iso4217_USD_per_shares">-0.10</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-K0013_STD_92_20161231_0" decimals="2" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_7_3" unitRef="iso4217_USD_per_shares">-0.10</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE46938---1610-K0013_STD_92_20161231_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_7_0" unitRef="iso4217_USD">38696000</us-gaap:SalesRevenueNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-K0013_STD_92_20161231_0" decimals="-3" id="id_6322976_2067962A-7D27-4A25-BCF7-253878B147AC_7_1" unitRef="iso4217_USD">-27453000</us-gaap:NetIncomeLoss>
  <context id="eol_PE46938---1610-K0013_STD_92_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_92_20151231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_92_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_92_20160930_0_1324529x1486557_1328615x1333865_1330096x1419380_1330788x1448881">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amrn:AsAdjustedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_92_20160930_0_1324529x1375482_1328615x1333865_1330096x1419380_1330788x1448881">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amrn:AsAdjustedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_92_20160930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_92_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_91_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_91_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1410977x1363599">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:DublinMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1331874_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1335482x1328677_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1443526_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amrn:ComputerEquipmentAndCapitalizedSoftwareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1443526_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amrn:ComputerEquipmentAndCapitalizedSoftwareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1331682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1335427x1328146">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1334996x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1334666x1326228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333817x1333518_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333817x1329312_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609_1333245x1417215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ChargesCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1389060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">amrn:IrelandAndUnitedKingdomMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1328188_1330161x1334203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1328188_1330161x1328472">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1325185_1330161x1334203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330098x1325185_1330161x1328472">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1330096x1335797">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782_1328480x1458944_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782_1328480x1458944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1327036x1498782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1407258_1330098x1336103_1330161x1334203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">amrn:StateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1407258_1330098x1336103_1330161x1328472">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">amrn:StateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1351290_1330098x1336103_1330161x1334203">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">amrn:FederalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1351290_1330098x1336103_1330161x1328472">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">amrn:FederalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1335913_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1335913_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1331049_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1331049_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185_1347414x1468724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:TaxesByNatureAxis">amrn:TradingActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185_1347414x1375306">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:TaxesByNatureAxis">amrn:NonTradingActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185_1328480x1515093">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:AmarinPharmaceuticalsIrelandLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1325224x1325185">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1461424_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583_1325804x1405848_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583_1325804x1405848_1336123x1429469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0_1324093x1528669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_366_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1334996x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1334666x1326228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333817x1333518_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333817x1329312_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333242x1356609_1333245x1417215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ChargesCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333242x1356609_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1451741_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330098x1389060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">amrn:IrelandAndUnitedKingdomMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330097x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1433040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797_1330097x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1330096x1335797">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1327036x1498782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1325224x1325185_1328480x1515093">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:AmarinPharmaceuticalsIrelandLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1325224x1325185">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1486557_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1461424_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1410374_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoAndThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324093x1528669_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0_1324093x1528669_1333245x1332387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1334666x1332399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1334666x1326228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1330098x1389060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">amrn:IrelandAndUnitedKingdomMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1325224x1325185_1328480x1515093">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:AmarinPharmaceuticalsIrelandLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1325224x1325185">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1324093x1528669_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0_1324093x1528669_1333245x1332387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20161231_0_1324529x1461424_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20091031_0_1330097x1403450_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1482069_1330097x1403450_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amrn:SofinnovaVenturePartnersVIILimitedPartnershipMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1477553_1330097x1403450_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amrn:FountainHealthcarePartnersFundOneLimitedPartnershipMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1395733_1330097x1403450_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amrn:OrbimedAdvisorsLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20091031_0_1326002x1383080_1330097x1403450_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amrn:AbingworthLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20140531_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_31_20120131_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1486557_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1375482_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160930_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380_1330125x1334812">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-02</startDate>
      <endDate>2016-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380_1330125x1328958">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-02</startDate>
      <endDate>2016-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_30_20160831_0_1330097x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-02</startDate>
      <endDate>2016-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_29_20151130_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_23_20160331_0_1333954x1528901_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">amrn:ClinicalTrialApplicationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-03-09</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-20</startDate>
      <endDate>2017-01-20</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-20</startDate>
      <endDate>2017-01-20</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20170120_0_1324529x1461424_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-20</startDate>
      <endDate>2017-01-20</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20170119_0_1324529x1519189_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-19</startDate>
      <endDate>2017-01-19</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20170119_0_1324529x1461424_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-19</startDate>
      <endDate>2017-01-19</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1423313_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-29</startDate>
      <endDate>2015-01-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-29</startDate>
      <endDate>2015-01-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150129_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-29</startDate>
      <endDate>2015-01-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20121215_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-15</startDate>
      <endDate>2012-12-15</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20121206_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-06</startDate>
      <endDate>2012-12-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20111206_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-12-06</startDate>
      <endDate>2011-12-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150630_0_1325894x1383385_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">amrn:SubleaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-30</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20091016_0_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20091016_0_1328615x1330534_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20160711_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-11</startDate>
      <endDate>2016-07-11</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20160711_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-11</startDate>
      <endDate>2016-07-11</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150710_0_1330096x1335797_1330097x1419380_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-10</startDate>
      <endDate>2015-07-10</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150710_0_1330096x1335797_1330097x1403450_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-10</startDate>
      <endDate>2015-07-10</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1456480_1325804x1405848_1336123x1425353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:PerformanceBasedOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1487759">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1336123x1429469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1487759">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150706_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20160308_0_1512983x1543436">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:BiologixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-03-08</startDate>
      <endDate>2016-03-08</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150330_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-30</startDate>
      <endDate>2015-03-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150305_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150305_0_1330096x1335797_1330097x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150305_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20140430_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-30</startDate>
      <endDate>2014-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20160201_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-01</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20160201_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-01</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150226_0_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-02-26</startDate>
      <endDate>2015-02-26</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20150131_0_1325894x1383385_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">amrn:SubleaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-31</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20140131_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-31</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_1_20130508_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-05-08</startDate>
      <endDate>2013-05-08</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170120_0_1324529x1519189_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-20</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170120_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-20</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1519189_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-19</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1519189_1328615x1333865_1330096x1419380_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-19</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1461424_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-19</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170119_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-19</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1335891">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1333816">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1331682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1335427x1328146">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1493724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1410232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:MarketingApprovalInEuropeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1512983x1364380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333245x1506247_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609_1367440x1517729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609_1367440x1347115">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330125x1468605_1330926x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1400959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:OrdinarySharesBasisMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330097x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1330096x1433040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1366356">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:AllowanceForEstimatedChargebacksMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327091x1324134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1327036x1498782_1328480x1458944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1326002x1332009_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1325224x1438374">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">amrn:RepublicOfIrelandUnitedKingdomAndIsraelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1325224x1335913">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1325224x1331049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324896x1327983_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324093x1528669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0_1324093x1330362_1333245x1332387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201517Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20161215_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-15</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1335891">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1333816">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1331682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1335427x1328146">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1333245x1332387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1333806_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1330220_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1327190_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1326044_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1326044_1333245x1332387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1325837_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1330097x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1366356">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:AllowanceForEstimatedChargebacksMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1327036x1498782_1328480x1458944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324896x1327983_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324896x1324925_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1333245x1332467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1486557">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0_1324093x1330360_1324529x1375482">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1330926x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20131231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20121231_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20121206_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-06</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20160930_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20160831_0_1330097x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-08-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20131101_0_1410977x1363599">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:DublinMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-11-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20110930_0_1410977x1363599">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:DublinMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20091031_0_1330097x1403450_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20091016_0_1330125x1468605_1333769x1451741_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20091016_0_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20091016_0_1328615x1330534_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-10</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330097x1400959_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:OrdinarySharesBasisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-10</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150710_0_1330096x1335797_1330097x1393080_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:PreferredSharesBasisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-10</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20140531_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20110701_0_1410977x1379917">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:LocationAxis">amrn:BedminsterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-07-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150330_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150305_0_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150305_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150305_0_1330097x1400959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:OrdinarySharesBasisMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150305_0_1330097x1393080">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:PreferredSharesBasisMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150305_0_1330096x1335797">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20150305_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170220_0_1330096x1433040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-02-20</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170220_0_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-02-20</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170131_0_1324529x1519189_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesFourMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20170131_0_1324529x1461424_1328615x1333865_1335955x1330134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20151130_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865_1334996x1364094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">amrn:OtherDebtObligationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865_1330096x1419380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-K0013_STD_0_20120131_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_GBP_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Point">
    <measure>amrn:Point</measure>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="Tranche">
    <measure>amrn:Tranche</measure>
  </unit>
  <unit id="iso4217_GBP">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="D">
    <measure>utr:D</measure>
  </unit>
  <unit id="Segment">
    <measure>amrn:Segment</measure>
  </unit>
  <unit id="Patient">
    <measure>amrn:Patient</measure>
  </unit>
  <unit id="Employee">
    <measure>amrn:Employee</measure>
  </unit>
  <unit id="Item">
    <measure>amrn:Item</measure>
  </unit>

</xbrl>
